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Strategies for the Synthesis of Glycosylated Small Molecule Libraries and New Bioactive 
Compounds 
  Zachary Cannone 
Ph.D., University of Connecticut, 2019 
                        Abstract: 
The synthesis of glycosylated small molecule compound libraries remains a difficult 
challenge in the field of organic chemistry. Leading techniques are hindered by the requirement 
of optimization based on substrate, and the generation of non-classical glycoside products. The 
development of a platform which takes advanced glycoside intermediates and utilizes reactive 
handles on the aglycone for rapid diversification to final products has been completed in this 
research. Use of amino sugars, derived from known antibiotics, as the carbohydrate component 
of final compounds was intended to exploit known binding interactions with biomacromolecules. 
Final compounds indeed showed ability to inhibit bacterial protein synthesis in vitro and limit 
growth in culture, suggesting binding interactions were retained. 
Development of new generations of therapeutics based on current classes of antibiotics 
remains a primary means of new drug discovery. The aminoglycoside family of antibiotics is no 
exception to this, as current members of this class show promise of improved pharmacological 
properties with diversification to their structures. Studies have been conducted but have not 
addressed novel alkylation patterns on the amino sugar component of these compounds. In this 
work we have shown the development of a synthetic methodology to access mono-, di-, and 
mixed- alkyl kanosamine sugars. Elaboration to glycosides and subsequent diversification 
efforts have led to the finding of novel bacterial protein synthesis inhibitors. 
New catalytic methodologies can lead to powerful synthetic transformations which would 
be inaccessible or of great difficulty otherwise. In particular, asymmetric hydrogenation 
reactions, while simple in terms of chemical transformation, yield enantiomerically pure 
compounds which are of great importance to drug discovery efforts. In this work, the use of 
prochiral starting materials and an Iridium based catalytic system using bidentate chiral 
phosphine ligands has been shown to yield a wide range of 2-substituted 1,4-benzodioxanes 
with excellent enantioselectivities. Compound bearing this chemical motif are known to be 
privileged structures in medicinal chemistry and have great potential for further development to 
lead compounds.  
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1.1. Introduction to antibiotics 
Antibiotics have revolutionized human health through the treatment and prevention of 
bacterial infections. It is evident, particularly in recent years, that bacterial infections still remain 
a major public health issue, however. Commercialization and routine administration of 
antibiotics have led to diminishing efficacies, and the emergence of multi drug resistant (MDR) 
strains of common bacteria.1 These factors have created an imminent crisis in our healthcare 
system.2 
Adding to the issue of drug resistance is the growing prevalence of nosocomial 
infections in the U.S. and abroad. In the U.S. alone the CDC estimates there to be 1.7 million 
hospital associated infections caused by microorganisms per year.47 Of those infections, nearly 
100,000 directly cause or contribute to the death of patients. Aside from the obvious direct 
impact on human mortality, the economic burden that has arisen due to MDR bacteria is 
estimated at $20 billion per year.47 To address this looming problem, there exists a need for 
developing novel antibiotic compounds that can operate by new mechanisms of action and or 
possess compositions which are intrinsically impervious to bacterial resistance mechanisms.  
Bacteria have been on earth for great lengths of time and owing to this fact is their innate 
ability to protect themselves from environmental factors, as well as rapidly evolve in the 
presence of external pressures.1 The first line of defense in the bacterial world, and a defining 
characteristic of microorganisms, is the cell wall. Bacteria can be differentiated into two broad 
categories; Gram-positive and Gram-negative. The former containing a cell wall composed of a 
thick layer of polysaccharide, peptidoglycan, followed by an inner plasma membrane. The latter 
containing a significantly thinner layer of peptidoglycan sandwiched between an inner plasma 
membrane in addition to an outer membrane composed of lipopolysaccharide and proteins.3 
Despite the thick polysaccharide membrane of Gram-positive bacteria, they tend to display 
greater receptiveness to antibiotics due to the lack of the protective outer membrane found in 
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their Gram-negative counterparts. Despite differences in cell wall compositions, both types of 
bacteria are known to develop drug resistance due to other means of defense. Common forms 
of resistance mechanisms in bacteria include; reducing permeability and increasing efflux, direct 
modification of the antibiotic compound, and mutation of the active/binding site of the antibiotic.1  
Decreasing the uptake of antibiotic compounds to their intercellular target is a primary 
defense mechanism for bacteria. Many compounds, particularly those that are hydrophilic, pass 
the cell membranes and enter the cell through passage proteins known as porins.1,4 Numerous 
types of porins have been described, and their effect on intercellular concentration of antibiotics 
can be significant. Resistance due to porin proteins stems from changes in the levels of porin 
expression, modification in the type of porins expressed, and impairment of porin function in the 
presence of antibiotics.1 While important in its own right, porin related resistance is often 
accompanied by increased expression of efflux proteins.1 Efflux pumps consist of several 
families of proteins capable of actively extruding toxic compounds from the intercellular space of 
bacteria. In conjunction with porin modification, this can knock the effective concentration of an 
antibiotic to sub-therapeutic levels. A well-studied example of efflux mediated resistance is that 
of macrolides. Macrolide efflux is mediated by genetic regions termed “MEGA-elements”, 
Macrolide Efflux Genetic Assembly, as well as related regions of genetic information coding for 
macrolide specific efflux pumps.5 Development of subsequent generation macrolides was 
guided in part to circumvent rampant efflux of first and second-generation compounds of the 
class; i.e. erythromycin, azithromycin, clarithromycin. Ketolide antibiotics, where the cladinose 
sugar of the parent macrolide has been substituted for a ketone group and the formation of a 
cyclic carbamate group added to the macrolide ring is the product of such studies (Figure 1.1). 
Due to their structural modifications, these compounds are poor substrates for macrolide efflux 
pumps.6 
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Figure 1.1. 1st generation macrolides to 3rd generation ketolide 
 
Direct modification of an antibiotic is one of the most successful strategies employed by 
bacteria to evade toxicity.1 As the mechanism of action for small molecules is defined by a 
binding interaction at a cellular target, modification of the structure has profound and permanent 
effect on its efficacy. Known modifying enzymes are numerous, and act to catalyze many 
reactions including; acetylation, phosphorylation, adenylation, and hydrolysis.1 Perhaps the 
most well-known example of this type of resistance mechanism is penicillin resistance. Penicillin 
was groundbreaking after its serendipitous discovery and subsequent commercialization in the 
early 1940s.7 However, bacteria were quick to develop resistance through the action of β-
lactamase enzymes which catalyzed the cleavage of the characteristic β-lactam ring of 
penicillin. Penicillin resistant S. aureus infections became clinically relevant soon after 
widespread introduction of penicillin to the general population.8 The mechanism underlying this 
resistance was found to be a plasmid coding for the enzyme that was easily transmitted 
between S. aureus strains. This drove the development of new generations of β-lactams, which 
have all seen subsequent resistance develop due to evolution of β-lactamase enzymes.9 
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Modification of the cellular target is another valuable adaptation bacteria employ to 
protect themselves from antibiotics, and is one of the most common means of resistance.1 
Modification of the target site is irrespective of the compound class and functionality of the 
antibiotic and therefore is a broad and powerful way bacteria confer resistance. As in direct 
modification of the antibiotic itself, modifying the cellular target acts to diminish binding affinity to 
a sub therapeutic level. Changes to the cellular target can take place through actions such as 
point mutations in genes encoding the cellular target, and alterations to the cellular target via 
enzymes. Of particular importance is enzymatic methylation to the target site.1,10 A relevant 
example of this includes enzymes encoded by the erm (erythromycin ribosomal methylation) 
genes. These enzymes have the ability to mono or di-methylate key adenosine residues within 
the bacterial ribosome.1,10 Specifically, modification of A2058, located in domain V of the 
23rRNA of the 50S ribosomal subunit, confers a high degree of macrolide resistance. Moreover, 
because of target site overlap between macrolides, lincosamides, and streptogramins, the 
expression of erm genes, and A2058 methylation, results in broad resistance spanning multiple 
classes of antibiotics.1,10  
It is easy for one to see that there exists a critical need for the development of new 
antibacterial compounds. However, this feat has been elusive due to a variety of factors, one of 
which is the pharmaceutical industry’s aversion to using resources and starting campaigns to 
develop new antibiotics. This aversion stems from the differing paradigm that exists between the 
usage of antibiotics and that of other pharmaceuticals. The window of usage for antibiotics is 
narrow, and over prescription diminishes the efficacy of the compound in the broad population. 
More so, due to the current state of bacterial resistance that we face, many new and novel 
antibacterial therapies are only prescribed as a last resort against MDR infections. This creates 
a very poor economic environment for profiting off a new drug in an industry bogged by 
astronomical costs of research and development, and commercialization though regulatory 
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agencies. For these reasons, many well established companies have shied away from antibiotic 
development in leu of developing compounds for other diseases which present a better return 
on investment. Governmental agencies have taken note, and created incentives companies can 
use to offset the economic downside of antibiotic development.11 However, it has become more 
common for university labs, and small start ups to take on the early stage development of 
antibiotic compounds. 
1.2. Classes of antibiotics 
All antibiotics have the common property of inhibiting the growth and/or killing bacteria. 
How they do so is a defining characteristic of each class. Such mechanisms include inhibitions 
of cell wall synthesis, DNA replication, protein synthesis, and critical enzymes.12 As previously 
stated, the cell wall is the first line of defense for bacteria, and therefore a logical site of attack 
for antibacterials. As bacteria grow and replicate, their cell walls are continuously being 
maintained and recycled. This action requires the use of enzymes. In particular is the enzyme 
transpeptidase. This enzyme is responsible for catalyzing the cross linking of peptidyl moieties 
to adjacent glycan chains to form structurally active peptidoglycan which constitutes the cell 
walls of both Gram-positive and Gram-negative bacteria.12 The β-lactam class of antibiotics, 
penicillins, owe their activity to inhibition of this critical enzyme. By mimicking the structure of the 
D-ala-D-ala terminus of the peptide chain, which is the natural substrate for transpeptidase, the 
β-lactam forms a covalent and irreversible bond with the enzyme, thus rendering it inactive 
(Figure 1.2).12 While cross linking of glycan chains is severely reduced, enzymes which 
catalyze the hydrolysis of peptide linkers remain unphased in the presence of β-lactams. Under 
these conditions, cell walls rapidly lose their stability and bacteria die as a consequence. 
 
 
8 
 
Figure 1.2. Penicillin vs D-ala-D-ala structure 
 
DNA replication is one of the most basic and important cellular functions for proliferation. 
Not surprisingly, antibacterial compounds also target this core process. DNA, being the store of 
a cell’s genetic information, is a densely packed and coiled structure within the cell when not 
actively being transcribed. Accessing DNA for transcription is a highly complex process 
requiring many events, one of which being the management of the coiling/supercoiling of DNA 
strands. This is the main function of a class of enzymes, topoisomerases.12 In a rapidly 
proliferating cell, such as bacteria and cancers, DNA is in a constant state of replication. In 
such, the enzymes responsible for the underlying processes are highly expressed and present 
themselves as key therapeutic targets. The quinolone and fluoroquinolone class of antibiotics 
exploit this and act by targeting topoisomerase enzymes.13 With an affinity for bacterial 
topoisomerase II and IV, quinolone-based antibiotics inhibit DNA translation and thus protein 
synthesis downstream which ultimately leads to cell death. Topoisomerase II is also a major 
target of chemotherapy drugs in human healthcare, ie. etoposide. Due to lack of conformational 
conservation between bacterial and eukaryotic topoisomerase isoforms, quinolone-based 
antibiotics are able to treat bacterial infections while leaving eukaryotic cells unaffected.13 
While topoisomerase inhibitors indirectly cause protein synthesis to cease, other classes 
of antibiotics take a direct approach to protein synthesis inhibition as their mechanism of action. 
Just as the homology of topoisomerase enzymes are not conserved from bacteria to eukaryotic 
cells, that too is the homology of the ribosome.14 The ribosome is the essential molecular 
machinery responsible to translating mRNA, transcribed from DNA, to newly formed proteins. 
This process is vital to cells viability and a continuous process in both bacteria and eukaryotic 
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cells. Such a major cellular process is the target of a number of antibiotics. Among the antibiotic 
classes that target the ribosome are the tetracyclines, chloramphenicols, aminoglycosides, 
oxazolidinones, and macrolides.12 Protein synthesis at the ribosome is a highly complex process 
and can be halted at many steps, and specific mechanisms differ between various classes of 
antibiotics. For example, oxazolidinones act by blocking the formation of the initiation complex 
between the 50S and 30S ribosomal subunits.15  
Tetracylclines owe their activity to blockage of the A site on the assembled 70S 
ribosome, which prevents aminoacyl tRNAs from binding.16 Peptidyl transfer at the PTC is 
blocked by chloramphenicols as well as macrolides, preventing new addition to the growing 
peptide.17 Aminoglycosides interfere with the proofreading step of protein synthesis, and cause 
a higher degree of error in synthesis as well as premature termination which leads to inactive 
proteins.18 Aside from blockage of peptidyl transfer, macrolides also bind within the exit tunnel of 
the 70S ribosome.19 Binding at this site hinders the exit of nascent peptides as they are being 
synthesized and causes a blockage at the PTC. Recent studies have shown that macrolide 
blockage of the exit tunnel is not absolute, but instead is selective based on the sequence of the 
nascent peptide.20 
Mankin and researchers have shown that depending on the peptide sequence, it has the 
ability to circumvent the bound macrolide and proceed down the exit tunnel.20 This work shows 
that macrolides alter the proteome of the bacteria rather than cease all protein synthesis. 
Further work by the Mankin lab has shown that in the presence of saturating concentrations of 
macrolides, up to 40% of cellular proteins continue to be produced.21 Altering the proteome has 
the consequence of downstream effects in numerous biochemical pathways, as well as buildup 
of toxic intermediates, which ultimately results in cell death.21 
1.3. Carbohydrate library synthesis: 
The mechanisms of action vary greatly across the differing classes of antibiotics. 
However, the discovery and development of these compounds have common difficulties. When 
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discovering and developing a drug, it is often necessary to generate a large library of 
compounds from which to screen for activity and identify a lead compound.22 Adding to this 
challenge is that many antibiotic compounds contain carbohydrate moieties.   
Carbohydrates play integral roles in biological systems and are responsible for 
processes such as cell-cell recognition, adhesion, cell signaling, target recognition, and immune 
response.23 Owning to the broad range of abilities carbohydrates confer is their ability to tune 
physiochemical properties and the unique binding properties associate with their structures 
which mediate interactions with their targets.23 Nature has made use of these properties 
extensively. In fact, the addition of a carbohydrate group is one of the most prevalent post 
transcriptional modifications made to lipids and proteins.24 Small molecule natural products are 
very often modified with the addition of a carbohydrate group as well. Highlighting how 
carbohydrates mediate physiochemical properties of small molecules are the macrolide class of 
antibiotics. As mentioned previously, some members of the macrolide family contain a cladinose 
sugar attached to the macrolactone ring that acts as a handle, through binding interactions, for 
efflux pumps.5 Removal of this handle, as in third-generation macrolides, alleviates efflux issues 
by making the molecule a poor binder to the efflux pumps.25 Illustrative of nature’s use of 
carbohydrates in the macrolide antibiotic world is that of methymycin. Produced by the bacteria 
Streptomyces venezuelae, the macrolide is synthesized with a glucose group glycosylated to 
the 2’ hydroxyl of the macrolactones desosamine residue.26  In this state, the molecule is 
biologically inactive as an antibiotic. Concurrent with excretion from the cell a hydrolase enzyme 
catalyzes the cleavage of glucose, thus freeing the desosamine residue and revealing the active 
form of the antibacterial compound.26 
Methymycin, along with all other macrolide compounds owe their activity, in part, to the 
desosamine sugar attached to their macrolactone rings. The desosamine sugar acts to “anchor” 
the macrolides to their binding site through two key interactions.27,28 Firstly, there is a hydrogen 
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bonding interaction between the 2’ hydroxyl and neighboring adenine residues within the 
ribosome.27 In addition, a strong binding interaction is added via electrostatic interaction 
between the negatively charged phosphate of the rRNA and the positively charged 3’ nitrogen, 
which is protonated at physiological pH.27,28 The importance of this desosamine moiety is 
highlighted by the conservation of its bound conformation within the ribosome between all 
known macrolide-ribosome crystal structures. 
Examples of carbohydrate’s ability to change biological properties of small molecules 
and macromolecules alike, and nature’s implementation of them, are numerous. For the 
reasons mentioned, glycosylated compound library synthesis has been an area of extensive 
research in drug discovery efforts. Methods for the synthesis of such libraries include 
glycorandomization, neo-glycorandomization, as well as classical total synthesis efforts among 
others. 
Leading the innovation in the field of glycosylated library synthesis has been the Thorson 
group at the University of Kentucky. Two complementary approaches have been developed in 
this group. One of which is an enzymatic process coined, glycorandomization.29 In this process, 
natural or engineered enzymes are used for their substrate promiscuity to enact chemical 
modification to a carbohydrate library. The enzymes involved in this process are; anomeric 
kinases, nucleotidyltransferases, and glycosyltransferases.29 Anomeric kinases and 
nucelotidyltransferases act sequentially on the carbohydrates to yield nucleotide 
diphosphosugar (NDP-sugar) donor libraries. Subsequently, in the same pot, the 
glycosyltransferases then couple activated donor sugars with various aglycones to give the final 
desired glycosylated sugar compounds.29 This process relies heavily on the ability of the 
enzymes to accept a range of sugar libraries as substrates, and then enact the final 
glycosylation. Unsurprisingly, these requirements make for glycorandomization to be a 
notoriously difficult process to carry out and often require optimization based on the substrates 
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being used. Representing one of the best examples of glycorandomization in practice is that of 
the Thorson group, where they implemented a glycorandomization strategy to synthesize 21 
novel vancomycin monoglycoside derivatives (Scheme 1.1).30 
Scheme 1.1. Glycorandomization of vancomycin aglycone30 
 
 
 
An analogous chemoselective process has also been reported by the Thorson group. In 
this methodology, termed neo-glycorandomization, unprotected reducing sugars act as donors 
in reaction with secondary alkoxyamines.31 Proceeding through an oxy-iminium intermediate, a 
subsequent ring closing step yields the corresponding neoglycosides. While 
neoglycorandomization presents itself as a powerful glycodiversification strategy, it has 
drawbacks in that it produces neoglycosides rather than classical linked glycosides. Further, the 
requirement for secondary alkoxyamines in this reaction is crucial, as primary alkoxyamines are 
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shown to give solely the open chain oximines through deprotonation of the transient iminium 
intermediate (Scheme 1.2).32  
Scheme 1.2. Neo-glycorandomization 
 
While platforms exist that incorporate carbohydrates onto small molecule compound 
libraries, the brute force approach of total synthesis is not lost in drug discovery efforts. In a 
recent undertaking by the Myers group, a total synthetic approach was taken to synthesize 
novel macrolide derivatives.33 By a convergent synthesis starting with simple building blocks, a 
platform for the synthesis of 14 and 15 membered macrolides containing the amino sugar 
desosamine was devised.  
Making use of eight “building-block” reagents (I-VIII), most of which are commercially 
available, the group was able to assemble 14-, and 15- membered synthetic macrolides with 
tunable functionality by choice of building blocks employed. Impressively, both 14, and 15 
membered compounds are shown to be synthesized in about 30% yield in 10 synthetic steps 
(Scheme 1.3).33 
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Scheme 1.3. “Building block” strategy for macrolide total synthesis33 
 
 
Using the synthesis platform, over 300 fully synthetic macrolides were produced and 
evaluated for antibacterial activity through MIC assays with standardized Gram-negative and 
Gram-positive strains. Results from theses assays showed that a majority of the compounds 
displayed antibiotic activity. The most promising compounds in initial MIC testing were then 
tested against bacteria with genetically characterized resistance mechanisms to macrolides, 
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including clinically isolated MDR stains of Staphylococcus aureus, Streptococcus pneumoniae, 
and Enterococcus faecalis. From these assays a number of compounds were identified as 
clinically promising. Most notably, two fully synthetic 14-membered ketolides displayed superior 
MIC values relative to any macrolide in current clinical use against bacteria stains containing 
ribosome-modifying methyltransferase (ermB), efflux (mefA), and constitutively-expressed 
erythromycin ribosome methyltransferase (c-erm) genes. In addition, one of these ketolides 
displayed improved activity against Gram-negative strains relative to most other macrolides. 
Displaying MICs ranging from 0.03-16µg/ml-1 against these various strains the synthetic 
compounds are promising leads for future generations of macrolide antibiotics, and promising 
as elusive Gram-negative treatments, however further work is needed to lower MICs to a 
clinically viable level.33  
1.4. Fluorescent probes used in drug discovery 
Aiding in the process of drug discovery is the use of fluorescent labeled probes. 
Evaluation of a compounds ability to bind a target can be a challenging, yet necessary, task. In 
recent years the advent of high through put assays utilizing fluorescence polarization anisotropy 
techniques has lowered the barrier of determining such properties.34 Fluorescence anisotropy is 
the phenomenon where light, emitted by a fluorophore, has unequal intensities along different 
axes of polarization. This property of light emission can be harnessed to gain insight on 
molecular level interactions between small molecules and various biological targets. In practice, 
a sample containing a fluorophore is excited with polarized light and the subsequent emission 
from the sample is measured for the degree of polarization/anisotropy. The small molecule 
fluorophore, while unbound to a macromolecule, is in a constant fast tumbling state. The light 
emission from this fluorophore is thus depolarized relative to the excitation source and is said to 
have low anisotropy. Conversely, when the small molecule is bound to a macromolecule, such 
as a protein, the tumbling of the fluorophore in solution is slowed. In this situation the 
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polarization of light emission is conserved and is therefore in a higher state of anisotropy 
(Figure 1.3). 
Figure 1.3. Anisotropy 
 
 
The result of being able to quantitatively measure anisotropy of a ligand allows to 
compare binding interactions with a desired target. For example, competitive binding 
experiments where a potential drug like compound competes with a fluorophore tagged probe 
can give the apparent Kd of your potential compound to the target in competition with competitor 
compound.35 
Recent drug discovery efforts have utilized such properties by tagging know antibiotic 
compounds with fluorophores.36,37 In one such effort, a team of researchers at Vernalis, a 
pharmaceutical research company in the UK, synthesized a series of three lincomycin derived 
fluorescent probes.37 Due to lincomycins binding site at the peptidyl transferase center (PTC) of 
the ribosome these probes were made so as to identify novel compounds binding to the PTC 
through competitive binding assays. Of the three probes made, two bore a TAMRA type 
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fluorophore and one a BODIPY type fluorophore. The series was made via coupling of a 
common lincomycin-amine intermediate with an NHS ester of the desired fluorophore 
compound.  
When modifying or adding on to a compound the binding properties will likely change. 
However, in order for fluorescent labeled probes to be useful as tools for competitive binding 
assays they must retain their original binding motif. To validate the lincomycin probes they had 
made, binding assays were conducted using increasing amounts of test compound in 10 nM 
probe solutions containing 2 µm S. carnosus or S. aureus ribosomes in buffer. For each 
concentration of test compound, a fluorescent anisotropy measurement was taken using 
excitation wavelength of 535 nm and emission wavelength of 580 nm. Compounds binding to 
the PTC will thus interfere with binding of TAMRA-lincosamide or BODIPY-lincosamide and 
cause a change in anisotropy. Using know PTC binders as positive controls (chloroamphenicol, 
erythromycin, lincomycin,clindamycin) and know non-PTC binders as negative controls 
(paromoycin and streptomycin), the assays showed strong evidence of competitive binding 
selectively at the PTC (Figure 1.4).37  
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Figure 1.4. BODIPY-, and TAMRA-lincosamide derivatives and their anisotropy studies37 
 
 
Similar work in this field has been conducted by Ma and coworkers, where a series of 
three BODIPY-erythromycin based fluorescent probes (IX,X,XI) were designed and 
synthesized.36 The series of compounds varied the placement of the fluorophore at either the 4’ 
or 9’-positions of the erythromycin structure (Figure 1.5).  
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Figure 1.5. BODIPY-erythromycin derivatives and their ribosome binding affinities36 
 
 
Evaluation of the probes included a determination of their binding affinities to the 70 S E. 
coli ribosome. Kds varied from 0.5 nM, 1.5 nM, and 30 nM for probes IX, X, and XI respectively. 
Only probes with appropriate binding affinities and kinetics are useful in competitive binding 
assays. Probes with high affinity allow for greater resolution and require less assay reagents, 
but result in slower displacement and signal intensity.36 Due to this, probe IX demonstrated the 
best binding affinity but competitive binding required up to two days incubation. Probe XI also 
showed strong binding and kinetics that required overnight incubation. In contrast, probe X, with 
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moderate binding (30 nM) required just 1-hour incubation time for full ligand exchange. With the 
proper kinetics, probe X was successfully applied to an ultra-high throughput screen to identify a 
series of novel ribosome binding ligands that competitively or allosterically displace the probe.36 
1.5. Project design 
Our project aims to develop a platform in which libraries of glycosylated small molecules 
can be synthesized rapidly, and ideally without the need for protecting group manipulations. We 
wish to guide the design of these compounds so that they will be candidates for protein 
synthesis inhibition. Using knowledge of macrolide binding motifs, in particular erythromycin-
ribosome crystal structure data, the amino sugar desosamine will be a central component of our 
compounds. As previously mentioned, desosamine forms strong interactions within the 
ribosome and “anchors” the macrolide to its binding site (Figure 1.6).27,28 
 
Figure 1.6. Erythromycin bound to E. coli ribosome28 
 
*Figure reproduced for use in this thesis with permission of publisher (Elsevier) 
 
Aside from its anchoring effects, the sugar itself, with both polar and basic groups, plays 
an important role in membrane permeability as well. Using desosamine as the sugar moiety we 
then aim to attach various aglycones. The aglycones will be functionalized with reactive groups, 
such as amine, azide or aryl bromide, that can be manipulated to give a series of derivatives 
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(Scheme 1.4). The variation on the aglycone through diversification will affect binding 
interactions within the ribosome. Evaluation of binding affinity will therefore give a structure 
activity relationship (SAR) for the series of compounds made.  
Scheme 1.4. Post Glycosylation Diversification (PGD) 
 
 
Key to our project design is the ability to furnish libraries of glycosylated small molecules 
from a common carbohydrate starting material. We term this method of carbohydrate library 
synthesis, post glycosylation diversification (PGD). The classical approach to forming a novel 
glycoside would be to functionalize an aglycone and then perform a glycosylation with a donor 
sugar. This approach requires a late stage glycosylation to deliver candidate compounds and 
introduces some challenging issues such as optimizing conditions, addressing anomeric 
configuration of products, and subsequent protecting group manipulations. One can think of this 
approach as “diversify then glycosylate”. With PGD, the use of an advanced intermediate 
glycoside with reactive aglycone flips this narrative to “glycosylate then diversify” and allows for 
much simpler and faster assembly of a library of derivatives. With this method, one can screen 
an initial library, and guided by the assay results, make minor structural changes to compounds 
that show activity in hopes of further optimization. Iterations of compounds based on SAR data 
in this fashion can be powerful in identifying potential lead compounds. 
Evaluation of our compounds for biological activity will be central to our efforts. To do so 
we envision using an in vitro co transcription translation assay to evaluate levels of protein 
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synthesis in the presence of our compounds. Using a commercially available assay system from 
New England Biolabs we will be able to quantitatively measure protein synthesis based on the 
production of EmGFP.39 In this system, E. coli ribosomes are incubated with DNA vector 
containing the emGFP gene. Fluorescence of the system is then measured and compared to 
the fluorescence from a control with no inhibitor compound present. The ratio of fluorescent 
values is then used to determine percentage of protein synthesis inhibition in each experiment. 
Complimentary to the transcription/translation assay will be a competitive binding assay. 
Results from the in vitro transcription assay will tell us whether protein synthesis is being 
inhibited but will not confirm the binding site of the inhibitory compounds. By design, we 
hypothesize that our compounds will bind to the ribosome.36,37 Utilizing desosamine, we hope 
the conserved nature of the sugars binding in the ribosome exit tunnel is maintained. To 
investigate whether this is the case we will synthesize fluorescent labeled probes known to bind 
to the ribosome at the exit tunnel and the peptidyl transferase center (PTC). Using these probes 
in competitive binding assays with our inhibitory compounds we will monitor the fluorescence 
anisotropy of the system to confirm binding at the specified sites. 
1.6. Results and discussion 
Our first step in forming PGD compounds was isolation of desosamine itself. As we had 
a readily available supply of erythromycin, hydrolysis of this natural product became the source 
of our sugar (Scheme 1.5). Treatment of erythromycin with ethanolic 6 M HCL followed by 
workup and recrystallization gave desosamine as its hydrochloride salt (1.1) in 50% yield. 
Formation of glycosyl donor from this point was done using well established procedures.40,41 
Desosamine was converted to pyrimidyl glycoside (1.2) via a Mitsonobu reaction with 
mercaptopyrimidine. Protection of the C2 hydroxyl group as the methyl carbamate followed and 
gave compound 1.3 in 49% yield over the two-step sequence.  
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Scheme 1.5. Synthesis of thioglycoside donor from erythromycin40,41 
 
Following the formation of glycosyl donor 1.3, proof of concept glycosylations were 
performed using simple alkyl alcohols to determine reactivity and selectivity (Table 1.1). Using a 
known glycosylation procedure using silver triflate as a thioglycoside activator, products (1.4-
1.7) were prepared in satisfactory yields following carbamate deprotection.42 To our delight, 
glycosylation reactions proceeded selectively to give the β glycosides. This finding simplified 
subsequent synthetic steps, and is consistent with a neighboring group participation effect by 
the C2 carbamate. 
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Table 1.1. Proof of concept alkyl and macrolide glycosylations 
 
 
 
 
 
 
 
 
 
 
Following successful glycosylations with alkyl acceptors, we then attempted to use 
macrolide acceptors, previously synthesized in our lab, to form synthetic desosamine containing 
macrolides. Under the same silver triflate activating conditions, synthetic macrolides 1.8 and 1.9 
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were formed in decent yield. Anomeric selectivity was mostly conserved, varying only slightly in 
the case of 1.9. 
In an attempt to reveal whether these compounds were of promise as bacterial 
inhibitors, minimum inhibitory concentration (MIC) assays we performed against various strains 
of s. aureus, k. pneumoniae, and e. coli. MIC values were determined to be >100µg/ml for s. 
aureus and >200µg/ml for k. pneumoniae and e. coli. While these values are far from clinically 
viable, they suggest the synthetic desosamine compounds do possess a certain degree of 
activity and that desosamine may be acting in the same “anchoring” fashion as it does with 
nature macrolides. 
Having proof of concept, our aim then became to generate a series of glycosides with 
reactive handles that could be used to generate libraries. To this end, we sought to incorporate 
azide, amine, and aryl bromide functional groups. Glycosylations of donor 1.3 with acceptors, 
amino ethanol, m-bromobenzyl, and p-bromobenzyl were conducted using silver triflate as 
activator. After glycosylation, carbamate deprotection was accomplished by solvolysis in 
methanol-water to yield PDG intermediates 1.10-1.12. In addition, amino ethyl glycoside 1.12 
was converted to the azido ethyl PGD intermediate 1.13 by reduction over Pd/C. Yields for the 
glycosylation/deprotection sequences are summarized in Scheme 1.6. We saw these 
intermediates as valuable in terms of diversification through cycloaddition, 
acylation/sulfonylation, and Pd coupling reactions. 
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Scheme 1.6. Glycosylation to PGD intermediates 
 
We began our diversification efforts on azidoethyl and aminoethyl precursors. Azidoethyl 
PGD precursor 1.12 was diversified via simple cycloaddition click reactions using 
different alkynes. Using established procedures, we coupled 1.12 to substituted alkynes in the 
presence of Cu(II) and catalytic ascorbic acid in aqueous alcohol.43 Use of aromatic containing 
phenyl acetylene gave triazole 1.14. In addition, propyargylic biphenyl compounds gave rise to 
biphenyl derivatives 1.15 and 1.16.  
Amide and sulfonamide analogues were also prepared from aminoethyl glycoside 1.13 
via acylation reactions. Use of an amino ethyl PDG intermediate was guided by simple access 
to this compound from the azido intermediate and was thought to be a simple means of 
generating structurally diverse library compounds. Treatment of the amines with acid chlorides 
in the presence of a base gave rise to amide products 1.17-1.19, in varying yields. Sulfonamide 
1.20 was prepared from amine 1.13 with phenylsulfonyl chloride in a similar manner (Table 1.2).  
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Table 1.2. Desosamine PGD cycloaddition derivatives 
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Table 1.3. Desosamine PGD aminoethyl derivatives 
 
Compounds 1.14-1.20 were then tested for MICs against S. aureus, S. pyogene, C. 
glabrata, K. pneumoniae, P. aeruginosa, E. coli, B. subtilus, C. albicans, B. anthracis, E. 
faecalis, and B. cereus. With results less than satisfying, all of the compounds returned MIC 
values >500 µM. While troublesome, it was speculated that the polar nature of these 
compounds was disfavored for the desired inhibitory properties we aimed for. 
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Palladium coupling had presented itself as an attractive means of diversification from the 
outset. By allowing for the incorporation of heteroaromatic and aromatic functionality, they are a 
prominent transformation in medicinal chemistry efforts. After identifying a general set of 
conditions,44 in which PGD intermediate (1.10 or 1.11) is reacted with boronic acid in the 
presence of Cs2CO3 and Pd(Cl)2(PPh3)3 in a dioxane/water mixture at elevated temperature, a 
series of meta substituted compounds 1.21-1.26 were first synthesized (Table 1.4). 
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Table 1.4. Desosamine PGD palladium coupling meta derivatives 
 
Meta-substituted compounds were then evaluated for MIC activity. Results for the MIC 
assays are summarized in Table 1.5. As can be seen, the activities for this series is drastically 
enhanced across the spectrum when compared to the previous series. In particular, compounds 
1.21 and 1.23 showed highly promising activity against s. aureus 29213, with MICs of 50 µg/ml 
and 25 µg/ml, respectively. 
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Table 1.5. MIC data to meta PGD derivatives (µM) 
 
 
The promising MIC results for this series of compounds, combined with the less than 
impressive results for the previous two series (amide/sulfonimide/cycloaddions) suggested that 
nonpolar functionality was favored as a diversification to the aglycone of our PGD intermediates. 
This result is proposed to be due to hydrophobic and/or pi stacking type interactions with the 
region of the ribosome where our compounds are binding. These findings led us to expand our 
Pd coupling efforts and generate a para-substituted series of compounds. Using PGD 
intermediate 1.11, with bromo functionality, under the same Pd coupling conditions, compounds 
1.27-1.32 were synthesized in varying yields (Table 1.6). 
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Table 1.6. Desosamine PGD palladium coupling para derivatives 
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Table 1.7. MIC data for para PGD derivatives (µM) 
 
 
As can be seen (Table 1.7), MIC values were once again promising for the Pd coupling 
products with para-substitution pattern. Combined with previous data, it became clear that the 
best performing compounds bore a mesityl group off of the aglycone. The reason for the mesityl 
functionalities activity was unknown, but we aimed to exploit this by further derivation of the 
compounds. One line of thought was to install a hydroxy group on the aglycone, which would 
act to mimic the C13 hydroxyl of erythromycin and hopefully participate in hydrogen bonding 
interactions with the ribosome. Synthesis of this compound required an aglycone which had the 
required functionality for yielding the free hydroxyl post glycosylation. To this end, the synthesis 
of glycosyl acceptor 1.37 commenced from isophthalic acid (Scheme 1.7).  
Treatment with NBS in concentrated sulfuric acid yielded the meta bromo derivative 1.33 
in excellent yield. Conversion to the bis methyl ester 1.34 proceeded in high yield with methanol 
and acid catalyst. Selective mono reduction using one equivalent of reducing agent gave the 
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hydroxymethyl intermediate 1.35 in good yield. Hydroxyl protection with TBSCl followed by 
reduction of the remaining ester yielded the glycosyl acceptor 1.37 in 44% yield from isophthalic 
acid over five synthetic steps. 
Scheme 1.7. Synthesis of hydroxymethyl acceptor 
 
 
Also, of interest to us was the variation of the linker length between the carbohydrate 
and the aglycone functionality. We envisioned a series of compounds, derived from phenol, and 
phenethyl alcohol acceptors, which would yield valuable SAR data along with the hydroxymethyl 
analog (Scheme 1.8). Glycosylations took place in like fashion to the previous series and were 
followed by carbamate deprotection. Pd coupling with mesityl boronic acid then yielded the 
mesityl derivatives 1.38-1.40 in varying yields. 
 
 
 
 
 
 
35 
 
Scheme 1.8. Synthesis of modified aglycon mesityl derivatives 
 
MIC assays were then conducted for the series of mesityl compounds against various 
bacteria strains (Table 1.8). Results for the newly synthesized compounds (1.38-1.40) closely 
matched that of the parent compound 1.23. However, phenethyl compound 1.39 displayed 
improved activity against certain strains. These findings suggested that the added flexibility 
afforded by the extra methylene group linking carbohydrate to aglycone allowed for improved 
binding contacts within the ribosome. 
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Table 1.8. MIC data for modified aglycone mesityl derivatives (µM) 
 
 
With promising MIC results, it was our hope to utilize a complimentary in vitro 
transcription/translation assay in an effort to quantify the level of protein synthesis inhibition. The 
PURExpress cell free system from New England Biolabs presented itself as an ideal test for our 
compounds. In this system, fluorescence of nascent EmGFP would be measured in the 
presence of inhibitory compound and compared to that of control experiments in the absence of 
inhibitor (negative control) and in the presence of known inhibitor (positive control). Compounds 
were assayed at a concentration of 25 µg/ml, and the best results for the series of desosamine 
compounds are shown in Figure 1.7. Pyrimidyl compound 1.24 demonstrated inhibition of 
EmGFP signal by about 35% relative to negative control. Best results were found with 
compound 1.40, the hydroxy methyl derivative of parent compound 1.23, where signal reduction 
of around 70% was observed. Erythromycin, used as a positive control at 1µg/ml, reduced the 
fluorescence signal by 99% suggesting close to complete inhibition of protein synthesis. 
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Figure 1.7. Co-transcription/translation assay results 
 
 
Results in MIC and translation inhibition assays suggested that our compounds 
displayed antibiotic activity, and it was our hypothesis from the onset that the compounds were 
acting via binding interactions with the bacterial ribosome. Efforts then turned to target 
confirmation in an attempt to validate this proposed mechanism. By use of fluorescent labeled 
probes which bind to the bacterial ribosome, we aimed to conduct competitive binding studies 
with our series of compounds. With the requirement that the labeled compound retain binding to 
the desired binding site, as well as maintain a certain Kd such that it could be competitively 
unbound, it became obvious that a novel compound for these studies would require too much 
effort in addition to synthetic operations. For these reasons, we began a synthesis of known 
compounds which had been shown to work in competitive binding studies to identify ribosome 
binding compounds. 
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First in our efforts was the synthesis of an erythromycin-based probe tagged with a 
BODIPY fluorophore. Synthesis began in similar manner to known BODIPY erythromycin 
compound, with the formation of erythromycin oxime 1.41 via reaction of hydroxylamine with 
erythromycin (Scheme 1.9).36 Initial attempts to reduce the oxime to an imine intermediate, as 
had been previously reported, were met with much difficulty. Eventually, we found conditions 
that allowed the formation of erythromylamine 1.42 in a single step from the oxime. This 
reaction proceeded in modest yield but afforded adequate product for fluorescent tagging. 
Coupling of the amine with an NHS ester of a BODIPY fluorophore provided the erythromycin-
BODIPY compound 1.43 in 72% yield. 
Scheme 1.9. Synthesis of erythromycin-BODIPY probe 
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It was our understanding that the novel desosamine compounds we had synthesized 
may not have retained absolute fidelity of macrolide binding site in the ribosome. Due to this, we 
envisioned the synthesis of a complementary probe based on the lincosamide antibiotic, 
clindamycin. Initially we proposed tagging the lincosamide with a BODIPY fluorophore coupled 
to the proline moiety. This sequence began with the hydrazinolysis of clindamycin to yield the 
free amine intermediate 1.44. Difficulties with this transformation were very extensive, and led to 
the formation of an unreported clindamycin derivative (1.45) resulting from hydrazine insertion to 
the carbonyl followed by and E2 elimination of the chlorine atom (Scheme 1.10).  
Scheme 1.10. Initially proposed lincosamide probe and E2 elimination product 
 
  
 
Synthesis of the free amine was eventually realized by use of lincomycin starting 
material, however, subsequent amide coupling presented new challenges. For these reasons, 
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and for simplicity, we resorted to the synthesis of a known clindamycin-BODIPY compound.37 
Synthesis of this compound commenced with nucleophilic substitution of the chlorine with 
sodium azide (scheme 1.11). Acetylation the gave the peracetyl intermediate 1.47 in good yield. 
Staudinger reduction then gave the amine 1.48 in 79% yield. Zemplén conditions provided the 
deprotected sugar which then underwent amide coupling with NHS ester BODIPY compound to 
give the desired clindamycin-BODIPY compound 1.50 in 85% isolated yield. 
Scheme 1.11. Synthesis of lincosamide-BODIPY probe 
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Efforts to use these probes in competitive binding studies were conducted via 
collaboration. Experiments are being conducted to optimize assay conditions and results are 
expected to be reported due time.  
1.7. Conclusion 
The goal of this project was to develop method to access glycosylated small molecule 
compound libraries. To do so, we looked at how these libraries are currently being assembled 
and devised a platform which flipped the conventional synthetic ideology. By changing the 
established “diversify then glycosylate” strategy to a more streamlined “glycosylate then 
diversify” route we have shown that they synthesis of small molecule glycosides is possible in a 
fashion which allows quick diversification of a core motif to final compounds. Showcasing this 
methodology, we utilized the amino sugar desosamine, found on naturally occurring antibiotics, 
to generate a moderate sized library of compounds which displayed retained antibiotic activity. 
By design, the compounds were assembled in such a way that provided initial SAR data which 
allowed for subsequent improvement of lead compounds.  
Envisioned to compliment this study was the use of fluorescence polarization assays to 
confirm binding sites. Use of desosamine was theorized to allow for binding of the subsequent 
glycosides at the natural binding site of the ribosome for the sugar. While activity was observed 
for various glycosides, confirmation of the binding site, and perhaps further structural data for 
this interaction, would greatly aid in optimization efforts.  
As a general synthetic platform for glycoside libraries, it would be logical to extend the 
methodology to other sugars beyond desosamine. By exploiting other known sugar binding 
interactions, novel bioactive glycosides may be identified using the PGD platform. 
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1.8. Experimental 
 
 
 
 
Compound 1.2: In flame dried glassware under N2 atmosphere, DIAD (3.31 mL, 0.0168 mmol) 
was added dropwise to a solution of Bu3P (4.15 mL, 0.0168 mmol) in toluene (75 mL) at -30 oC. 
The resulting solution was stirred for 20 mins while maintaining temperature. A solution of 
desosamine in 75 mL toluene was added in one portion to the reaction. The mixture was stirred 
at -30 oC for 45 min. Solid 2-mercaptopyridine (1.87 g, 0.0168 mmol) was added and cooling 
bath removed. The reaction was allowed to stir at rt for 16hrs. The reaction was filtered through 
a pad of celite and concentrated in vacu to yield a thick yellow syrup which was purified by 
chromatography (90:10:1, DCM,MeOH,TEA) to yield a crude product containing 
tributylphosphine oxide. The crude product was dissolved in 90 ml EtOAc and extracted with 2 
M HCl (4 x 10 ml). The HCl solution was made basic (pH 12) with 6 M NaOH and the resulting 
aqueous solution was saturated with NaCl (s) and extracted with EtOAc (4 x 20 mL). The 
organic fractions were washed with brine (25 mL), dried over Na2SO4, and concentrated to give 
the desired crude compound. Chromatography (90:10:1, DCM:MeOH:TEA) gave the pure 
product (788 mg, 21%); 1H NMR (400MHz, CDCl3) δ ppm 8.39 (d, J = 4.5Hz, 1H), 7.51 (dt, J = 
1.4/7.9 Hz, 1H), 7.28 (d, J = 7.9 Hz, 1H), 7.02 (dd, J = 5.1/6.7 Hz, 1H), 5.34 (d, J = 9.6 Hz, 1H), 
3.72 (m, 1H), 3.57 (t, J =9.7 Hz, 1H), 3.07 (q, J = 7.6/15.1 Hz, 1H), 2.86 (m, 1H), 2.46 (s, 6H), 
1.96 (dd, J = 1.8/13.0 Hz, 1H), 1.40 (dd, J = 12.0/23.5 Hz, 1H), 1.25 (d, J = 6.1 Hz, 3H); 13C 
NMR (100MHz, CDCl3) δ ppm 157.2, 149.5, 136.4, 123.3, 120.4, 85.4, 73.9, 68.9, 67.4, 45.9, 
40.4, 29.4, 21.6, 8.9; LRMS (ESI+) m/z calcd. for C12H19N3O2S [M+H]+ 269.12, found 269.3 
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Compound 1.3: Desosamine thioglycoside (750 mg, 2.79 mmol) was dissolved in THF (15 mL) 
and saturated NaHCO3 aq. (15 mL). Methyl chloroformate (0.276 mL, 3.35 mmol) was added 
dropwise and the reaction mixture stirred at rt 1hr. Upon completion by TLC, the reaction was 
diluted with EtOAc (60 mL) and the aqueous fraction extracted with EtOAc (3 x 10 mL). The 
combined organic layers were pooled and washed with brine, dried over Na2SO4, and 
concentrated to give a crude oil which was purified by chromatography (90:10:1 
DCM:MeOH:TEA) to give 580 mg (64%) of the desired product as a thick yellow oil; 1H NMR 
(400Mhz, CDCl3) δ ppm 8.34 (d, J = 4.5 Hz, 1H), 7.43 (dt, J = 2.1/7.9/9.5 Hz, 1H), 7.13 (d, J = 
7.9 Hz, 1H), 6.94 (qd, J =0.9/4.7/5.7 Hz, 1H), 5.55 (d,  J = 10.1 Hz, 1H), 4.75 (t, J = 10.1 Hz, 
1H), 3.69 (s, 3H), 2.86 (m, 1H), 2.25 (s, 6H), 1.80 (qd, J = 1.4/4.2/5.8 Hz, 1H), 1.41 (q, J = 
12.3/24.2 Hz, 1H), 1.20 (d, J = 6.1 Hz, 3H); 13C (100Mhz, CDCl3) δ ppm 156.7, 155.1, 149.4, 
136.3, 122.9, 120.3, 82.9, 73.5, 72.7, 64.7, 54.9, 40.7, 31.2, 21.3; LRMS (ESI+) m/z calcd. for 
C14H21N3O4S [M+H]+ 327.12, found 327.2 
 
 
 
 
 
 
 
 
 
44 
 
 
GP1: Representative procedure for the desosamine glycosylation reactions 
A representative procedure is given for the synthesis of desosamine glycosides: Compound 1.11 
protected: AgOTf (0.055 g, 0.212 mmol, 3.0 eq.) was added to a suspension of 4Å molecular 
sieves (0.150 g) in dry DCM (1 mL) at 0 °C in darkness (wrapping with aluminum foil). A solution 
of desosamine donor 1.3 (0.023 g, 0.071 mmol, 1.0 eq.) and p-bromobenzyl alcohol (0.141 mmol, 
2.0 eq.) in dry DCM (1 mL) were then added to the AgOTf solution. The mixture was stirred for 2 
h at 0 °C and then quenched by the addition of saturated NaHCO3 (0.5 mL). The reaction mixture 
was then diluted with EtOAc (10 mL) and filtered through a pad of celite; the filter cake was 
washed with additional EtOAc (1 x 5 mL). The filtrate was then washed with water (1 x 5 mL) and 
brine (1 x 5 mL). The organic layer was dried over Na2SO4, and then concentrated in-vacuo and 
the residue was purified by flash-chromatography to give compound 1.11 protected (71%) as a 
light yellow oil.  
 
 
Rf 0.5 (75:20:5 EtOAc:Hex:TEA); 
1H NMR (400MHz, CDCl3) δ ppm 7.42 (d, J= 9.1 Hz, 2H), 7.17 
(d, J = 9.1 Hz, 2H), 4.82 (d, J = 12.1 Hz, 1H), 4.67 (dd, J= 7.6/10.6 Hz, 1H), 4.54 (d, J= 12.5 Hz, 
1H), 4.40 (d, J = 7.6 Hz, 1H), 3.76 (s, 3H), 3.54 (sep, J = 7.2/12.5/17.5 Hz, 1H), 2.76 (td, J = 
3.8/11.4/15.2 Hz, 1H), 2.29 (s, 6H), 1.77 (dd, J = 3.0/12.5 H, 1H), 1.27 (d, J = 6.0, 3H) ); 13C 
NMR (100MHz, CDCl3) δ ppm 136.7, 131.4, 129.1, 121.4, 101.2, 74.9, 69.6, 69.4, 62.9, 54.9, 
40.6, 30.7, 21.0; HRMS (DART-TOF) m/z calcd. for C17H24BrNO5 [M+H]+ 402.0908, found 
402.0886.  
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GP2: Representative procedure for carbamate deprotection 
A representative procedure is given for the synthesis of carbamate deprotected desosamine 
glycosides: Compound 1.11: Desosamine glycoside 1.11 protected (~0.120 mmol) was taken 
up in MeOH (8 mL) and solid K2CO3 (0.0005 g, 0.004 mmol, 5%) was then added. The mixture 
was stirred overnight at rt and after it was concentrated in-vacuo. The residue was purified by 
flash chromatography to give the product.  
 
 
 
Title compound 1.11 was prepared according to GP2 in 92% yield as a light-yellow oil. Rf 0.45 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.45 (d, 2H), 7.29 (d, 2H), 4.87 (d, 
1H), 4.64 (d, 1H), 4.34 (d, 1H), 3.55 (m, 1H), 3.34 (dd, 1H), 2.53 (td, 1H), 2.29 (s, 6H), 1.71 (dq, 
1H), 1.28 (d, 3H); 13C NMR (100MHz, CDCl3) δ ppm 136.8, 131.4, 129.6, 121.6, 103.1, 69.9, 
69.8, 69.6, 65.6, 40.3, 28., 21.3; HRMS (DART-TOF) m/z calcd. for C15H22NO3Br [M+H]+ 
344.0856, found 344.0868. 
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Compound 1.40 protected was prepared according to GP1 in 76% yield as a yellow oil. Rf 0.55 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl
3
) δ ppm 7.36 (s, 1H), 7.22 (s, 1H), 7.14 (s, 
1H), 4.85 (d, J = 12.4 Hz, 1H), 4.57 (d, J = 12.4 Hz, 1H), 4.62-4.76 (8H, m), 4.41 (d, J = 8.4 Hz, 
1H), 3.82 (s, 3H), 3.56 (m, 1H), 2.79 (dt, J = 4.1/7.7/14.7, 1H), 2.30 (s, 6H), 1.78 (dd, J = 2.2/7.0 
Hz, 1H), 1.41, (q, J= 11.9/23.6 Hz, 1H), 1.30 (d, J= 5.9 Hz, 3H), 0.95 (s, 9H), 0.11 (s, 9H); 13C 
NMR (100MHz, CDCl3) δ ppm 170.9, 155.6, 143.8, 138.6, 130.3, 129.8, 125.2, 102.1, 101.5, 
75.1, 65.5, 64.4, 63.1, 55.1, 40.9, 26.2, 21.3, 21.2. 
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Compound 1.40 was prepared according to GP2 in 82% isolated yield as a light-yellow oil. Rf 
0.29 (75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl
3
) δ ppm 7.47 (s, 1H), 7.42 (s, 1H), 7.34 
(s, 1H), 4.87 (d, J = 12.3 Hz, 1H), 4.65 – 4.60 (m, 3H), 4.33 (d, J = 7.3 Hz, 1H), 3.59 – 3.52 (m, 
1H), 3.33 (dd, J = 7.4/10.4 Hz, 1H), 2.51 (ddd, J = 3.9/10.4/14.2 Hz, 1H), 2.27 (s, 6H), 1.69 (ddd, 
J = 1.8/3.6/12.8 Hz, 1H), 1.30 – 1.25 (m, 4H); 13C NMR (100MHz, CDCl3) δ ppm 143.5, 140.5, 
130.0, 129.2, 124.9, 122.7, 103.4, 70.1, 70.0, 69.7, 65.6, 64.6, 40.5, 28.8, 21.5; HRMS (DART-
TOF) m/z calcd. for C16H24NO4Br [M+H]+ 374.0967, found 374.0948. 
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GP3: Representative procedure for Suzuki couple of desosamine glycosides 
A representative procedure is given for the synthesis of Suzuki derivatized desosamine 
glycosides: Compound 1.27: Starting material 1.11 (29.2 mg, 0.0848mmol) along with phenyl 
boronic acid (20.68 mg, 0.1696mmol), Cs2CO3 (82.89 mg, 0.2544mmol), and PdCl2(PPh3)2 
(11.9 mg, 0.017 mmol) was purged under high vacuum and flushed with nitrogen. 2.8 mL 
Dioxane/H2O was added (2:1, 0.03M) and mixture stirred at rt under nitrogen for 15 min. The 
reaction was then heated to 80 oC and followed by TLC. Once complete (4 Hr) the reaction was 
quenched with saturate bicarbonate solution and extracted with EtOAc (3 x 2 mL). The organic 
fractions were pooled and washed with brine, dried over Na2SO4 and concentrated. The crude 
material was purified by chromatography (70:25:5, EA:Hex:TEA) to yield 1.27 (13 mg, 45%)  
 
 
 
Rf 0.30 (75:20:5 EtOAc:Hex:TEA); 
1H NMR (400MHz, CDCl3) δ ppm 7.60 (q, J = 5.5/7.12 Hz, 4H), 
7.51 (d, J = 8.1 Hz, 2H), 7.45 (t, J = 7.4 Hz, 2H), 7.36 (t, J = 6.6 Hz, 1H), 4.99 (d, J = 12.4 Hz, 
1H), 4.76 (d, J = 12.4 Hz, 1H), 4.41 (d, J = 7.5 Hz, 1H), 3.60 (m, 1H), 3.40 (dd, J = 7.2/10.2 Hz, 
1H), 2.57 (m, 1H), 2.32 (s, 6H), 1.73 (m, 1H), 1.33 (d, J = 5.7 Hz, 3H); 13C NMR (100MHz, CDCl3) 
δ ppm 141.0, 140.6, 136.7, 128.8, 128.5, 127.2, 127.1, 127.1, 103.0, 70.2, 70.1, 69.7, 65.4, 40.4, 
28.8, 21.3; HRMS (DART-TOF) m/z calcd. for C21H27O3N [M+H]+ 342.2058, found 342.2062. 
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Compound 1.28 was prepared according to GP3 in 52% yield as a light-yellow oil. Rf 0.50 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.47 (d, J = 7.7 Hz, 2H), 7.13 (d, J 
= 7.7 Hz, 2H), 6.95 (s, 2H), 5.01 (d, J = 11.6 Hz, 1H), 4.74 (d, J = 11.6 Hz, 1H), 4.46 (d, J = 7.4 
Hz, 1H), 3.62 (m, 1H), 3.41 (m, 1H), 2.61 (m, 1H), 2.33 (s, 9H), 2.01 (s, 6H), 1.75 (m, 1H), 1.33 
(d, J= 5.9 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 136.0, 132.2, 132.0, 129.3, 128.6, 128.1, 
128.0, 103.5, 90.7, 70.0, 69.8, 65.4, 40.4, 28.9, 21.4, 21.0, 20.8; HRMS (DART-TOF) m/z calcd. 
for C24H33O3N [M+H]+ 384.2528, found 384.2497. 
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Compound 1.29 was prepared according to GP3 in 41% yield as a light-yellow oil. Rf 0.20 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 8.86 (s, 1H), 8.60 (s, 1H), 7.89 (d, J 
= 8.3 Hz, 1H), 7.56 (q, J = 8.3/13.5 Hz, 4H), 7.37 (q, J = 4.4 Hz, 7.21, 1H), 5.00 (d, J = 12.3 Hz, 
1H), 4.76 (d, J = 12.3 Hz, 1H), 4.41 (d, J = 7.2  Hz, 1H), 3.60 (m, 1H), 2.57 (m, 1H), 2.32 (s, 6H), 
1.74 (m, 1H), 1.33 (d, J = 6.2 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 148.4, 148.3, 137.8, 
137.1, 134.3, 128.7, 127.2, 123.6, 103.1, 70.0, 70.0, 69.8, 65.4, 40.4, 29.7, 28.8, 21.3; HRMS 
(DART-TOF) m/z calcd. for C20H26O3N2 [M+H]+ 343.2011, found 343.1958. 
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Compound 1.30 was prepared according to GP3 in 55% yield as a light-yellow oil. Rf 0.18 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 8.67 (m, 2H), 7.64 (d, J= 7.8 Hz, 
2H), 7.56 (d, J = 7.8 Hz, 2H), 7.52 (d, J = 5.4 Hz, 2H), 5.01 (d, J = 12.4 Hz, 1H), 4.77 (d, J = 12.4 
Hz, 1H), 4.42 (d, J = 7.4 Hz, 1H), 3.61 (m, 1H), 3.39 (dd, J = 6.8/9.9 Hz, 1H), 2.56 (m, 1H), 2.32 
(s, 6H), 1.73 (m, 1H), 1.33 (d, J = 7.8 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 150.2, 138.9, 
137.4, 128.7, 127.1, 121.6, 121.7, 103.3, 70.0, 69.8, 65.4, 40.4, 29.7, 28.7, 21.4; HRMS (DART-
TOF) m/z calcd. for C20H26O3N2 [M+H]+ 343.2011, found 343.1958. 
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Compound 1.31 was prepared according to GP3 in 42% yield as a light-yellow oil. Rf 0.30 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.52 (d, J= 8.3 Hz, 2H), 7.47 (d, J= 
8.3 Hz, 1H), 7.31 (d, J= 8.3 Hz, 1H), 7.24 (d, 8.3 Hz, 2H), 4.99 (d, J= 11.4 Hz, 1H), 4.89 (d, J = 
11.4 Hz, 0.4H), 4.73 (d, J = 11.4 Hz, 1H), 4.65 (d, J = 11.4 Hz, 0.4H), 4.43 (d, J = 7.4 Hz, 1H), 
4.35 (d, J = 7.4 Hz, 0.4H), 3.6 (m, 1.6H), 3.37 (m, 1.8H), 2.56 (m, 1.6H), 2.41 (s, 3H), 2.31 (s, 
6H), 2.28 (s, 3H), 1.74 (m, 2H), 1.33 (m, 10H); 13C NMR (100MHz, CDCl3) δ ppm 137.2, 131.5, 
129.8, 119.6, 129.1, 128.4, 103.4, 103.1, 70.3, 70.0, 69.9, 69.8, 69.6, 65.4, 40.3, 29.7, 28.7, 21.4, 
11.6, 10.9, 1.0; HRMS (DART-TOF) m/z calcd. for C20H28N2O4 [M+H]+ 361.2116, found 361.2102. 
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Compound 1.32 was prepared according to GP3 in 37% yield as a light-yellow oil. Rf 0.25 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400 MHz, CDCl3) δ ppm 7.6-7.4 (m, 8H), 7.1 (d, 2H), 5.45 (t, 
1H), 4.93 (d, 1H), 4.64 (d, 1H), 4.39 (d, 1H), 3.92 (dt, 1H), 3.5-3.7 (m, 3H), 2.63 (m, 1H), 2.34 (s, 
6H), 2.05 (m, 2H), 1.5-1.8 (m, 2H), 1.1-1.5 (m, 4H); 13C NMR (100MHz, CDCl3) δ ppm 141.0, 
140.6, 136.7, 128.8, 128.5, 127.2, 127.1, 127.1, 103.0, 96.3, 70.2, 70.1, 69.7, 65.4, 62.0, 40.4, 
30.4, 28.8, 25.2, 21.3, 18.8; HRMS (DART-TOF) m/z calcd. for C26H35NO5 [M+H]+ 442.2515, 
found 442.2604. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
54 
 
 
 
Compound 1.40 was prepared according to GP3 in 45% yield as a light yellow oil. Rf 0.46 
(75:20:5 EtOAc:Hex:TEA); 1H NMR (400MHz, CDCl3) δ ppm 7.45 (s, 1H), 7.05 (s, 2H), 6.92 (s, 
2H), 4.97 (d, J = 12.0 Hz, 1H), 4.73 – 4.67 (m, 3H), 4.39 (d, J = 7.3 Hz, 1H), 3.62 – 3.54 (m, 1H), 
3.41 (dd, J = 7.3/10.2 Hz, 1H), 2.72 (ddd, J = 4.0/10.3/14.1 Hz, 1H), 2.40 (s, 6H), 2.32 (s, 3H), 
1.99 (s, 3H), 1.98 (s, 3H), 1.82 (ddd, J = 2.0/3.912.9 Hz, 1H), 1.37 – 1.31 (m, 1H); 1.29 (d, J = 6.2 
Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 141.6, 138.8, 138.3, 126.8, 36.1, 136.0, 128.2, 127.5, 
124.9, 103.1, 70.8, 70.2, 69.7, 65.5, 40.5, 29.8, 21.4, 21.2, 21.0; HRMS (DART-TOF) m/z calcd. 
for C25H35NO4 [M+H]+ 414.2644, found 414.2640. 
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Compound 1.43: Compound 1.42 (8.6 mg, 0.01 mmol) and BODIPY-NHS ester (5 mg, 0.012  
mmol) were dissolved in THF (0.5 mL, dry). The reaction stirred at rt overnight while shielded from 
light. Upon completion, the THF was distilled off and the residue purified by column 
chromatography (0-10% MeOH:CH2Cl2) to yield title compound 1.43 (4.5 mg, 72%) as a red solid; 
1H (400Mhz, CD3OD): δ ppm 7.43 (s, 1H), 6.99 (d, J = 4.6 Hz, 1H), 6.36 (d, J = 3.8 Hz, 1H), 6.23 
(s, 1H), 5.50 (s, 1H), 5.08 (b.s., 1H), 4.97 (dd, J = 2.9/10.1 Hz, 1H), 4.05-4.16 (multiple peaks, 
2H), 3.97 (b.s., 1H), 3.75 (m, 8H), 3.61 (dd, J = 3.5/9.8 Hz, 1H), 3.56 (b.s., 1H), 3.35-3.40 (multiple 
peaks, 7H),  3.25 (t, J = 7.3 Hz, 3H), 3.02-3.11 (multiple peaks, 3H), 2.86 (s, 2H), 2.52-2.65 
(multiple peaks, 20H), 2.30 (s, 5H), 1.89 (m, 13H), 1.58-1.68 (m, 3H), 1.19-1.33 (multiple peaks, 
26H), 1.09-1.19 (multiple peaks, 13H), 1.02 (d, J = 6.7 Hz, 4H), 0.85-0.94 (multiple peaks, 6H); 
13C NMR (100Mhz, CD3OD) δ ppm 172.8, 159.9, 157.0, 144.4, 135.1, 133.6, 132.3, 131.7, 131.6, 
128.6, 128.5, 128.1, 126.5, 124.3, 119.9, 116.5, 88.3, 77.5, 75.1, 73.0, 10.0, 69.3, 69.2, 67.7, 
67.3, 66.3, 64.3, 57.7, 40.7, 35.6, 35.4, 34.3, 32.0, 29.6, 24.3, 21.3, 20.2, 20.0, 18.2, 17.7, 15.9, 
11.9, 10.1, 9.8, 7.8, 1.4; HRMS (DART-TOF) m/z calcd. for C51H83BF2N4O13 [M+H]+ 1009.60521, 
found 1009.60529 
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Compound 1.50: Compound 1.49 (3.7mg, 0.01 mmol) and BODIPY TMR-X succinimide ester 
(5 mg, 0.0082 mmol) were dissolved in DMF (0.55 mL, dry) and Et3N (1.9 mg, 0.019 mmol) was 
added. The reaction stirred at rt overnight while shielded from light. Upon completion, the DMF 
was distilled off and the residue purified by column chromatography (0-10% MeOH:CHCl3) to 
yield title compound 1.50 (6.9mg, 85%) as a purple solid; 1H NMR (400Mhz, CDCl3) δ ppm 8.07 
(d, J = 8.9 Hz, 1H), 7.77 (d, J = 8.3 Hz, 2H), 7.19 (s, 2H), 7.01 (s, 1H), 6.85-6.92 (multiple 
peaks, 3H), 6.45 (d, J = 4.2 Hz, 1H), 6.05 (t, J = 4.87 Hz, 1H), 5.72 (d, J = 7.5 Hz, 1H), 5.19-
5.24 (multiple peaks, 3H), 4.30 (quint., J = 7.6/14.2 Hz, 1H), 4.10 (t, J = 9.15 Hz, 1H), 4.02 (dd, 
J = 5.3/10.0 Hz, 1H), 3.72-3.80 (multiple peaks, 4H), 3.63 (d, J = 2.6 Hz, 1H), 3.39-3.46 
(multiple peaks, 2H), 3.00-3.21 (multiple peaks, 3H), 2.89 (dd, J = 4.0/10.7 Hz, 1H), 2.59-2.77 
(multiple peaks, 3H), 2.45 (s, 3H), 2.32 (s, 3H), 2.16-2.27 (multiple peaks, 3H), 2.13 (s, 3H), 
2.10 (s, 3H), 1.70-2.06 (multiple peaks, 10H), 1.28-1.61 (multiple peaks, 8H), 1.12-1.26 (multiple 
peaks, 10H), 1.07 (d, J = 6.69 Hz, 4H), 0.77-0.85 (multiple peaks, 6H); 13C (100Mhz, CDCl3) δ 
ppm 177.0, 173.6, 172.0, 160.8, 159.9, 140.5, 135.3, 134.8, 131.0, 128.2, 125.8, 123.1, 118.6, 
114.1, 89.2, 72.0, 71.4, 69.5, 69.0, 68.9, 63.2, 55.7, 53.2, 46.7, 42.4, 39.6, 38.3, 38.0, 36.6, 
36.3, 36.0, 30.0, 29.4, 26.6, 25.5, 21.9, 20.5, 16.8, 14.9, 16.6, 9.9; HRMS (DART-TOF) m/z 
calcd. for C45H65BF2N6O8 [M+H]+ 899.4725, found 899.4513. 
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Chapter 2 
A Versatile Method for the Preparation of Alkylated Kanosamine Sugars 
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2.1. Introduction to amines 
Amine groups are ubiquitous in biology and biologically active compounds.1 This 
versatile chemical group is found in neurotransmitters, alkaloids, and proteins, as well as many 
other classes of compounds. Owning to natures broad use of amines are the advantageous 
properties which they confer. In proteins, amines are typically in a protonated, ammonium, state. 
This facilitates many processes such as the binding to anionic DNA fragments by DNA binding 
proteins.2 Ammonium groups also form salt bridges with other chemical groups, including 
carboxylate groups, which aid in protein function.3 
Properties of amines on small molecules offer similar effects. Basic amine groups can 
become protonated and positively charged. The ionic nature of such compounds allows for the 
formation of salts, which can not only aid in synthetic efforts, but also allows solubility in 
aqueous solution.1 Amines on small molecules also participate in hydrogen bonding 
interactions, as well as electrostatic interactions. The effect of these interactions is crucial for 
many binding events which confer biological activity to the compounds. Therefore, it is not 
surprising that amines are highly prevalent in pharmaceutical compounds and discovery efforts 
for such compounds.  
2.2. Synthetic utility of amines 
As a synthetic handle, the reactivity of amines is broad. They can be used to form 
amides with activated carboxylic acids, imines with carbonyl compounds, as reagents in 
multicomponent reactions, transformed to nitroso groups by oxidation, or to biorthogonal azide 
groups among many other transformations. An illustrative example of amine reactivity in the 
field of drug discovery is that of azithromycin. 
Erythromycin, the first 14-membered macrolide, has been in clinical use since the early 
1950s. Improvement upon this naturally derived compound via semisynthesis and isolation of 
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other natural macrolides led to the clinical application of spiramycin, roxithromycin, 
dirithromycin, and clarithromycin, which all exhibit improved pharmacological properties.4 
Expansion upon the 14 membered macrocylic ring, and insertion of a basic nitrogen, to yield a 
15 membered macrolide, azithromycin, was a breakthrough in the field of antibiotics in the 
1980s.4 
Synthesis of this blockbuster drug commenced with the reaction of erythromycin with 
hydroxyl amine, forming the erythromycin oxime intermediate (XII, Scheme 2.1). Following this 
initial step is a key Beckmann rearrangement reaction. This reaction is characterized by the 
migration of an alkyl group which positions the nitrogen in the macrolide ring and leads to the 
formation of an imino-ether intermediate XIII. Hydrogenation cleaves this ether functionality and 
yields the free amine intermediate (not shown). Following is the final step in the synthesis, a 
mono alkylation of the free amine, via reductive amination, to the N-methyl compound, 
azithromycin. 
Scheme 2.1. Azithromycin semisynthesis form erythromycin 
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Key to the activity of azithromycin is the simple final step of amine methylation. This is 
but one case showing how alkylation of amines is a powerful diversification strategy and can 
potentiate biological activity of the compound drastically. Perhaps one of the best examples of 
amine alkylation modulating biological activity is that of the neurotransmitter serotonin (XIV). 
Serotonin is amongst the most well-known neurotransmitters in popular culture and plays a role 
in numerous physiological processes including cognition, memory, learning, and emotional 
states.5 
Nature has made use of an amine methylation strategy to diversify this integral 
neurotransmitter to its dimethyl analog, psilocin (XV, Figure 2.1). Psilocin, and its 
phosphorylated counterpart psilocybin (XVI), are the active components of psychedelic 
mushrooms, whose use is documented as far back as an estimated 10,000 years.7 Exhibiting 
effects similar to that of notorious psychedelics DMT (XVII) and LSD (XVIII), these compounds 
are theorized to have had significant implications in the development of human culture.6  
Both psilocin and psilocybin were first isolated, and named, by Swiss chemist Albert Hofmann, 
famous for the discovery of LSD. Hofmann was later successful in devising synthetic routes to 
these chemicals.8 
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Figure 2.1. Serotonin dimethylation and its psychedelic analogs 
 
With the power to influence activity in such drastic fashion, methodologies for the 
alkylation of amines has seen a great deal of effort in their development over the years. One of 
the simplest techniques used for alkylation of amines is the nucleophilic reaction of an alkyl 
halide with an amine or ammonia (Scheme 2.2).9 Problematic in these reactions is that the 
primary and/or secondary amine product can in turn react with the alkyl halide producing 
unwanted higher order products.9 For this reason, this method is mostly used in the synthesis of 
tertiary amines. Furthermore, in industrial applications, amines are generally alkylated using 
alcohols as the alkylating agent, as the use of alkyl halides is not advantageous on scale. 
Scheme 2.2: Alkylation with alkyl halides 
 
 
Reactions of amines with aryl halides, nucleophilic aryl substitution, are very sluggish 
and require activated aryl rings in the cases where they do succeed. In such cases, Pd 
catalyzed reactions, such as Buckwald-Hartwig coupling, are best (Scheme 2.3).9,10 
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Scheme 2.3. Aryl amines via Buckwald-Hartwig coupling 
 
 
Reductive amination, as in previously mentioned synthesis of azithromycin, converts a 
carbonyl to an alkyl amine through an imine intermediate. The Escweiler-Clark reaction, and 
analogous reactions with borohydride reducing agents, are powerful and robust methods of 
forming amines by reduction processes.11 Limiting the utility, however, is that these reactions 
typically give rise to tertiary amines as products.9 In the case of azithromycin, this was desired, 
but this is not always the case. When one desires a mono alkylated amine, the procedures are 
limited as N-alkylation tends to be an unselective synthetic operation.  
Techniques developed for mono alkylation include the Delepine reaction, and the 
Gabriel synthesis (Scheme 2.4). The previous being a reaction between benzyl or alkyl halides 
with the commercially available reagent, hexamethylenetetramine XIX. This reaction produces a 
quaternary ammonium salt XX which is then subjected to acidic conditions to liberate the 
primary amine XXI.9,12 
The latter process again invokes the use of alkyl halides, this time in reaction with a 
phthalimide salt XXII. The intermediate N-alkyl phthalimide XXIII, is then treated with hydrazine 
which facilitates a hydrazinolysis to give the primary amine and phthalhydrazide.9,13 
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Scheme 2.4. Techniques for the mono alkylation of amines 
 
 
2.3. Aminoglycosides 
As stated, amines are ubiquitous in biology and biologically relevant molecules, and 
amine containing compounds are prevalent in pharmaceutical compounds. Highly illustrative of 
this are the aminoglycoside (AG) class of antibiotics. The AGs are a family of related 
compounds which display Gram-negative antibacterial activities.14 Characteristic to this class, 
they contain amino modified sugars in their structure as well as a deoxystreptamine ring bearing 
two primary amines. However, the first in class clinical compound for this class, streptomycin, 
lacks the deoxystreptomine ring in place of a furanose ring (Figure 2.2).  
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Figure 2.2. Representative compounds of the aminoglycoside family of antibiotics 
 
 
In clinical practice, AG antibiotics, which had not been considered an option for some 
time, have seen a resurgence in their utilization given the emergence of infections caused by 
MDR bacteria (See chapter one for more on MDR). Clinical use has been hindered by common 
side effects such as nephro- and ototoxicity.15 While AGs remain active against many clinical 
isolates of MDR bacteria, their toxicity limits their utility. The observed retention of activity gives 
promise that these compounds hold potential for new generations with improved 
pharmacodynamic properties to alleviate such issues. A member of the AG class, and a target 
of research in our lab, which has been given new life in light of resistant bacteria are the 
kanamycins (Figure 2.3). 
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Figure 2.3. Structures of Kanamycin A and B 
 
 
2.4. Mechanism of action 
AGs, including Kanamycins A and B, are a potent class of antibiotics that act via protein 
synthesis inhibition. This mechanism of action requires binding to the ribosome as the key factor 
to their potency. Just as the structures of AGs vary, so too do the specifics of their binding 
interactions. In general, AGs derive their activity by interacting with 16s rRNA of the decoding A-
site of the bacterial ribosome. Crystal structures of various AGs in complex with oligonucleotides 
mimicking the A-site topology show that AG binding enforces that A1492 and A1493 take up a 
“bulged-out” conformation that leads to a loss in translational fidelity (Figure 2.4).16,18 
Additionally, the neamine (rings A and B) portion of the AGs are conserved in their binding 
orientation over the class of compounds. Other carbohydrate rings of AGs are found to be less 
ordered in their binding orientations, yet still confer much needed interactions.  Due to their 
polycationic nature, AGs also owe much of their binding properties to electrostatic interactions 
which are in part derived from these rings structures (C, D, E, etc..).17,18 
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Figure 2.4. Aminoglycoside binding to 16s rRNA18 
 
*Figure reproduced for use in this thesis with permission of publisher (Portland Press) 
 
2.5. Resistance mechanisms and diversification efforts 
Resistance mechanisms to AGs are predominantly due to aminoglycoside modifying 
enzymes (AMEs).19 This is in contrast to primary resistance mechanisms to other classes of 
antibiotics, such as the macrolides, where ribosomal base mutation and methylation dominate 
resistance. AMEs act on the AGs and facilitate acetylation, phosphorylation, or nucleotide 
addition to their structure. These modifications irreversibly render the compounds inactive 
against the bacteria (Figure 2.5). 
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Figure 2.5. Sites of modification by AMEs on kanamycin B19 
 
*Figure reproduced for use in this thesis with permission of publisher (Future Science) 
 
 
Based on these molecular level understanding of resistance and binding, many studies 
have been conducted to develop derivatives of the kanamycins. 
Analysis of crystal structure data lead a team of researchers to identify the C4’ position 
of ring A of the neamine moiety to be a position which would benefit from chemical 
modification.20 Efforts to do so by direct modification of Kanamycin B were unsuccessful and the 
researchers were forced to take a glycosylation approach to access the desired compounds. In 
their route, they first disconnected ring A from kanamycin B to yield a glycosyl acceptor 
containing rings B and C. Protecting group modification and epimerization led to a thioglycoside 
glycosyl donor based on Ring A which now bore a protected C4- amino group. NIS activated 
glycosylation conditions gave rise to a protected C4-amino Kanamycin intermediate. 
Subsequent modification and deprotection steps yielded a small series of C-4-amine/amide 
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derivative of kanamycin B (Table 2.1). Compounds were then subjected to MIC assays against 
standard and resistant strains of Gram-positive and Gram-negative bacteria, with kanamycin A 
and B as controls. Remarkably, antibiotic activity was retained across the series, showing at 
times even better activity than the parent compounds themselves. Of note, is that compounds 
XXVI and XXIX displayed enhanced activity against strains with known resistance mechanisms. 
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Table 2.1. C4-modified kanamycin derivatives and their MIC activity20 
 
 
In a different approach, a series of conformationally constrained Kanamycin A 
derivatives were studied by the Li research group.21 By bridging the C2’-OH of the neamine ring 
(A) with the 5’-OH of the central deoxystreptamine ring (B) constrained rotation between the two 
rings was achieved (Table 2.2). The methodology resulted in the formation of 8-, 9-, 10-, and 
11-membered ethers of Kanamycin A. This modification has the ability limit conformational 
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freedom and pre-configure the molecule for binding to the rRNA target. Also, of advantage is 
that these sites would be masked from deactivation by AMEs. MIC activity for the series was 
found to vary with the length of the chain linking the two rings, though no analog performed 
better than Kanamycin A itself.  
Table 2.2. Conformationally constrained kanamycin derivatives and their MIC activity  
 
 
In addition to the Neamine core (rings A and B), the Kanamycins bear a 3-deoxy-3-
amino glucose unit (kanosamine, ring C in Figure 2.3) that aides in recognition via electrostatic 
and hydrogen bonding interactions.17 This ring is integral to binding with the ribosome, and a 
site of acetylation by AMEs.4 Modification of this motif was the central aspect of work employing 
a glycodiversification approach by Chang and coworkers.22 A library of Kanamycin B derivatives 
varying the placement and number of the amino groups on the C ring were synthesized utilizing 
a neamine glycosyl acceptor and a modified C ring thioglycoside donor sugar. Activation using 
NIS and TfOH gave glycoside products with varying anomeric selectivity and modest yields. 
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Subsequent deprotections gave final products (XXXV-L) which were then evaluated by MIC 
assays against standard e. coli and s. aureus strains (Table 2.3). No compound in the series 
performed better than kanamycin B itself, however activity was retained in most cases. Results 
also reinforced the placement of the amino group at the natural C3 position. 
Table 2.3. Kanosamine modified kanamycin derivatives and their MIC activity22 
 
 
The examples given show that the kanamycins are applicable to broad diversification 
strategies, where their antibacterial activity is retained and/or improved. Drawing from the 
observed conservation of binding confirmation of the neamine core, and the preferred natural 3-
amino confirmation of the kanosamine sugar we began to wonder if alkyl modification to this 
functional group could yield positive results. While several studies on AG derivatives have been 
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conducted, a study using N-alkylated kanosamines has yet to be reported. Here we present a 
methodology for accessing various N-alkyl kanosamine derivatives, including mono, di-, and 
mixed compounds, and attempts at their incorporation into kanamycin B analogs 
2.6. Project design 
In the course of our PGD studies we became interested in changing the sugar itself, 
which led us to the synthesis of alkylated kanosamines. Kanosamine analogs were attractive 
targets because of their additional functionality relative to desosamine. We envisioned starting 
with N,N-dimethyl kanosamine, whose structure formally adds a hydroxyl group at C6 relative to 
desosamine ( as well as C4 hydroxyl). The C6 hydroxyl group could ultimately be an additional 
site of diversification (Figure 2.6). 
Figure 2.6. Proposed C6 acetylation of PGD compounds 
 
 
Initial synthesis of the N,N-dimethyl analog led us to believe that we could improve upon 
our synthetic route as well as access other alkylation patterns on the amine. Herein, we 
describe our efforts at optimizing the synthesis of the N,N-dimethyl analog and subsequent 
reaction scope studies to access novel mono-, di-, and mixed alkyl derivatives of kanosamine.  
2.7. Results and discussion 
In our efforts to synthesize the N,N-dimethyl compound we recognized the utility of known 
triflate 2.2, itself obtained from the epimerized product of 2.1, as a useful intermediate. Treatment 
of 2.2 with an excess of dimethylamine in a pressure vessel, followed by acid catalyzed acetonide 
deprotection, gave dimethyl kanosamine 2.4 in 96% yield over two steps (Scheme 2.5). 
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Optimization of the amine equivalents, triflate concentration, and volume of the pressure vessel 
were all required to obtain this yield. The challenges encountered when using other amine 
partners required a different route if additional analogs were to be obtained. We turned, therefore, 
to a reductive amination approach in place of triflate displacement. Reductive amination using 2.6 
as the amine presented itself as a robust and facile method. Synthesis of 2.6 followed a previously 
established synthetic route to kanosamine.23 
Scheme 2.5. Synthesis of dimethyl kanosamine through key triflate intermediate 
 
*a, b, c, d: See experimental for conditions 
 
 
Epimerization of diacetone D-glucose 2.1, through an oxidation-reduction sequence, gave 
the C3-epimerized allo-configured product (not shown) in 86% yield over two steps. Its treatment 
with triflic anhydride and pyridine then converted it to triflate 2.2. Without further purification, this 
compound was then subjected to nucleophilic displacement using sodium azide to give 
intermediate 2.5 (96% over two steps) followed by reduction with LiAlH4 yielding amine 2.6, 
diacetone D-kanosamine, as a single diastereomer in 86% yield. To test the reductive amination, 
amine 2.6 was reacted with three equivalents of both formaldehyde and sodium 
cyanoborohydride. TLC indicated complete consumption of the starting material after two hours. 
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Workup and purification of the crude material via column chromatography gave N,N-dimethyl 
kanosamine diacetonide 2.3 in near quantitative yield. This represented a significant improvement 
on the previous route using pressure vessel. 
Following on the heels of the successful preparation of 2.3 by reductive amination, we 
aimed to extend the methodology to other N-alkylated derivatives. The scope was tested using a 
series of aldehydes and ketones (Table 2.4). To our delight, the reactions proceeded in very good 
yields (91-97%), similar to the initial reaction with formaldehyde. Di-alkylation products were 
observed in the case of small aldehydes such as formaldehyde and acetaldehyde (entries 1 and 
2), which gave products 2.3 and 2.7. Longer chain aldehydes primarily gave mono-alkylation. 
Table 2.4. mono and di alkylations of diacetonide substrate  
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Propionaldehyde (entry 3) gave 2.8 whereas butyraldehyde (entries 4 and 5) gave both 
mono- (2.9) and di-alkylated (2.10) products in separate runs, where di-alkylated product was the 
only exception to the trend. The methodology was further extended to aromatic aldehydes such 
as benzaldehyde or vanillin, yielding products 2.11 and 2.12. Reactivity with ketones proceeded 
to give mono-alkylation products (entries 8-10), giving products 2.13-2.15.  
The observed mono alkylations are most likely due to steric interactions between the substrate 
and aldehydes/ketones that prevents di-alkylation. Due to the required iminium intermediate in 
the mechanism, the congested amine disfavors di-alkylation for bulky carbonyls. 
We next considered exploiting the mono-alkylation selectivity to prepare disubstituted 
analogs containing two different alkyl groups. The logic was to do serial alkylations in one pot - 
first with a large aldehyde or ketone, and then a small one to give the mixed di-alkyl product. To 
test the approach, amine 2.6 was reacted with 1.5 equivalents of propionaldehyde under the 
established reaction conditions, monitored by TLC. Upon consumption of starting material and 
formation of a less polar spot, excess formaldehyde was added. After a short period, a new spot 
appeared on TLC, accompanied with the disappearance of the mono-alkylated product. Work up 
and purification gave N-methyl,N-propyl derivative 2.16 in high yield (97%) with no evidence of 
N,N-dimethyl or N-propyl side products. The scope of this methodology to form mixed alkyl 
derivatives was then extended as summarized in Table 2.5. Other carbonyl partners such as 
butyraldehyde, benzaldehyde, vanillin, cyclohexanone, and acetone were utilized in the reaction 
sequence with formaldehyde to deliver products 2.17-2.21 in 91-97% yield (entries 2-6). 
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Table 2.5. Mixed alkylations of diacetonide substrate 
 
 
 
Deprotection of purified alkylated acetonide intermediates (2.3, 2.7-2.21) was 
accomplished by treatment with 2 M HCl. Evaporation of the acidic aqueous solution upon 
completion gave rise to the corresponding hydrochloride salts 2.4, 2.22-2.37 in quantitative yields 
(Scheme 2.6) 
Scheme 2.6. Acid catalyzed diacetonide cleavage 
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In a case of interesting reactivity, in early experiments with dimethyl compound (2.3), 
acetonide deprotection proceeded to give a mono deprotected product (Scheme 2.7). We 
attribute this reactivity to the use of less equivalents of HCl and a shorter reaction length. This 
was the only observed mono deprotection in the series and was not observed again even with 
the dimethyl compound. Following acetonide deprotection, acetylation gave compound 2.38, 
which was confirmed by NMR and mass spec studies. 
Scheme 2.7. Mono deprotection of dimethyl diacetonide substrate 
 
 
A telescoped sequence would eliminate the need for isolating the protected acetonide 
intermediate, and facilitate the formation of a pyranose suitable for further manipulation, starting 
from our key intermediate 2.6. To illustrate the strategy, 2.6 was alkylated with vanillin, then 
acetaldehyde, to form the dialkyl diacetonide intermediate LI (Scheme 2.8). Addition of HCl to the 
reaction mixture at this point served two purposes. It quenched the residual borohydride from the 
reductive amination and it also facilitated acetonide deprotection, giving lactol LII, which was not 
isolated. Workup to remove unreacted aldehyde was followed by acetylation and purification by 
chromatography to deliver 2.39 in 80% yield. Remarkably, the sequence included four reactions 
with only one chromatography. 
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Scheme 2.8. One pot mixed alkylation procedure to dialkyl peracetyl kanosamine 
 
 
 Synthetic efforts to make alkyl kanosamine derivatives has promise in leading to novel 
antibiotic compounds. To this end, it was our desire to incorporate these newly formed sugars 
into novel Kanamycin derivatives. Our efforts began with the formation of a suitable acceptor 
(2.42) derived from neomycin sulfate by a known process,22,24 and the formation of thioglycoside 
donor (2.44) of our kanosamine sugars (Scheme 2.9). 
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Scheme 2.9. Synthesis of neamine glycosyl acceptor and dimethyl kanosamine thioglycoside 
donor22,24 
 
 
 Attempts at glycosylation began by using previously established conditions to form 
kanamycin derivatives.22 using NIS and TfOH activators. These conditions were chosen due to 
their applicability to neamine acceptor and selectivity for the desired alpha anomeric 
configuration. Under these conditions we were unable to see product formation. Reactions 
resulted in re-isolation and/or degradation of starting materials.  
 Thinking the activator may be the cause of the lack of reactivity we then tried 
glycosylations with a Me2S2-Tf2O thioglycoside activator.25 The choice of this system was guided 
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by the need for a mild thioglycoside activator to alleviate degradation, and the ability to influence 
the anomeric configuration based on solvent ratios. Results with this activating system did not 
show significant improvement. However, trace amounts of non-isolatable product were identified 
via mass spectrometry. Having difficulty finding conditions for the desired reactivity we then set 
our efforts on getting the bond formation using more classical, less selective, methods. To 
determine whether the bond could be formed via glycosylation we used Koenigs-Knorr type 
conditions with the anomeric bromide (2.45, shown below) or thioglycoside (2.44) reacting with 
neamine based acceptor under AgOTf activating conditions. Under these conditions, we again 
only observed trace product formation at best and were unable to isolate any desired compound 
 We suspended our efforts to glycosylate our alkyl kanosamine compounds with 
neamine acceptor at this point. Use of the NIS/TfOH system by Chang and co-workers to yield 
kanamycin derivatives was carried out using benzyl protected azido sugars. It is our thinking 
that the acetate protected amino sugars we were trying to utilize have a negative electronic 
consequence on the reactivity which led us to observe no product formation. Furthermore, the 
presence of the amino functionality can lead to a protonated intermediate under glycosylation 
conditions which will disfavor oxocarbenium formation. In conjunction with the non-ideal donor, 
the neamine based acceptor bears two secondary hydroxyls on a somewhat crowded 
cyclohexyl (deoxystreptamine) ring. This makes for a weak nucleophilic partner for 
glycosylation, and taken together could be the reason for lake of observed reactivity. 
 In lieu of direct glycosylation of alkyl kanosamine sugars to neamine acceptor, we 
have theorized alternative methods for this coupling (Figure 2.7). One method to achieve this 
would be an azide-alkyne click chemistry approach. By conversion of the kanosamine sugar to a 
1-azido glycoside and functionalizing neamine with an alkyne we would set the compound up for 
an azide-alkyne cycloaddition. This route would require deprotection of azido groups on 
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neamine and would have to be carried out in aqueous alcohol solvent to address solubility 
issues of substrates. 
 Alternatively, an alkene-thiol radial coupling is envisioned as a means of linking the 
two compounds. Also considered a “click” type of chemistry, this reactivity would require the 
formation of a 1-thiol sugar, which has been shown to form readily though a thiourea 
intermediate in work by Shavva and coworkers.26 Rather than formation of a propargyl neamine 
derivative, an olefinic derivative would be needed. This functionalization is accessible in similar 
fashion to the propargyl neamine. 
 Lastly, it is proposed that a mitsonobu approach could be used to enact the desired 
transformation. This route would be possible by formation of a peracetyl kanosamine lactol, and 
a thiol functionalized neamine derivative. Treatment with azodicarboxylate reagent and 
triphenylphosphine in theory would facilitate the desired bond formation. 
 The alternative coupling strategies postulated rely on functionalized neamine 
derivatives at the C6 position of the deoxystrepamine ring (Ring C). Selective alkylation of C6 of 
deoxystreptamine is shown to be possible, and we believe use of our neamine acceptor (2.42) 
would give rise to the desired selectivity in alkylation at this position.27 
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Figure 2.7. Possible coupling techniques between neamine and kanosamines 
 
90 
 
 With the formation of kanamycin derivatives on the back burner we then turned our 
attention to applying our PGD methodology to the kanosamine derivatives formed in this 
study.28 Conversion of N,N-dimethyl lactol to the peracetate (2.43) with acetic anhydride was 
followed by formation of the anomeric bromide (2.45), in 56% yield over the two steps, which 
served as the donor for glycosylation reactions (Scheme 2.10). 
Scheme 2.10. Kanosamine lactol to anomeric bromide glycosyl donor 
 
 
 Using Ag2CO3 activating conditions glycosides 2.46-2.49 were furnished in moderate 
yields (46-55%) (Table 2.6).  
Table 2.6. Glycosylations of dimethyl kanosmaine anomeric bromide 
 
 
                                                       A: Donor, Acceptor (4 eq.), Ag2CO3 (3 eq.), 4Å mol sieves 
                                                       B: Donor, Acceptor (4 eq.), Ag2CO3 (3 eq.), I2, 4Å mol sieves 
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 The new glycosides contained latent reactivity handles that were exploited in post 
glycosylation diversification reactions. As a proof of concept, we conducted Suzuki couplings on 
bromobenzyl glycosides 2.48 and 2.49 to prepare, after de-acetylation, compounds 2.50 and 
2.51 in 82% and 72% yields, respectively (Scheme 2.11).  
Scheme 2.11. Palladium coupling diversifications on kanosamine PGD intermediates 
 
 
 Chloroethyl glycoside 2.47 was converted to the azido ethyl compound 2.52 by 
substitution, and was then subjected to a click reaction with phenyl acetylene to give, after de-
acetylation, compound 2.53 in 73% yield over two steps (Scheme 2.12). 
Scheme 2.12. Cycloaddition diversification on kanosamine PGD intermediate 
 
 
 As in our previous PGD efforts, we proposed the use of a cell free, in vitro 
transcription-translation assay that monitors the fluorescence of EmGFP to evaluate new 
compounds 2.50, 2.51, and 2.53.28 Compounds 2.51 and 2.53 exhibited inhibition of 
approximately 70% relative to negative control of protein synthesis in the absence of inhibitor 
(Figure 2.8). The m-mesityl compound 2.50 reduced protein synthesis by ~40%. 
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Figure 2.8. Co-transcription/translation assay results for kanosamine PGD compounds 
 
 These results show that the PGD methodology identified new protein synthesis 
inhibitors that are amenable to modification to improve pharmacological properties. While the 
PGD derivatives tested are limited to the dimethyl kanosamine sugar for simplicity in our proof 
of concept reactions, we are optimistic that the sugars with varying alkylation patterns presented 
in this study are promising candidates for subsequent series of PGD compounds. 
2.8. Conclusion 
 In conclusion, we have presented a method for the preparation of alkylated 
kanosamine sugars from diacetone D-glucose. The robust and versatile method allows mono, 
di- and mix alkyl patterns to be accessed in a single pot fashion. In addition, the method was 
further developed to take the diacetonide starting material to a peracetylated pyranose, with a 
single purification, over a four-step process. While efforts to incorporate the sugars yielded from 
this process into Kanamycin B derivatives fell short, they have been shown to be applicable to a 
diversification platform (PGD) which has identified novel inhibitors of bacterial protein synthesis.  
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2.9. Experimental 
Preparation of diacetone kanosamine substrate 
 
 
Compound 2.2: Diacetone d-allofuranose (664 mg, 2.55 mmol) was dissolved in dry DCM (7.6 
mL, 0.04 M). Pyridine (0.41 mL, 5.15 mmol) was added and the solution cooled to -30 oC. Triflic 
anhydride (864 mg, 3.06 mmol) was added dropwise over 15 min and stirring was continued at -
30 oC for 30 min. The reaction was then quenched with MeOH (1 mL), warmed to rt, diluted with 
DCM (5 mL) washed with H2O (2 x 5 mL), dried over Na2SO4  and concentrated to a clear, slight 
yellow oil (2.2 1.05 g, quantitative); 1H NMR (400MHz, CDCl3) δ ppm 5.85 (d, J = 3.7 Hz, 1H), 
4.92 (t, J = 5.7 Hz, 1H), 4.79 (d, J = 4.6 Hz, 1H), 4.10-4.24 (multiple peaks, 3H), 3.92 (dd, J = 
4.4/8.8 Hz, 1H), 1.60 (s, 3H), 1.46 (s, 3H), 1.40 (s, 3H), 1.37 (s, 3H); 13C NMR (100MHz, 
CDCl3) δ ppm 114.4, 110.3, 104.2, 80.0, 77.8, 77.7, 75.2, 66.3, 26.8, 26.5, 26.2, 24.8; HRMS 
(DART-TOF) m/z calcd for C13H19F3O8S [M+H]+ 415.0639, found 415.0776 
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Compound 2.5: 2.2 (800 mg, 2.04 mmol) and NaN3 (397 mg, 6.12 mmol) was dissolved in DMF 
(4 mL, 0.5 M) and allowed to stir at 50 oC overnight. Upon completion the reaction was 
quenched and washed with H2O (2 x 2 mL), extracted with EtOAc (3 x 2 mL), washed with brine, 
dried over Na2SO4 and concentrated to a clear to slightly yellow oil (2.5, 560 mg, 96%) which 
was used unpurified in the following synthetic step; 1H NMR (400MHz, CDCl3) δ ppm 5.84 (d, J 
= 3.8 Hz, 1H), 4.60 (d, J = 3.3 Hz, 1H), 4.23 (m, 1H), 4.05-4.15 (m, 3H), 3.96 (dd, J = 5.1/8.8 
Hz, 1H), 1.49 (s, 3H), 1.42 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 
112.2, 109.5, 105.0, 83.4, 80.4, 73.0, 67.6, 66.3, 26.8, 26.6, 26.1, 25.1; LRMS (ESI+) m/z calcd 
for C12H19N3O5 [M+Na] 308.13, found 308.10 
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Compound 2.6: 2.5 (280 mg, 0.98 mmol) was dissolved in dry Et2O (12.55 mL, 0.078 M) and 
cooled to 0 oC in an ice bath. Solid LiAlH4 (149 mg, 3.92 mmol) was added portion wise and the 
reaction was stirred and allowed to warm to rt over 2 hr. The reaction was then cooled again in 
an ice bath and quenched with H2O (2 mL), 1M NaOH (aq) (3 mL), followed by H2O again (2 
mL). The mixture was filtered through celite, dried over Na2SO4 and concentrated to a slight 
yellow oil (2.6, 215.9 mg, 85%); 1H NMR (400MHz, CDCl3) δ ppm 5.82 (d, J = 3.6 Hz, 1H), 4.32 
(d, J = 3.6 Hz, 1H), 4.06-4.17 (m.p., 2H), 3.89-3.99 (m, 2H), 3.48 (d, J = 3.4 Hz, 1H), 1.45 (s, 
3H), 1.38 (s, 3H), 1.29 (s, 3H), 1.24 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 11.4, 109.2, 
104.9, 86.4, 81.4, 72.9, 68.0, 57.3, 26.8, 26.7, 26.0, 25.2; LRMS (ESI+) m/z calcd for C12H21NO5 
[M+H]+ 260.14, found 260.60 
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Synthesis of mono- and di- alkyl diacetonides 
GP4: General procedure for mono and di alkylations 
A representative procedure is given for the synthesis of mono- and di- alkyl diacetonide 
compounds: Compound 2.3: 2.5 (59 mg, 0.23 mmol) formaldehyde (33% solution in MeOH, 3 
eq.) was dissolved in MeOH (1.14 mL, 0.2 M). Solid NaCNBH3 (3 eq.) was added followed by 
addition of glacial AcOH (pH 4-5, ~2 drops). The reaction was stirred at rt and monitored by TLC 
(25% EA:Hex). Upon consumption of the starting material (~2 hrs) the reaction was quenched 
with saturated NaHCO3 (aq.) (2ml), extracted with DCM (3 x 2 mL), washed with water (3 mL), 
brine (3 mL), dried over Na2SO4 and concentrated to a crude oil. The crude oil was purified by 
column chromatography (10-25% EA:Hex) to yield 2.3 (97%) as a colorless oil. 
 
 
 
Rf (0.3) (25%EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.8 Hz, 1H), 4.77 (d, J = 
3.9 Hz, 1H), 4.38 (dt, J = 5.3/9.1 Hz, 1H), 4.08 (3H, m), 3.19 (d, J = 5.6 Hz, 1H), 2.35 (s, 6H), 
1.51 (s, 3H), 1.43 (s, 3H), 1.38 (s, 3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 110.6, 
109.3, 105.0, 81.2, 78.0, 72.5, 69.4, 67.4, 43.1; HRMS (DART-TOF) m/z calcd for C14H25NO5 
[M+H]+ 288.1800, found 288.1893 
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Compound 2.7 was prepared according to GP4 in 95% yield as a colorless oil; Rf (0.70) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.76 (d, J = 4.0 Hz 1H), 4.74 (d, J = 3.7 Hz, 1H), 
4.27 (dt, J = 5.7/8.3 Hz, 1H), 4.11 (m, 2H), 3.99 (dd, J = 5.57.3 Hz,1H), 3.37 (d, J = 5.5 Hz,1H), 
2.61 (m, 2H), 2.49 (m, 2H), 1.50 (s, 3H), 1.41 (s, 3H), 1.35 (s, 3H), 1.31 (s, 3H), 1.04 (t, J = 7.0 
Hz, 6H); 13C NMR (100MHz, CDCl3) δ ppm 110.6, 108.8, 105.2, 81.6, 80.5, 72.9, 67.3, 66.6, 
44.9, 26.9, 26.6, 25.9, 25.1, 13.6; HRMS (DART-TOF) m/z calcd for C16H29NO5  [M+H]+ 
316.2113, found 316.2128 
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Compound 2.8 was prepared according to GP4 in 93% yield as a colorless oil; Rf (0.15) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.7 (d, J = 3.8 Hz,  1H), 4.55 (d, J = 4.1 Hz, 1H), 
4.17 (m, 3H), 3.98 (dd, J = 5.1/8.3 Hz, 1H), 3.29 (d, J = 3.6 Hz,1H), 2.67 (m, 2H), 1.52 (m, 5H), 
1.43 (s, 3H), 1.37 (s, 3H), 1.33 (s, 3H), 0.95 (t, J = 7.4 Hz, 3H); 13C NMR (100MHz, CDCl3) δ 
ppm 111.3, 109.3, 105.1, 83.4, 81.2, 72.9, 68.2, 64.0, 49.8, 26.8, 26.1, 25.3, 23.1, 11.6; HRMS 
(DART-TOF) m/z calcd for C15H27NO5 [M+H]+ 302.1957, found 302.2000 
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Compound 2.9 was prepared according to GP4 in 92% yield as a colorless oil; Rf (0.15) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.87 (d, J = 3.9 Hz, 1H), 4.55 (d, J = 4.2 Hz,1H), 
4.17 (m, 3H), 3.96 (dd, J = 5.0/8.1 Hz, 1H), 3.29 (d, J = 4.1 Hz, 1H), 2.76 (m, 1H), 2.65 (m, 1H), 
2.38 (bs,1H), 1.82 (m, 1H), 1.45-1.6 (m, 7H), 1.43 (s, 3H), 1.3-1.4 (m, 9H), 0.99 (t, J = 6.8 Hz, 
2H), 0.94 (t, J = 6.8 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 111.3, 109.4, 105.1, 83.3, 81.1, 
72.9, 68.2, 47.6, 32.0, 26.8, 26.1, 25.3, 20.2, 17.9, 13.9, 13.4; HRMS (DART-TOF) m/z calcd for 
C16H29NO5 [M+H]+ 316.2113, found 316.2128 
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Compound 2.10 was prepared according to GP4 in 33% yield as a colorless oil; Rf (0.80) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.7 Hz, 1H), 4.75 (d, J = 3.7 Hz, 1H), 
4.30 (m, 1H), 4.11 (dd, J = 5.3/8.1 Hz, 2H), 3.95 (dd, J = 6.4/8.1 Hz, 1H), 3.35 (d, J = 4.6 Hz, 
1H), 2.47-2.57 (m, 2H), 2.38-2.46 (m, 2H), 1.52 (s, 3H), 1.20-1.47 (m.p., 20H), 0.91 (t, J = 6.8 
Hz, 6H); 13C NMR (100MHz, CDCl3) δ ppm 110.5, 108.8, 105.3, 81.9, 80.5, 72.7, 67.6, 67.0, 
51.5, 30.7, 26.8, 26.6, 25.9, 25.5, 20.3, 14.1; HRMS (DART-TOF) m/z calcd for C20H37NO5 
[M+H]+ 372.1776, found 372.1776 
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Compound 2.11 was prepared according to GP4 in 96% yield as a colorless oil; Rf (0.30) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.33-7.4 (m, 6H), 5.89 (d, J = 3.9 Hz,1H), 4.68 (s, 
1H), 4.59 (d, J = 3.8 Hz, 1H), 4.25 (m, 1H), 4.15 (dt, J = 5.8/8.6 Hz, 2H), 3.97 (dd, J = 5.2/8.2 
Hz, 2H), 3.85 (d, J = 13.7 Hz,1H), 3.37 (d, J = 4.0 Hz, 1H), 1.53 (s, 3H), 1.42 (s, 3H), 1.38 (s, 
3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 139.6, 129.0, 128.5, 128.0, 127.2, 127.0, 
111.5, 109.4, 105.1, 83.4, 81.1, 72.9, 68.1, 63.3, 51.6, 26.8, 26.2, 25.3; HRMS (DART-TOF) m/z 
calcd for C19H27NO5 [M+H]+ 350.1957, found 350.2034 
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Compound 2.12  was prepared according to GP4 in 94% yield as a colorless oil; Rf (0.15) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 6.87 (m, 3H), 5.89 (d, J = 3.4 Hz, 1H), 4.59 (d, J = 
4.1 Hz, 1H), 4.29 (dt, J = 5.8/8.8 Hz,1H), 4.16 (m, 2H), 3.99 (dd, J = 5.1/8.1 Hz, 1H), 3.86-3.9 
(m, 2H), 3.88 (s, 3H), 3.7 (d, J = 13.3 Hz, 1H), 3.36 (d, J = 4.3 Hz, 1H), 1.52 (s, 3H), 1.43 (s, 
3H), 1.38 (s, 3H), 1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 146.6, 144.8, 131.6, 120.7, 
114.3, 111.5, 110.7, 109.3, 105.1, 83.4, 81.1, 72.9, 68.1, 63.2, 55.8, 51.5, 26.8, 26.2, 25.4; 
HRMS (DART-TOF) m/z calcd for C20H29NO7 [M+H]+ 396.2011, found 396.2002 
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Compound 2.13 was prepared according to GP4 in 91% yield as a colorless oil; Rf (0.40) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.82 (d, J = 4.2 Hz, 1H), 4.46 (d, J = 4.6 Hz, 1H), 
4.19 (m, 1H), 4.11 (m, 2H), 3.94 (dd, J = 5.4/8.4 Hz, 1H), 3.33 (d, J = 3.8 Hz, 1H), 2.93 (sep., 
18.4/11.8/5.5 Hz, 1H), 1.49 (s, 3H), 1.4 (s, 3H), 1.33 (s, 3H), 1.3 (s, 3H), 1.06 (dt, J = 6.3/5.1 Hz, 
6H); 13C NMR (100MHz, CDCl3) δ ppm 111.4, 109.1, 105.01 84.5, 80.9, 72.9, 67.9, 61.3, 46.7, 
26.8, 26.2, 25.3, 24.6, 22.5; HRMS (DART-TOF) m/z calcd for C15H27NO5 [M+H]+ 302.1957, 
found 302.1934 
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Compound 2.14 was prepared according to GP4 prepared in 96% yield as a colorless oil 
(mixture of two diastereomers); Diastereomer 1:Rf = (0.30) (25% EA:Hex); 1H NMR (400MHz, 
CDCl3) δ ppm 7.36 (m, 5H), 7.27 (m, 1H), 5.76 (d, J = 3.3 Hz, 1H), 4.31 (m, 2H), 4.20 (t, J = 7.9 
Hz, 1H), 3.96-4.16 (m, 4H), 3.31 (d, J = 2.9 Hz, 1H), 1.48 (s, 3H), 1.46 (s, 3H), 1.43 (s, 3H), 1.24 
(s, 3H), 1.22-1.62 (m, 11H); 13C NMR (100MHz, CDCl3) δ ppm 146.1, 125.5, 127.1, 126.6, 
111.4, 109.2, 104.7, 84.7, 81.3, 72.8, 68.1, 61.7, 56.4, 26.8, 26.7, 26.1, 25.5, 24.2; HRMS 
(DART-TOF) m/z calcd for C20H29NO5 [M+H]+ 364.2113, found 364.2127; Diastereomer 2: Rf = 
(0.25) (25% EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.30-7.41 (m, 4H), 7.22-7.29 (m, 1H), 
5.92 (s, 1H), 4.61 (s, 1H), 4.34 (m, 1H), 4.18 (t, J = 7.3 Hz, 1H), 4.08 (m, 1H), 3.96 (m, 2H), 3.12 
(s, 1H), 1.25-1.54 (m.p., 20H); 13C NMR (100MHz, CDCl3) δ ppm 144.6, 128.3, 126.7, 111.4, 
109.1, 105.0, 83.3, 80.8, 73.1, 67.8, 61.1, 55.4, 26.7, 26.7, 26.1, 25.4, 25.3; HRMS (DART-
TOF) m/z calcd for C20H29NO5 [M+Na] 386.1932, found 386.2102 
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Compound 2.15 was prepared according to GP4 in 92% yield as a colorless oil; Rf (0.45) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.85 (d, J = 3.8 Hz, 1H), 4.47 (d, J = 4.0 Hz, 1H), 
4.21 (m, 1H), 4.12 (m, 2H), 3.93 (dd, J = 5.5/8.1 Hz, 1H), 3.39 (d, J = 3.9 Hz, 1H), 2.55 (m, 1H), 
2.08 (m, 2H), 1.94 (m, 1H), 1.5-1.89 (m, 11H), 1.50 (s, 3H), 1.41 (s, 3H), 1.34 (s, 3H), 1.31 (s, 
3H), 0.97-1.29 (m, 7H); 13C NMR (100MHz, CDCl3) δ ppm 111.4, 109.1, 104.9, 84.4, 81.0, 72.9, 
67.9, 60.9, 54.4, 37.9, 34.6, 32.8, 26.7, 26.2, 26.0, 25.3, 25.0, 24.8, 24.5, 22.4; HRMS (DART-
TOF) m/z calcd for C18H31NO5 [M+H]+ 342.2270, found 342.2248 
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Synthesis and characterization of mixed alkyl compounds. 
GP5: General procedure for mixed alkylations: 
A representative procedure is given for the synthesis of mixed alkyl diacetonide compounds: 
Compound 2.16: 2.5 (59 mg, 0.23  mmol) along with propanaldehyde (1.5 eq.) was dissolved in 
MeOH (1.14 mL, 0.2M). Solid NaCNBH3 (3 eq.) was added followed by addition of conc. AcOH 
(pH 4-5, ~2 drops). The reaction was stirred at RT and monitored by TLC (25% EA:Hex). Upon 
consumption of the starting material 38% methanolic formaldehyde solution was added (0.1 mL, 
in excess). Upon consumption of the intermediate by TLC the reaction was quenched with 
saturated NaHCO3 (aq.) (2 mL), extracted with DCM (3 x 2 mL), washed with water (3 mL), brine 
(3 mL), dried over Na2SO4 and concentrated to a crude oil. The crude oil is purified by column 
chromatography (10-25% EA:Hex) to yield 2.16 (97%) as a colorless oil 
 
 
 
Rf (0.80) (25% EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.79 (d, J = 3.9 Hz, 1H), 4.77 (d, J = 
3.9 Hz, 1H), 4.36 (dt, J = 6.2/8.7 Hz, 1H), 4.12 (m, 2H), 4.02 (dd, J = 6.0/8.7 Hz, 1H), 3.29 (d, J 
= 5.4 Hz, 1H), 2.48 (m, 2H), 2.31 (s, 3H), 1.52 (s, 3H), 1.51 (m, 2H) 1.43 (s, 3H), 1.38 (s, 3H), 
1.33 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm110.6, 109.0, 105.2, 81.7, 79.3, 72.6, 68.6, 67.5, 
57.7, 39.5, 27.0, 26.6, 25.9, 25.6, 21.0, 11.5; HRMS (DART-TOF) m/z calcd for C16H29NO5 
[M+H]+ 316.2113, found 316.2206 
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Compound 2.17 was prepared according to GP5 in 95% yield as a colorless oil; Rf (0.85) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.78 (d, J = 3.6 Hz, 1H), 4.77 (d, J = 2.7 Hz, 1H), 
4.35 (dt, J = 6.0 Hz, 1H), 4.11 (m, 2H), 4.01 (dd, J = 5.8 Hz, 1H), 3.29 (s, 1H), 2.51 (m, 2H), 
2.30 (s, 3H), 1.51 (s, 3H), 1.42 (s, 3H), 1.37 (s, 3H), 1.33 (s, 3H), 1.25-1.53 (m, 6H), 0.92 (t, J = 
6.9 Hz, 3H); 13C NMR (100MHz, CDCl3) δ ppm 110.6, 109.1, 105.1, 81.6, 79.2, 27.7, 68.5, 55.6,  
39.5, 30.0, 26.9, 26.7, 25.9, 25.6, 20.2, 14.0; HRMS (DART-TOF) m/z calcd for C11H23NO5 
[M+H]+ 250.1644, found 250.1618 
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Compound 2.18 was prepared according to GP5 in 93% yield as a colorless oil; Rf (0.75) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.42 (d, J = 7.3 Hz, 2H), 7.33 (t, J = 6.9 Hz, 2H), 
7.27 (m, 1H), 5.86 (d, J = 3.9 Hz, 1H), 5.05 (dd, J = 16.4/24.0 Hz, 1H), 4.85 (d, J = 3.9 Hz, 1H), 
4.45 (m, 1H), 4.16 (m, 3H), 4.01 (dd, J = 6.5/9.9 Hz, 1H), 3.84 (d, J = 14.3 Hz, 1H), 3.67 (d, J = 
13.8 Hz, 1H), 3.42 (d, J = 4.7 Hz, 1H), 2.42 (m, 2H), 2.32 (s, 3H), 1.52 (s, 3H), 1.45 (s, 3H), 1.45 
(s, 3H), 1.35 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 139.0, 136.5, 128.3, 128.2, 128.0, 
127.0, 115.5, 110.7, 109.1, 105.2, 81.9, 79.3, 72.6, 68.5, 67.8,  60.9, 60.1, 39.3, 33.4, 28.8, 
28.0, 26.9, 26.6, 25.9, 25.7; HRMS (DART-TOF) m/z calcd for C20H29NO5 [M+H]+ 364.2113, 
found 364.2242 
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Compound 2.19 was prepared according to GP5 in 92% yield as a colorless oil; Rf (0.20) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 7.01 (s, 1H), 6.88 (m, 2H), 5.83 (d, J = 4.4 Hz, 1H), 
4.83 (s, 1H), 4.45 (m, 1H), 4.14 (m, 2H), 4.03 (dd, J = 5.6/8.6 Hz, 1H), 3.9 (s, 3H), 3.77 (d, J = 
13.3 Hz, 1H), 3.61 (d, J = 13.3 Hz,1H), 3.42 (d, J = 4.9 Hz, 1H), 2.3 (s, 3H), 1.5 (s, 3H), 1.43 (s, 
3H), 1.41 (s, 3H) 1.34 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 146.6, 121.1, 113.9, 110.8, 
105.0, 81.8, 79.3, 72.7, 68.0, 67.7, 30.0, 55.9, 39.2, 26.9, 26.6, 26.0, 25.7; HRMS (DART-TOF) 
m/z calcd for C21H31NO7 [M+H]+ 410.2168, found 410.2248 
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Compound 2.20 was prepared according to GP5 in 91% yield as a colorless oil; Rf (0.60) (25% 
EA:Hex); 1H NMR (400MHz, CDCl3) δ 5.80 (d, J = 3.7 Hz, 1H), 4.78 (d, J = 3.9 Hz, 1H), 4.28 (q, 
J = 5.7/13.4 Hz, 1H), 4.14 (dd, J = 4.6/7.3 Hz, 1H), 4.09 (dd, J = 5.9/13.4 Hz, 1H), 4.01 (dd, J – 
6.1/8.2 Hz, 1H), 3.36 (d, J = 4.8 Hz, 1H), 2.92 (sep., J = 6.2/12.7/18.1 Hz, 1H), 2.28 (s, 3H), 
1.51 (s, 3H), 1.41 (s, 3H), 1.36 (s, 3H), 1.31 (s, 3H), 1.08 (t, J = 6.6 Hz, 6H); 13C NMR (100MHz, 
CDCl3) δ ppm 110.5, 108.6, 105.1, 81.9, 81.7, 73.3, 66.9, 64.6, 55.2, 34.4, 26.9, 26.6, 25.9, 
25.7, 19.8, 18.4; HRMS (DART-TOF) m/z calcd for C16H29NO5 [M+H]+ 316.2113, found 
316.2206 
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Compound 2.21 was prepared according to GP5 in 92% yield as a colorless oil; Rf (0.80) 
(EA:Hex); 1H NMR (400MHz, CDCl3) δ ppm 5.79 (d, J = 3.8 Hz, 1H), 4.77 (b.s., 1H), 4.28 (q, J = 
6.0/13.3 Hz, 1H), 4.14 (dd, J = 4.8/7.3 Hz, 1H), 4.08 (dd, J = 6.2/8.1 Hz, 1H), 3.99 (dd, J = 
6.3/8.2 Hz, 1H), 3.39 (d, J = 3.2 Hz, 1H), 2.43 (b.s., 1H), 2.31 (s, 3H), 1.55-1.95 (m, 6H), 1.50 
(s, 3H), 1.40 (s, 3H), 1.35 (s, 3H), 1.30 (s, 3H), 1.02-1.28 (m, 5H); 13C NMR (100MHz, CDCl3) δ 
ppm 110.5, 108.7, 82.1, 81.9, 73.3, 66.9, 65.6, 64.5, 35.2, 29.2, 26.8, 26.6, 26.0, 25.2; HRMS 
(DART-TOF) m/z calcd for C19H33NO5 [M+H]+ 356.2426, found 356.2535 
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Synthesis and characterization of pyranose sugars 
GP6: General Procedure for acetonide deprotection 
A representative procedure is given for the synthesis of mixed alkyl diacetonide compounds: 
Compound 2.4: 2.3 (30 mg) was dissolved in 2M HCl (~2 mL) and allowed to stir at RT 
overnight. Upon completion (TLC showing a single spot at baseline with 1:1 EA:Hex), the 
aqueous solution was extracted with EtOAc (2 x 1 mL) to remove any residual organic soluble 
impurities. The aqueous solution was then concentrated under vacuum to yield 2.24 as its 
hydrochloride salt in quantitative yield. 
 
 
Rf (0.00) (EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.19 (d, J = 3.7 Hz, 1H), 4.65 (d, J = 7.3 Hz, 
1H), 3.3-4.08 (28H, m), 2.92-3.03 (26H, m); 13C NMR (100MHz, D2O) δ ppm 96.1, 91.4, 76.5, 
71.5, 70.1, 68.2, 67.5, 65.8, 63.6, 63.4, 60.1, 59.9, 41.5, 40.9; HRMS (DART-TOF) m/z calcd for 
C8H17NO5 [M+H]+ 208.1174 , found 208.1224 
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Compound 2.22 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.21 (d, J = 4.0 Hz, 1H), 4.67 (d, J = 8.0 Hz, 1H), 
3.13-4.0 (20H, m); 13C NMR (100MHz, D2O) δ ppm 96.0, 91.1, 76.8, 71.2, 70.5, 68.1, 65.9, 65.8, 
60.1, 60.0, 57.8, 55.1; HRMS (DART-TOF) m/z calcd for C6H13NO5 [M+H]+ 180.0861, found 
180.0947 
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Compound 2.23 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.20 (d, J = 3.6 Hz, 1H), 4.68 (d, J = 6.1 Hz, 1H), 3.2-
4.02 (29H, m), 1.34 (t, J = 7.2 Hz, 17H); 13C NMR (100MHz, D2O) δ ppm 96.2, 91.5, 76.6, 71.6, 
68.4, 67.4, 65.8, 64.9, 63.7, 63.5, 62.1, 60.1, 59.9, 48.6, 48.4, 48.1, 10.0; HRMS (DART-TOF) 
m/z calcd for C10H21NO5 [M+H]+ 236.1487, found 236.1532 
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Compound 2.24 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.21 (d, J = 3.5 Hz, 1H), 4.66 (d, J = 7.8 Hz, 1H), 
3.08-3.88 (18H, m), 1.7 (sep., J = 6.9/14.8/22.3 Hz, 4H), 0.94 (t, J = 7.4 Hz, 6H); 13C NMR 
(100MHz, D2O) δ ppm 96.1, 91.3, 76.7, 71.4, 69.2, 66.9, 64.6, 64.5, 63.1, 47.1, 47.1, 19.2, 10.2; 
HRMS m/z calcd for C9H19NO5 [M+H]+ 222.1331 , found 222.1397 
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Compound 2.25 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.20 (d, J = 3.6 Hz, 1H), 4.65 (d, J = 7.3 Hz, 1H), 
3.12-3.88 (18H, m), 1.66 (dt, J = 7.1/14.8 Hz, 5H), 1.36 (sep., J = 7.1/14.8/23.1 Hz, 5H), 0.87 (t, 
J = 7.7 Hz, 7H); 13C NMR (100MHz, D2O) δ ppm 96.2, 91.4, 76.7, 71.4, 69.2, 66.8, 64.6, 64.5, 
63.1, 45.3, 45.2, 27.5, 19.1, 12.7; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 
236.1487, found 236.1473 
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Compound 2.26 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (d, J = 3.5 Hz, 1H), 4.68 (d, 1H), 3.19-4.02 (m, 
32H), 1.74 (m, 10H), 1.35 (m, 10H), 0.89 (t, J = 7.7 Hz, 16H); 13C NMR (100MHz, D2O) δ ppm 
96.3, 91.6, 76.6, 71.6, 68.4, 65.9, 65.8, 63.7, 63.5, 63.1, 60.1, 59.9, 53.7, 53.6, 26.7, 19.3, 12.7; 
HRMS (DART-TOF) m/z calcd for C14H29NO5 [M+H]+ 292.2113 , found 292.2168 
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Compound 2.27 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.36-7.51 (m, 18H), 5.21 (d, J = 3.9 Hz, 1H), 4.62 (d, 
J = 7.8 Hz, 1H), 4.34-4.45 (m, 7H), 3.19-4.05 (m, 23H); 13C NMR (100MHz, D2O) δ ppm 130.0, 
129.77, 129.7, 129.3, 96.2, 91.3, 76.7, 69.5, 67.2, 64.9, 64.7, 62.7, 60.1, 60.0, 59.9, 49.6, 49.5; 
HRMS (DART-TOF) m/z calcd for C13H19NO5 [M+H]+ 270.1331 , found 270.1412 
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Compound 2.28 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.00 (s, 2H), 6.85 (m, 5H), 5.17 (d, J = 3.1 Hz, 1H), 
4.58 (d, J = 8.0 Hz, 1H), 4.25 (s, 5H), 3.12-3.97 (m, 26H), 1.97 (s, 3H); 13C NMR (100MHz, D2O) 
δ ppm 147.6, 146.0, 123.5, 122.9, 115.8, 114.0, 96.1, 91.3, 76.8, 71.4, 69.6, 67.3, 64.9, 62.5, 
60.1, 59.9, 59.7, 55.9, 49.6, 20.3; HRMS (DART-TOF) m/z calcd for C14H21NO7 [M+H]+ 
316.1385 , found 316.1454 
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Compound 2.29 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.18 (d, J = 3.9 Hz, 1H), 4.65 (d, J = 7.5 Hz, 1H), 
3.22-3.93 (m, 24H), 2.02 (s, 2H), 1.31 (d, J = 7.6 Hz, 22H); 13C NMR (100MHz, D2O) δ ppm 
96.1, 91.2, 76.7, 71.5, 70.7, 69.6, 66.1, 66.0, 61.8, 60.1, 60.0, 59.2, 57.8, 52.5, 18.8; HRMS 
(DART-TOF) m/z calcd for C9H19NO5 [M+H]+ 222.1331, found 222.1340 
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Compound 2.30 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.18 (d, J = 3.8 Hz, 1H), 4.64 (d, J = 7.3 Hz, 1H), 
3.26-3.99 (m, 24H), 2.09 (d, J = 11.0 Hz, 7H), 1.78 (d, J = 11.7 Hz, 7H), 1.59 (d, J = 12.5 Hz, 
3H), 1.05-1.42 (m, 18H); 13C NMR (100MHz, D2O) δ ppm 96.1, 91.3, 76.7, 71.4, 70.63, 68.2, 
66.0, 65.9, 61.4, 60.1, 59.9, 59.0, 58.9, 29.4, 24.4, 24.0; HRMS (DART-TOF) m/z calcd for 
C12H23NO5 [M+H]+ 262.1644, found 262.1652 
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Compound 2.31 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.19 (d, J = 2.3 Hz, 0.18H), 5.13 (d, J = 3.6 Hz, 1H), 
4.85 (q, J = 6.7/14.1 Hz, 3H), 4.47 (d, J = 7.5 Hz, 1H), 3.57-3.86 (m.p., 11H), 3.34-3.42 (m.p., 
3H), 3.13-3.26 (m.p., 1.3H), 3.02 (t, J = 10.2 Hz, 1.3H), 1.66 (dd, J = 1.4/6.9 Hz, 7.3H); 13C NMR 
(100MHz, D2O) δ ppm 136.0, 135.9, 129.7, 129.4, 127.8, 127.7, 95.9, 91.0, 76.6, 71.2, 70.1, 
67.7, 66.3, 66.1, 62.0, 59.9, 59.8, 59.6, 59.5, 19.4, 19.1; HRMS (DART-TOF) m/z calcd for 
C14H21NO5 [M+H]+ 284.1487, found 284.1451 
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Compound 2.32 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 6.02 (d, J = 4.0 Hz, 0.3H), 5.89 (d, J = 4.0 Hz, 1H), 
5.22 (dd, J = 3.5/7.8 Hz, 3H), 5.03 (m, 4H), 3.39-4.21 (m.p., 100H), 3.18 (m, 11H), 2.97 (m, 
33H), 1.76 (m, 23H), 0.90-0.99 (m.p., 35H); 13C NMR (100MHz, D2O) δ ppm 96.2, 96.1, 96.0, 
91.1, 91.3, 77.6, 76.6, 76.4, 75.1, 72.4, 71.5, 71.4, 70.6, 69.1, 68.4, 68.0, 67.4, 66.0, 65.8, 65.5, 
65.4, 64.9, 64.6, 63.6, 63.5, 63.4, 63.3, 63.2, 60.0, 60.0, 59.8, 58.3, 58.1, 53.5, 49.7, 48.4, 40.1, 
38.4, 38.3, 38.2, 28.2, 18.0, 9.9; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 236.1487, 
found 236.1481 
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Compound 2.33 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.02 (dd, 3.3/8.4 Hz, 1H), 3.20 (m, 3H), 1.71 (m, 7H), 
1.33 (sex., (7.2/14.3/21.8 Hz, 7H), 0.87 (t, 7.1 Hz, 10H); 13C NMR (100MHz, D2O) δ ppm 96.2, 
91.6, 91.3, 76.6, 71.5, 68.4, 68.1, 66.0, 64.8, 64.6, 63.5, 63.2, 60.0, 59.8, 38.3, 38.2, 37.8, 26.4, 
19.1, 12.7; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 250.1644 , found 250.1618 
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Compound 2.34 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 7.48 (s, 12H), 5.19 (d, J = 5.9 Hz, 1H), 4.48 (m, 3H), 
3.18-4.13 (m, 21H), 3.03 (s, 7H); 13C NMR (100MHz, D2O) δ ppm 131.0, 130.2, 129.4, 96.2, 
91.6, 77.6, 76.5, 75.2, 75.5, 71.5, 70.7, 69.2, 68.2, 66.2, 64.0, 63.7, 63.4, 63.1, 60.8, 60.1, 59.9,  
58.7, 53.5, 49.7, 48.5, 40.2, 38.0, 37.8, 37.5, 33.8, 28.3; HRMS (DART-TOF) m/z calcd for 
C14H21NO5 [M+H]+ 284.1487, found 284.1544 
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Compound 2.35 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.17 (m, 2H), 6.8-6.98 (m, 4H), 5.17 (m, 1H), 4.27-
4.63 (m, 6H), 3.21-4.06 (m, 23H), 2.98 (m, 6H); 13C NMR (100MHz, D2O) δ ppm 147.7, 146.3, 
124.6, 121.5, 121.5, 115.8, 115.7, 114.9, 114.7, 114.7, 96.2, 9.6, 76.5, 71.6, 68.4, 67.9, 66.1, 
65.7, 65.5, 63.6, 63.0, 62.7, 60.9, 60.0, 59.9, 59.8, 56.0, 37.6, 37.5, 37.1; HRMS (DART-TOF) 
m/z calcd for C15H23NO7 [M+H]+ 330.1542, found 330.1606 
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Compound 2.36 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (dd, J = 3.4/10.7 Hz, 1H), 4.68 (d, J = 3.8 Hz, 
1H), 3.42-4.20 (m, 23H), 2.89 (s, 6H), 2.89 (s, 3H), 2.62 (s, 3H), 1.37 (dd, J = 6.3/13.2 Hz, 19H); 
13C NMR (100MHz, D2O) δ ppm 96.2, 96.1, 91.7, 91.3, 76.6, 76.3, 71.6, 71.4, 68.5, 68.4, 67.2, 
66.0, 65.8, 64.5, 64.4, 63.8, 63.8, 63.6, 63.5, 60.2, 60.1, 60.0, 59.9, 59., 33.66, 33.6, 33.4, 33.2, 
20.4, 18.5, 18.4, 17.6, 17.5, 17.5, 17.4; HRMS (DART-TOF) m/z calcd for C10H21NO5 [M+H]+ 
236.1487, found 236.1627 
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Compound 2.37 was prepared according to GP6 in quantitative yield as a white solid; Rf (0.00) 
(EA:Hex); 1H NMR (400MHz, D2O) δ ppm 5.22 (dd, J = 3.5/9.2 Hz, 1H), 3.27-4.16 (m, 18H), 
2.87 (d, J = 4.0 Hz, 6H), 2.06-2.28 (m, 6H), 2.03 (s, 2H), 1.75-1.9 (m, 5H), 1.6 (d, J = 12.8 Hz, 
3H), 1.03-1.5 (m, 13H); 13C NMR (100MHz, D2O) δ ppm 96.3, 96.1, 91.7, 91.3, 76.6, 76.4, 71.6, 
71.4, 68.5, 68.3, 67.0, 67.0, 66.7, 66.6, 66.1, 65.7, 64.3, 64.2, 63.7, 63.6, 63.5, 60.2, 60.1, 59.9, 
33.4, 33.3, 33.2, 32.9, 29.4, 28.9, 28.8, 28.8, 27.9, 27.9, 27.8, 27.8, 24.5, 224.3, 24.0, 20.4; 
HRMS (DART-TOF) m/z calcd for C13H25NO5 [M+H]+ 276.1800, found 276.1890 
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Synthesis and characterization of one pot mixed alkylation 
 
Compound 2.39: 2.6 (330 mg, 1.27mmol) along with vanillin (289.84 mg, 1.90 mmol, 1.5 eq.) 
were dissolved in MeOH (6.35 mL, 0.2M). Solid NaCNBH3 (3 eq.) was added followed by the 
addition of conc. AcOH (pH 4-5, ~8 drops). The reaction was stirred at rt and monitored by TLC 
(25% EA:Hex). Upon consumption of the starting material acetaldehyde was added (0.25 mL, in 
excess). Upon consumption of the intermediate, conc. HCl was added (1.5 mL) to bring the 
solution to 2M in HCl and allowed to stir at rt overnight. Upon completion (TLC showing a single 
spot at baseline with 1:1 EA:Hex), the aqueous solution was extracted with EtOAc (2 x 4 mL) to 
remove any residual organic soluble impurities. The aqueous solution was then concentrated 
under vacuum to yield the corresponding crude alkyl kanosamine hydrochloride salt. The crude 
salt was then taken up in pyridine (5 mL) and an equal volume of acetic anhydride added (5 
mL). Upon stirring overnight, the solution was quenched with water (1 mL), washed with sat. 
bicarbonate (aq.) (3 x 4 mL), washed with water (2 x 3 mL), washed with brine, dried over 
Na2SO4 and concentrated to a crude oil. The crude oil is purified by column chromatography 
(10-25% EA:Hex) to yield 2.39 (562 mg, 80% over 4 steps, 57:43 α:β) as a yellow oil; 1H NMR 
(400MHz, CDCl3) δ ppm 6.92 (dd, 2.2/8.1 Hz, 1.76H), 6.87 (d, 3.3 Hz, 1.8H) 6.79 (t, J = 7.6 Hz, 
1.84H), 6.27 (d, 3.5 Hz, 1H), 5.62 (d, 7.6 Hz, 0.74H), 5.07-5.22 (m, 3.55H), 3.94-4.20 (m, 6.7H), 
3.80 (t, J = 6.6 Hz, 6.35H), 3.54-3.75 (m.p., 3.5H), 3.37 (t, J = 10.6 Hz, 1H), 3.18 (t, J = 10.1 Hz, 
0.74H), 2.59 (m, 3.8H), 2.28 (s, 6H), 2.59 (m, 3.8H); 13C NMR (100MHz, CDCl3) δ ppm 170.6, 
169.5, 169.2, 169.0, 168.9, 150.9, 138.7, 138.5, 122.1, 121.0, 120.9, 112.9, 112.8, 93.1, 89.5, 
74.1, 70.8, 69.1, 69.6, 66.3, 65.9, 62.4, 62.2, 62.0, 60.3, 58.0, 55.9, 21.0, 20.9, 20.8, 20.8, 20.7, 
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20.6, 14.3, 14.3, 14.1; HRMS (DART-TOF) m/z calcd for C24H33NO11 [M+H]+ 512.2121, found 
512.2140 
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Synthesis and characterization of PGD and neamine compounds 
 
 
 
Compound 2.43: 4 (840 mg, 3.45 mmol), was dissolved in pyridine (6 mL) and an equal volume 
of acetic anhydride (6 mL) was then added. The solution was allowed to stir at rt overnight and 
then quenched with water (1 mL), washed with sat. bicarbonate (aq.) (3 x 3mL), washed with 
water (2 x 3mL), washed with brine (3 mL), dried over Na2SO4 and concentrated to a crude oil. 
The crude oil was purified by column chromatography (15-40% EA:Hex) to yield 2.43 (1191 mg, 
92%) yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.16 (d, J = 3.18 Hz, 1H), 5.56 (d, J = 7.7 Hz, 
0.83H), 4.88-5.05 (m, 4H), 4.06-4.16 (m, 2H), 3.90-4.06 (m, 4H), 3.65 (m, 0.83H), 3.05 (t, J = 
10.85 Hz, 1H), 2.84 (t, J = 10.41 Hz, 0.87H), 2.27 (s, 12H), 1.92-2.02 (m, 23H); 13C NMR 
(100MHz, CDCl3) δ ppm 170.5, 169.4, 169.2, 169.2, 169.0, 168.8, 92.9, 89.4, 73.9, 70.6, 68.2, 
67.0, 65.6, 62.1, 62.0, 41.1, 41.0, 20.8, 20.7, 20.6; LRMS (ESI+) m/z calcd for C16H25NO9 
[M+H]+ 376.16, found 376.5 
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Compound 2.44: 2.43 (227 mg, 0.61 mmol), and 2-mercaptopyridine (101 mg, 0.91 mmol, 1.5 
eq.) were dissolved in DCM (4 mL, dry). 4 Å mol sieves (0.1 g) were added and the solution 
stirred for 30min. The solution was then cooled to 0 oC and BF3.Et2O (0.34 mL, 3.02mmol, 5 eq.) 
was added dropwise. The solution was stirred at 0 oC for 20 minutes and then warmed to rt and 
stirred overnight. Upon completion, the reaction was quenched and washed with sat. 
bicarbonate (aq.) (2 x 2 mL), washed with water (2 x 2 mL), washed with brine, dried over 
Na2SO4 and concentrated to a crude oil. The crude product was purified by column 
chromatography (10-40% EA:Hex) to yield 2.44 (152 mg, 59%) as a semi solid oil; 1H NMR 
(400MHz, CDCl3) δ ppm 8.39 (bs, 0.6H), 7.47 (dt, J = 1.4/8.1 Hz, 0.66H), 7.17 (d, J = 7.8 Hz, 
0.61H), 7.00 (t, J = 5.5 Hz, 0.64H), 6.19 (d, J = 3.6 Hz, 1H), 5.62 (d, J = 10.4 Hz, 0.65H), 4.92-
5.08 (3H, mp), 3.93, 4.08 (4H, mp), 3.72 (m, 0.68H), 3.08 (t, J = 10.5 Hz, 1H), 2.94 (t, J = 1.1 
Hz, 0.63H), 2.32 (s, 3H), 2.30 (s, 6H), 1.93-2.05 (mp, 17H); 13C NMR (100MHz, CDCl3) δ ppm 
170.6, 169.5, 169.4, 169.3, 169.2, 168.6, 156.1, 149.4, 136.4, 122.2,  120.5, 89.4, 83.0, 77.0, 
70.6, 68.9, 67.6, 67.6, 65.2, 65.5, 62.5, 62.4, 62.2, 60.2, 41.2, 41.1, 21.1, 20.9, 20.8, 20.8, 20.6, 
14.1; LRMS (ESI+) m/z calcd C19H26N2O7S [M+H]+ 427.15, found 427.50 
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Compound 2.45: 2.43 (428 mg, 1.28 mmol) was dissolved in DCM (2.5 mL, dry). The solution 
was cooled to 0 oC and a solution of HBr in AcOH (1.1 mL, 33 wt %HBr, 3.5 eq.) was added 
dropwise. The cooling bath was removed and reaction stirred for 4hrs at rt. Upon completion the 
reaction was pour over ice, and the organic fraction washed with sat. bicarbonate solution (4 x 2 
mL), washed with water (2 mL), washed with brine, dried over Na2SO4 and concentrated to a 
crude oil of 2.45  (300 mg, 60%). A portion of the product was purified by column 
chromatography (10-30% EA:Hex) for characterization; 1H NMR (400MHz, CDCl3) δ 6.52 (d, J = 
3.8 Hz, 1H), 4.94 (t, J = 10.8 Hz, 1H), 4.74 (dd, J = 3.9/10.8 Hz, 1H), 4.15 (dd,  J = 4.5/12.5 Hz, 
1H), 4.04-4.10 (m, 1H), 3.11 (t, J = 10.4 Hz, 1H), 2.27 (s, 6H), 2.01 (s, 3H), 1.97 (s, 3H), 1.96 (s, 
3H); 13C NMR (100MHz, CDCl3) δ 170.2, 169.3, 169.1, 89.8, 72.9, 69.1, 64.5, 62.9, 61.5, 41.2, 
20.8, 20.6, 20.5; LRMS (ESI+) m/z calcd C14H22BrNO7 [M+H]+ 397.0559, found 397.935 
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Compound 2.46: 2.45 (99 mg, 0.25 mmol), Ag2CO3 (207 mg, 3 eq.), chloroethanol (68 µL, 4 
eq.), 4 Å mol sieves, and a small I2 crystal were charged to a reaction vial covered in foil. DCM 
(2.5 mL, dry) was added and the mixture stirred at rt overnight. Upon completion the reaction 
was quenched with sat. bicarbonate (aq.) and the organic fraction washed with sat. Na2S2O3 
(aq.) (2 x 1mL), water (2 mL), brine (2 mL), dried over Na2SO4 and concentrated to a crude oil. 
Crude product was then purified by column chromatography (10-30% EA:Hex) to yield 2.46 (46 
mg, 49%) as a yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.22 (d,  J = 3.9 Hz, 0.16H), 5.81 
(oct. J = 4.9/10.4/16.4/21.4 Hz, 1H), 5.10-5.27 (multiple peaks, 2H), 4.96 (m, 2H), 4.41 (d, J = 
7.7 Hz, 1H), 4.28 (dd,  J = 4.3/12.8 Hz, 1H), 4.09 (m, 5H), 3.54 (oct., J = 2.7/5.1/7.9/9.6 Hz, 1H), 
3.09 (t, J = 11.2 Hz, 0.16H), 2.80 (t, J = 9.8 Hz, 1H), 2.30 (s, 7H), 1.98-2.05 (m.p.,12H); 13C 
NMR (100MHz, CDCl3) δ ppm 170.7, 169.4, 169.2, 133.6, 117.1, 100.7, 89.5, 73.1, 70.7, 69.4, 
67.7, 66.3, 65.6, 62.4, 62.2, 73.1, 70.7, 69.4, 67.7, 66.3, 65.6, 62.4, 62.2, 60.3, 41.2, 21.1, 21.0, 
20.7; LRMS (ESI+) m/z calcd C17H27NO8 [M+Na] 396.174, found 396.215 
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Compound 2.47: 2.45 (97 mg, 0.25 mmol), Ag2CO3 (207 mg, 3 eq.), chloroethanol (67 µL, 4 
eq.), 4 Å mol sieves, and a small I2 crystal were charged to a reaction vial covered in foil. DCM 
(2.5 mL, dry) was added and the mixture stirred at rt overnight. Upon completion the reaction 
was quenched with sat. bicarbonate (aq.) and the organic fraction washed with sat. Na2S2O3 
(aq.) (2 x 1 mL), water (2 mL), brine (2 mL), dried over Na2SO4 and concentrated to a crude oil. 
Crude product was then purified by column chromatography (10-30% EA:Hex) to yield 2.47 (45 
mg, 46%) as a yellow oil; 1H NMR (400MHz, CDCl3) δ ppm 6.26 (s, J = 3.8 Hz, 1H), 5.51 (d, J = 
7.7 Hz, 0.24H), 5.08-5.16 (m, 2H), 4.93-5.07 (m, 7H), 4.00-4.23 (m, 20H), 3.69-3.79 (m, 4H), 
3.57-3.66 (m, 8.74H), 3.14 (t, J = 10.9 Hz, 1H), 2.86 (t, J = 10.7 Hz, 3H), 2.36 (s, 26H), 2.17 (s, 
3H); 13C NMR (100MHz, CDCl3) δ ppm 170.7, 169.4, 169.3, 102.3, 89.5, 73.2, 70.7, 69.6, 69.2, 
67.7, 66.9, 66.2, 65.6, 62.5, 62.5, 62.2, 42.6, 41.2, 42.1, 20.9, 20.7; LRMS (ESI+) m/z calcd 
C16H26ClNO8 [M+Na] 418.135, found 418.035 
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Compound 2.48: 2.45 (107 mg, 0.27 mmol), p-bromo benzyl alcohol (187 mg, 1 mmol, 4 eq.), 
and 4 Å mol sieves were dissolved in DCM (2.7 mL, dry). The mixture was stirred for 30 min 
followed by the addition of solid Ag2CO3 (224 mg, 0.813 mmol, 3 eq.). The vial was covered in 
foil and the reaction stirred overnight. Upon completion the reaction was quenched and washed 
with sat. bicarbonate (aq.) (2 x1 mL), water (2 x1 mL), brine (2 mL), dried over Na2SO4 and 
concentrated to a crude oil. Crude product was purified by column chromatography (10-30% 
EA:Hex) to yield 2.48 (75 mg, 55%) as a colorless oil; 1H NMR (400MHz, CDCl3) δ ppm 7.48 (d, 
J = 8.4 Hz, 2H), 7.18 (d, J = 8.1 Hz, 2H), 5.06 (q, J = 7.6/10.4 Hz, 1H), 5.02 (t, J = 9.9 Hz, 1H), 
4.83 (d, J= 12.5 Hz, 1H), 4.56 (d, J = 12.4 Hz, 1H), 4.45 (d,  J = 7.4 Hz, 1H), 4.1-4.24 (m, 1H), 
3.59 (oct., J = 2.5/5.3/7.8/9.5 Hz, 1H), 2.83 (t, J = 10.3 Hz, 1H), 2.36 (s, 6H), 2.10 (s, 3H), 2.06 
(s, 3H), 2.05 (s, 3H); 13C NMR (100MHz, CDCl3) δ 169.4, 169.2, 136.1, 131.5, 129.2, 121.7, 
100.5, 73.2, 69.5, 69.4, 67.0, 66.3, 62.6, 41.2, 21.1, 20.8; LRMS (ESI+) m/z calcd C21H28BrNO8 
[M+Na] 524.099, found 523.939 
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Compound 2.49: 2.45 (100 mg, 0.25 mmol), p-bromo benzyl alcohol (142 mg, 0.76 mmol, 4 
eq.), and 4 Å mol sieves were dissolved in DCM (1.7 mL, dry). The mixture was stirred for 30 
min followed by the addition of solid Ag2CO3 (209 mg, 0.76 mmol, 3 eq.). The vial was covered 
in foil and the reaction stirred overnight. Upon completion the reaction was quenched and 
washed with sat. bicarbonate (aq.) (2 x1 mL), water (2 x1 mL), brine (2 mL), dried over Na2SO4 
and concentrated to a crude oil. Crude product was purified by column chromatography (10-
30% EA:Hex) to yield 2.49 (35 mg, 48%) as a colorless oil; 1H NMR (400MHz, CDCl3) δ ppm 
7.41-7.49 (m.p., 2H), 7.23 (m.p., 2H), 6.28 (d, J = 3.8 Hz, 0.05H), 4.99-5.10 (m.p., 2H), 4.85 (d, 
J = 12.8 Hz, 1H), 4.59 (d, J = 12.8 Hz, 1H), 4.46 (d, J = 7.8 Hz, 1H), 4.12-4.25 (m.p., 2H), 3.59 
(oct., 2.6/5.2/7.8/9.6 Hz, 1H), 2.84 (t, J = 9.9 Hz, 1H), 2.37 (s, 6H), 2.12 (s, 3H), 2.09 (s, 3H), 
2.06 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 100.6, 73.2, 69.4, 69.3, 67.0, 66.3, 62.6, 41.2, 
29.6, 21.2, 21.0, 20.8; LRMS (ESI+) m/z calcd C21H28BrNO8 [M+Na] 524.099, found 524.175 
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Compound  2.51 protected was prepared according to GP3 in 50% yield as mixture of 
rotamers; 1H NMR (400MHz, CDCl3) δ ppm 7.49 (d, J = 8.5 Hz, 1H), 7.35 (d, J = 7.5 Hz, 1.3H), 
7.18 (d, J = 8.5 Hz, 1H), 7.13 (d, J = 7.9 Hz, 1.3H), 6.96 (s, J = 1.2 Hz, 1H), 4.98-5.14 (m, 2H), 
4.94 (d, J = 12.2 Hz, 0.66H), 4.84 (d, J = 12.4 Hz, 0.47H), 4.67 (d, J = 12.2 Hz, 0.66H), 4.53-
4.60 (m, 1H), 4.46 (d, J = 7.5 Hz, 0.53H), 4.17-4.28 (m, 2H), 3.62 (m, 1H), 2.86 (q, J = 9.9/22.9 
Hz, 1H), 2.39 (s, 3H), 2.37 (s, 3H), 2.35 (s, 3H), 1.99-2.14 (m.p.,15H); 13C NMR (100MHz, 
CDCl3) δ ppm 170.5, 169.3, 135.9, 131.5, 129.3, 129.2, 128.0, 127.6, 100.8, 100.5, 73.2, 73.2, 
70.4, 69.5, 69.4, 67.2, 66.4, 66.3, 62.7, 62.6, 41.2, 21.1, 21.0, 21.0, 20.8, 20.7; LRMS (ESI+) 
m/z calcd C30H39NO8 [M+Na] 564.267, found 564.214 
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Compound 2.51: 2.51 protected (8mg, 0.015 mmol) was dissolved in MeOH (0.2 mL), and 5.2 
µL of NaOMe solution was added (0.5M in MeOH). Upon consumption of starting material by 
TLC the reaction was quenched with acidic Amberlite resin (0.1 g). The mixture was filtered and 
the resin washed with MeOH. The MeOH was then pooled and concentrated to yield 2.51 (5 
mg, 82% as mixture of rotamers) as a colorless oil; 1H NMR (400MHz, CDCl3) δ 7.47 (d,  J = 8.5 
Hz, 0.67H), 7.38 (d, J = 9.0 Hz, 1H), 7.21 (d, J = 9.0 Hz, 0.63H), 7.12 (d, J = 8.5 Hz, 1H), 6.92 
(s, 1H), 4.95 (d, J = 12.0 Hz, 0.48H), 4.84 (d, J = 12.5 Hz, 0.33H), 4.67 (d, J = 11.5 Hz, 0.5H), 
4.57 (d, J = 11.5 Hz, 0.37H), 4.49 (d, J = 7.0 Hz, 0.5H), 4.39 (d, J = 8.5 Hz, 0.33H), 3.87-3.97 
(m, 0.8H), 3.74-3.85 (m, 0.85H), 3.56-3.71 (m, 1H), 3.32- 3.43 (m, 1.5H), 2.49 (d, J = 4.3 Hz, 
4H), 2.30 (s, 2H), 1.97 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 135.9, 135.2, 131.7, 129.7, 
129.5, 128.1, 128.0, 103.7, 103.4, 71.6, 70.3, 70.2, 69.9, 66.2, 63.1, 41.6, 21.0, 20.7, 1.0; LRMS 
(ESI+) m/z calcd C24H33NO5 [M+H]+ 416.24, found 416.50 
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Compound 2.50 protected was prepared according to GP3 in 72% yield as a yellow oil; 1H 
NMR (400MHz, CDCl3) δ ppm 7.41 (t, J = 7.4 Hz, 1H), 7.09 (m, 2H), 6.95 (s, 2H), 4.98-5.12 
(m.p., 2H), 4.93 (d, J = 12.9 Hz, 1H), 4.67 (d, J = 12.9 Hz, 1H), 4.48 (d, J = 8.0 Hz, 1H), 4.10-
4.23 (m.p., 3H), 3.57 (oct., J = 2.8/5.2/7.8/9.6 Hz, 1H), 2.83 (t, J = 10.4 Hz, 1H), 2.36 (s, 6H), 
2.34 (s, 3H), 2.06 (s, 6H), 2.01 (s, 6H), 1.94 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 170.8, 
169.4, 169.2, 141.2, 138.6, 137.1, 136.6, 135.7, 128.8, 128.6, 128.5, 128.0, 125.9, 100.3, 73.2, 
70.2, 69.4, 67.1, 66.3, 62.7, 41.2,  21.0, 21.0, 20.7; LRMS (ESI+) m/z calcd C24H33NO5 [M+Na] 
564.267, found 564.064 
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Compound 2.52: 2.47 (44mg, 0.11mmol) was dissolved in DMF (0.5 mL). NaN3 (22 mg, 3 eq.) 
was added and the reaction was heated and stirred at 100 oC under N2 atmosphere. Upon 
consumption of starting material by TLC, the reaction was quenched with water (1 mL) and 
extracted with DCM (3 x 1 mL). The organic fractions were pooled and washed with water (2 
mL), brine (2 mL), dried over Na2SO4 and concentrated. The crude oil was purified by column 
chromatography (10-30% EA:Hex) to yield 2.52 (18 mg, 42%) yellow oil; 1H NMR (400MHz, 
CDCl3) δ ppm 4.95-5.02 (m.p., 2H), 4.67 (s, 0.4H), 4.48 (d, J = 7.5 Hz, 1H), 4.08-4.2 (m, 2H), 
3.98 (m, 1H), 3.64-3.69 (m,1H), 3.6 (m, 1H), 3.40-3.50 (m, 1H), 3.29 (m, 1H), 2.84 (t, J = 10.2 
Hz, 1H), 2.35 (s, 6H), 2.07 (s, 3H), 2.06 (s, 3H), 2.04 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 
170.7, 169.4, 169.3, 101.9, 73.2, 69.2, 68.0, 67.1, 66.3, 62.6, 50.6, 41.2, 21.1, 21.0, 20.8; LRMS 
(ESI+) m/z calcd C6H26N4O8 [M+Na] 425.175, found 425.103 
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Compound 2.53 protected: 2.52 (15 mg, 0.04 mmol) was dissolved in BuOH:H2O (1:1, 0.16 
mL). CuSO4.5H2O (0.1 mg, 1mol %) and added along with sodium ascorbate (3.3 µL 1M aq. 
Solution, 0.1 eq.). Phenyl acetylene (8.6 µL, 2 eq.) was then added and the reaction stirred at rt. 
Upon completion the reaction was diluted with water (1 mL), extracted with EtOAc (2 x 2 mL), 
organic fractions pooled and washed with brine (1 mL), dried over Na2SO4 and concentrated. 
Purification by chromatography (70:25:5; Hex:EA:TEA) gave 2.53 protected (9.5 mg, 47%) as a 
clear oil; 1H NMR (400MHz, CDCl3) δ ppm 7.86 (m.p. 3H), 7.40 (t, J = 8.0 Hz, 2H), 7.30 (t, J = 
7.6 Hz, 1H), 4.91-5.02 (m, 2H), 4.67 (dt, J = 3.6/6.9/15.0 Hz, 1H), 4.45-4.53 (m, 1H), 4.33 (d, J = 
7.9 Hz, 1H), 4.20-4.27 (m, 1H), 4.17 (dd, J = 5.3/12.1 Hz, 1H), 4.09 (dd, J = 2.0/12.2 Hz, 1H), 
3.85 (dt, J = 2.3/9.2 Hz, 1H), 3.56 (oct., J = 2.5/5.4/7.7/9.8 Hz, 1H), 2.77 (t, J = 10.4 Hz, 1H), 
2.30 (s, 6H), 2.05 (s, 3H), 2.02 (s, 3H); 13C NMR (100MHz, CDCl3) δ ppm 170.7, 169.5, 169.4, 
130.6, 128.8, 128.0, 125.7, 121.5, 101.7, 73.3, 69.1, 67.5, 66.8, 66.0, 62.4, 50.1, 41.2, 29.6, 
21.0, 20.9, 20.7 
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Compound 2.53: 2.53 protected (9.5 mg) was dissolved in MeOH (0.2 mL) followed by the 
addition of NaOMe (846 µL, 25% solution in MeOH, 0.2 eq.). Upon consumptions of starting 
material the reaction was quenched with Amberlite resin. The mixture was filtered and the resin 
washed with MeOH. The MeOH was then pooled and concentrated to yield 2.53 (4.3 mg, 62%) 
as a colorless oil; 1H NMR (400Mhz, CDCl3) δ ppm  8.45 (s, 1H), 7.84 (d, J = 7.3 Hz, 2H), 7.45 
(t, J = 7.3 Hz, 2H), 7.36 (t, J = 7.6 Hz, 1H), 4.72 (t, J = 4.6 Hz, 2H), 4.40 (d, J = 7.8 Hz, 1H), 
4.29-4.36 (m, 1H), 4.06-4.14 (m, 1H), 3.88 (dd, J = 2.4/12.1 Hz, 1H), 3.69 (dd, J= 5.6/11.8 Hz, 
1H), 3.34-3.57 (m, 2H), 2.66 (s, 6H); 13C NMR (100MHz, CDCl3) δ ppm 128.5, 127.8, 125.2, 
121.9, 104.0, 77.7, 70.4, 68.9, 67.7, 65.1, 61.1, 50.3, 40.7; LRMS (ESI+) m/z calcd C18H26N4O5 
[M+H]+ 379.193, found 379.30 
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Compound 2.40: Neamine hydrochloride (300 mg, 0.064 mmol) was dissolved in 8 mL H2O. 
The freshly prepared TfN3 solution (8 mL) was then added along with MeOH (24 mL) and a 
solution of CuSO4 (9.9 mg, 0.062 mmol, in 2 mL of 3:3:4 MeOH:H2O:TEA). The resulting 
solution was stirred to 2 hrs and monitored by TLC. Upon completion the reaction was 
quenched with solid NaHCO3 (800 mg). The organics were then distilled off and the resulting 
aqueous mixture extracted with EtOAc (3 x 5 mL). The pooled organics were washed with 
water, brine, dried over Na2SO4 and concentrated to a crude oil which was purified by 
chromatography (25-50%EA:Hex) to yield 2.40 (166 mg, 61%) as a white solid; 1H NMR 
(400Mhz, CDCl3) δ ppm 5.66 (d, J = 4.0 Hz, 1H), 4.19 (ddd, J = 2.4 Hz, 1H), 3.88 (dd, J = 9.1 
Hz, 1H), 3.34-3.57 (m, 7H), 3.28 (t, J = 8.9 Hz, 1H), 3.14 (dd, J = 3.6 Hz, 1H), 2.26 (dt, J = 3.9 
Hz, 1H), 1.43 (q, J = 12.3 Hz, 1H); 13C NMR (100Mhz, CDCl3) δ ppm 98.3, 79.6, 76.5, 71.8, 
71.3, 70.8, 63.3., 60.4, 59.5, 31.8; HRMS (DART-TOF) m/z calcd for C12H18N12O6 [M+H]+ 
449.1359, found 449.1429 
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Compound 2.41: To a solution of 2.40 (300 mg, 0.704mmol) and p-toluenesulfonic acid 
monohydrate (67 mg, 0.352mmol) in dry ACN (2.6 mL, 0.27M) was added cyclohexone dimethyl 
ketal (0.482 mL, 3.168 mmol) and the solution stirred overnight at rt. The reaction was 
quenched with TEA (0.1 mL) and concentrated to a crude residue. The residue was then taken 
up in EtOAc (5 mL), washed with water (3 mL), brine (3 mL), dried over Na2SO4 and 
concentrated to a crude oil. The oil was purified by column (25-50% EA:Hex) to yield both 
unreacted starting material (90 mg) as well as the 2.41 (152 mg, 43%, 61% BRMS) as a white 
solid; 1H NMR (400Mhz, CDCl3) δ ppm 5.56 (d, J = 3.6 Hz, 1H), 4.02 (ddd, J = 2.4 Hz, 1H), 3.95 
(t, J = 9.4 Hz, 1H), 3.83 (t, J = 9.4 Hz, 1H), 3.38-3.7 (m, 8H), 3.26 (dd, J = 3.4 Hz, 1H), 2.33 (dt, 
J = 5.1 Hz, 1H), 1.32-1.78 (m, 16H); 13C NMR (100Mhz, CDCl3) δ ppm 113.8, 96.3, 79.3, 79.2, 
77.0, 71.3, 71.1, 71.1, 62.6, 60.8, 57.1, 51.2, 36.2, 36.0, 33.7, 24.8, 23.7; HRMS (DART-TOF) 
m/z calcd for C18H26N12O6 [M+H]+ 529.1985, found 529.2064 
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Compound 2.42: Crude starting material (Diacetlyated 2.41, not shown) (200 mg) was 
dissolved in dioxane/H2O (1:1, 1.8 mL). Glacial acetic acid (1.35 mL) was added and the 
reaction refluxed at 65 oC overnight. Upon completion the reaction was quenched with sat.  
NaHCO3 (aq.) (to basic pH), and extracted with EtOAc (3 x 4 mL). The pooled organics were 
washed with sat. NaHCO3 (aq.) (4 mL), water (4 mL), brine (4 mL), dried over Na2SO4 and 
concentrated to a crude oil. The oil was purified by chromatography (25-50%EA:Hex) to yield 
2.42 (127 mg, 83% over two steps) as a white solid; 1H NMR (400Mhz, CDCl3) δ ppm 5.47 (t, J 
= 9.7 Hz, 1H, t), 5.40 (d, J = 3.7 Hz, 1H), 5.05 (t, J = 9.7 Hz, 1H, t), 4.36 (m, 1H), 3.93 (bs, 1H), 
3.62 (dd, J = 3.8 Hz, 1H), 3.2-5.9 (m, 9H), 2.35 (m, 2H), 2.09 (s, 3H), 2.05 (s, 3H), 1.54 (q, J = 
9.7 Hz, 1H); 13C NMR (100Mhz, CDCl3) δ ppm 98.5, 82.6, 76.0, 75.5, 71.1, 69.4, 69.3, 61.6, 
59.7, 58.6, 50.8, 30.8, 20.7, 20.6; HRMS (DART-TOF) m/z calcd for C16H22N12O8 [M+H]+ 
533.1570, found 533.1612 
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Iridium Catalyzed Hydrogenations to Access 2-substituted 1,4-benzodioxanes 
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My work on the above manuscript included the synthesis of various substrate compounds, 
particularly of the carboxylate series, but also examples of the alkyl and aryl series. Extensive 
work was conducted performing hydrogenation reactions on substrates in both symmetric and 
asymmetric fashion. I would like to sincerely acknowledge and thank the large team of 
researchers from Boehringer Ingelheim Pharmaceuticals who developed this project and 
allowed me to be an integral part of bringing it to completion. The work done by myself and the 
chemical development team at Boehringer Ingelheim is the basis for the following thesis 
chapter; 
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3.1. Introduction to catalysis 
 Defined as a substance that increases the rate of reaction without itself being 
consumed, the field of chemistry would be unrecognizable without catalysts. Catalytic species 
exist in many fields of study, including biological, inorganic, and organic chemistry. Biology has 
made extensive use of catalysis in the form of proteins and enzymes which regulate and control 
biological processes.1 So essential is catalysis to biological function, it is hard to imagine a 
biological pathway that does not depend of some form of catalysis. Inorganic chemistry relies 
heavily on catalysis as well. Illustrating the importance of catalyst development in inorganic 
chemistry is the electrolysis of water.2 An attractive source of alternative energy production, 
sustainable water splitting (to hydrogen and oxygen) remains a holy grail in the field. The 
development and use of catalysts in synthetic organic chemistry has allowed novel bond 
formations and access to selective confirmations otherwise inaccessible. Owning to the 
powerful transformations that are allowed with catalysis, we have seen major strides in synthetic 
methodologies in a short time frame. Of particular importance in the field of catalysis has been 
the addition of hydrogen to an organic compound; catalytic hydrogenation.  
3.2. Development of hydrogenation reactions 
 Hydrogenation is the earliest reported forms of catalysis in the field of synthetic 
chemistry.3 In particular, the Pt catalyzed addition of hydrogen to oxygen being one of the first 
know examples. This reaction was the basis of the commercialization of a lamp in the 1820s, 
known as Dobereiners lamp. Named after the chemist who invented it, Johnan Wolfgang 
Dobereiner, Zinc metal is reacted with dilute sulfuric acid producing hydrogen gas. The gas is 
then funneled to a platinum sponge which catalyzes its reaction with atmospheric oxygen 
yielding water and an illuminating flame in the process (Scheme 3.1).4 
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Scheme 3.1. Hydrogenation of molecular oxygen 
 
 Marking a revolution in hydrogenation methodology was Paul Sabatier, who in the late 
1800s discovered the first catalytic addition of hydrogen to yield hydrocarbons. The reaction, 
now known as the Sabatier process reacts hydrogen with carbondioxide in the presence of Ni 
catalyst to give methane gas and water (Scheme 3.2). The process is carried out at elevated 
temperature and pressure (~40 oC), and is also known to be catalyzed by ruthenium on 
aluminum oxide.5 This work later earned Sabatier a shared Nobel prize in chemistry in 1912. 
The relevance of this process persists to this day, and its application is currently being applied 
to space station technology in order to regenerate water from exhaled CO2 from astronaut 
respiration.6 
Scheme 3.2. Hydrogenation of carbon dioxide 
 
 
 
 What is arguable one of the most important catalytic hydrogenations to date, and 
analogous to the aforementioned Dobereiner process, is the catalytic reaction of hydrogen gas 
with nitrogen gas. Known as the Haber process, the fixation of nitrogen to form ammonia is 
carried out by iron-based catalysts at elevated temperature and pressure (Scheme 3.3).7 The 
process is historically of great importance in the agriculture sector, as it is used to produce 
fertilizers. The fertilizers from this process, along with advancements in pesticides, have 
quadrupled the productivity of agricultural land.8 Having such drastic impact on food production, 
the process is thought to be a key factor in the human population explosion in the 20th century.9 
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For his development of the process and its subsequent impact on human culture, Fritz Haber 
was later awarded a Nobel prize in chemistry. 
Scheme 3.3. Hydrogenation of molecular nitrogen  
 
 The examples given represent the earliest development of hydrogenation reactions, 
and are limited to the addition of hydrogen to the simplest of substrates. Subsequent develop of 
catalytic methodology in the following decades has led to the field of homogeneous catalysis 
and the hydrogenation of much more complex organic compounds. In addition to complex 
substrates, the ability to selectively reduce compounds to yield enantiomerically pure products 
has been realized. 
3.3. Homogeneous catalysis 
 Homogeneous catalysts are catalysts which dissolve in the reaction solvent along with 
substrates. This property allows for a higher level of control over the reaction conditions and has 
opened to door to asymmetric methodologies as well. Pioneering the field of homogeneous 
catalysis was English chemist, Sir Geoffrey Wilkinson. His development of a coordination 
complex between rhodium and triphenylphosphine in the 1960s marked a great advance in the 
field.10 The complex, Wilkinsons catalyst, bears three triphenylphosphine ligands on a central 
rhodium atom with a single chlorine atom attached to the metal center. Synthesis of which is 
carried out by reacting rhodium (III) chloride with triphenylphosphine in refluxing ethanol.10,11 
 The catalyst is best known for its use in the hydrogenation of alkenes to give saturated 
alkanes. Mechanistically, the catalyst undergoes a loss of one of its phosphine ligands and an 
oxidative addition with molecular hydrogen follows. Complexation with alkene substrate is then 
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accompanied by a hydride transfer and lastly a reductive elimination to yield the saturated 
alkane and regeneration of the active catalyst (Figure 3.1).12  
Figure 3.1. Mechanism for the hydrogenation of olefins by Wilkinsons catalyst12  
 
 While best known for use in hydrogenations, Wilkinsons catalyst is also shown to 
catalyze other reactions such as hydroacylation, hydroboration, and hydrosilylation of alkenes.13 
This catalyst, and its transformations, marked a large leap forward in the field of catalysis, and 
the introduction of the use of phosphine ligands to transition metal complexes for the application 
of catalysis.  
 Expanding the power of homogeneous catalysis was the development of asymmetric 
methodologies. By use of chiral induction using enantiomerically pure ligands complexed to the 
transition metals it is possible to influence facial selectivity and yield an enantiomerically 
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enriched/pure product. This work was first developed by American chemist William Knowles in 
the late 1960s when he developed the first asymmetric hydrogenation catalyst by replacing the 
achiral triphenylphosphine ligands in Wilkinsons catalysts with chiral methyl-, phenyl-, isopropyl-
phosphine ligands.14 The catalyst was effective at achieving a 15% ee on their test substrate 
(Figure 3.2). 
Figure 3.2. First asymmetric hydrogenation reaction14 
 
 Following these findings, the field of chiral metal centered ligands has since exploded 
and has led to great advancements in synthetic chemistry. With the modest early selectivity of 
15%ee subsequent ligands quickly drove selectivity to the high 90 ranges within a short period 
of years.15  
 The applicability of these methodologies was immediate, and the first industrial 
application of asymmetric hydrogenation was conducted by Knowles while working for 
Monsanto, in the late 1970s, in the production to Parkinsons drug, L-DOPA.15,16 From achiral 
starting material (LIII), Knowles made use of rhodium complexed with a chiral bidentate 
phosphine ligand, (R,R-DIPAMP). Under hydrogen atmosphere, the reaction carried through 
with excellent enantioselectivity to the biologically active isomer (Figure 3.3). For his 
contribution to asymmetric catalysis and the synthesis of L-DOPA, Knowles later shared the 
Nobel Prize in chemistry.15 
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Figure 3.3. Asymmetric synthesis of L-DOPA15 
 
 From the above examples, one can see that the addition of the simplest atom, 
hydrogen, can be a most powerful tool in chemical synthesis. With many early examples being 
deemed worthy of a Nobel Prize. Doing so in an asymmetric fashion only adds to this power. 
The utility of such reactivity has been used in the synthesis of many privileged structures in 
medicinal chemistry, as shown in the L-DOPA example. One other such motif is that of 2-
substituted 1,4-benzodioxanes. 
3.4. 2-substituted 1,4-benzodioxanes 
 The idea of privileged structures in medicinal chemistry has become an attractive 
concept for drug discovery.17 Privileged structures are chemical scaffolds which through 
diversification tend to show biological activity for a range of different biological targets. Along 
with activity, such structures tend to display favorable pharmacological properties as well.17 
These properties taken together, lead to compounds which are drug-like and amenable to 
optimization efforts to enhance properties. Illustrative of this concept is that of 2-substituted 1,4-
benzodioxanes.  
 There are numerous examples of compounds with core benzodioxane structure that 
have varying targets/activities (Figure 3.4). Of clinical importance it that of doxazosin (LIV), a 
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chiral 1,4-benzodioxane based compound prescribed for hypertension and prostate 
hypertrophy.18 
Figure 3.4. Examples of chiral 2-substituted 1,4-benzodioxanes 
 
 Naturally, a great deal of effort has been expended at accessing this motif 
synthetically, as its derivatives are promising medicinal candidates. Important to note, is that 
one can observe the substituents at the 2-position varies greatly amongst the known 
compounds. In particular, there are 2- alkyl, aryl, heteroaryl, and carboxyl compounds. This 
variation at the chiral center presents itself as a truly difficult synthetic hurdle as most reactions 
do not tolerate such broad substrate scope. 
 With such prized structures, work on their synthetic accessibility began in the early 
2000s in the lab of Stephen Buckwald. In their approach, functionalized aryl halides are treated 
with palladium to catalyze intramolecular etherification reactions (Figure 3.5).19 Employing an 
achiral di-tert-butylphosphinobiaryl ligand, these reactions proceeded without enantioselectivity 
to give rise to a number of unsubstituted benzodioxanes. Use of enantiomerically enriched 
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alcohols as starting materials was found to be tolerated by the methodology and chiral products 
were yielded without loss of optical purity. 
Figure 3.5. Intramolecular etherification route to chiral 1,4-benzodioxanes19 
 
 Marking the first enantioselective process to access these chiral benzodioxanes was 
the work by Larry Overmann and coworkers (Figure 3.6). By use of a phenolic (E)-allylic 
trichloroacetimidate starting material (LV), in the presence of Colbalt Oxazoline Palladacycle 
(COP) catalyst, the group was able to synthetically yield chiral 2-vinyl 1,4 benzodixoanes in the 
80-90% ee range where the aryl group tolerated nominal substitutions.20 Significantly limiting 
this methodology is the requirement of a difficult substrate and limited scope of only generating 
a 2-vinyl 1,4-benzodioxane. 
Figure 3.6. First enantioselective synthesis of chiral 1,4-benzodioxanes20 
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 Building on the president set by the Overman lab, a new palladium catalyzed 
methodology was reported in 2015 by the Cai group (Figure 3.7).21 In their approach, Pd(OAc) 
was complexed with a chiral spirodiphosphine monoxide ligand to form the active catalytic 
species. The starting substrate being an aryl halide with a symmetric 1,3-propane diol moiety 
(LVI). The reaction acts to form an O-aryl bond, with enantioselectivity, to give the 2-
hydroxymethyl 1,4-benzodioxanes in varying yield and high ee. While marking the first 
enantioselective synthesis of chiral 1,4-benzodioxanes, the methodology is limited to the 2-
hydroxymethyl derivative and tolerates only simple aryl derivation. 
Figure 3.7. Palladium catalyzed bidentate phosphine route to chiral 1,4-benzodioxanes21 
 
 
 Another intramolecular methodology which was being developed concurrently to that 
of the Cai group was an intramolecular alkene aryloxyarylation reaction by the Tang group 
(Figure 3.8).22 In this reaction, an olefinic starting material (LVII) is reacted with Palladium in the 
presence of chiral phosphine ligand, of the (R)-AntPhos family, as well as an arylbromide. Chiral 
induction lead to the aryloxyarylation taking place selectively to give chiral tertiary 1,4-
benzodioxane products in moderate to good yields and fairly decent selectivity. While an 
elegant means of generating such compounds, the methodology is limited as it can only give 
C2-tertiary products, and the substituents off this chiral center are limited. 
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Figure 3.8. Palladium catalyzed route to chiral, tertiary 1,4-benzodioxanes22 
 
 The previous methodologies make use of palladium catalysts to facilitate 
intramolecular cyclizations to form the heterocyclic core of the benzodioxanes. As alluded to in 
the introduction, and of importance to our efforts, is that of asymmetric hydrogenation. To this 
end, recent years have seen the report of two complimentary processes which make use of this 
route.23,24 
 The group of Xumu Zhang first reported on a rhodium catalyzed asymmetric 
hydrogenation using ZhoaPhos ligands (Table 3.1).23 Substrates for these transformations were 
prochiral 2-substitiuted 1,4-benzodioxines. The transformations took place at 1 mol% Rh and 
ligand loading with 10-30 atm H2 at rt. Both yields, and selectivity for the reactions were 
excellent. However, the choice of rhodium, which is a metal center known to act via substrate 
coordination, as well as ZhoaPhos, whose thiourea functionality takes part in hydrogen bonding 
interactions with the substrate, the substrate scope is limited to compounds with polar functional 
groups at C2.23 The high degree of selectivity observed is due to these substrate/catalyst 
interactions, and while excellent with polar functional groups, selectivity is not retained for alkyl 
and aryl derivatives. 
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Table 3.1. Rhodium catalyzed asymmetric hydrogenation route to 1,4-benzodioxanes23 
 
 
 Analogous with the methodology by Xamu Zhang, a similar hydrogenation 
methodology was reported around the same time detailing an iridium catalyzed asymmetric 
hydrogenation technique (Table 3.2).24 This work, by the group of Wanbin Zhang, also utilized 
prochiral 2-aryl 1,4-benzodioxine substrates. Using a torpos biphenyl phosphine-oxazoline 
(BiphPHOX) ligand bearing a tetrakis(3,5-bis(trifluoromethyl)phenyl)borate (BArF) counter 
anion, they showed the conversion of substrates to chiral 2-aryl 1,4-benzodioxanes in high yield 
and moderate selectivity. By use of the ionic Ir/BiphPHOX/BArF catalytic system, the 
methodology is applicable predominantly to non-polar functionalized substrates, as can be seen 
from the substrate scope. The researches extended the scope to a single alkyl substrate, 2-
ethyl, and a drastic loss in selectivity was observed. 
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Table 3.2. Iridium catalyzed asymmetric hydrogenation route to 1,4-benzodioxanes24 
 
 The above examples showcase different routes and invoke elegant chemistries to 
access the core motif. However, each method suffers from a limitation in its scope of 
substitution at C2. While numerous palladium-based techniques are known, they suffer from the 
necessity for advanced substrates, and yield a narrow range of products. More recently, both 
rhodium and iridium-based hydrogenation methods have been reported. These methodologies 
show great promise in yielding enantiomerically pure products, however there use of catalytic 
systems, including ligands, have narrowed their general applicability. This leaves a field where 
there still exists a need for a general catalytic system which can furnish the desired chirality at 
C2 of the 1,4-benzodioxane structure. 
3.5. Project design 
 The aim of this project is to develop a synthetic methodology which allows formation of 
enantiomerically pure 1,4-benzodioxanes. In particular, it is our goal to identify a general 
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catalytic system which tolerates a broad scope of substituents at the C2 position. Building on 
the previous work that has been conducted in this area, we propose to start with prochiral 2-
substituted 1,4-benzodioxines (Scheme 3.4).23,24 By asymmetric hydrogenation reaction 
employing an Ir based catalyst system using bidentate chiral phosphine ligands we hope to 
provide highly enantiomerically enriched products displaying alkyl, aryl, heteroaryl, and carbonyl 
functionality at C2. 
Scheme 3.4. General transformation from prochiral starting material 
 
 Where previous methodologies fell short, we hope the choice of Ir as the transition 
metal coupled with neutral phosphine ligands will eliminate unwanted substrate coordination 
and allow for a broadened substrate scope. 
 Synthesis of substrates for the project is envisioned to start from a common 2-bromo 
1,4-benzodioxine intermediate. As the goal is to evaluate broad diversification at C2, it is 
imperative that we can access the substrates in a simple manner. To do so, we will employ Pd 
catalyzed Suzuki, Negishi, Kumada, and Carbonylation reactions to install aryl, heteroaryl, alkyl, 
and carbonyl functionality. 
3.6. Results and discussion 
 With the aim to begin with 2-substituted benzodioxine substrates, the first task was 
synthesis of the common 2-bromo benzodioxine starting material (Scheme 3.5). This synthesis 
commenced with the alkylation of catechol (and ortho methyl ester derivative) with allylbromide. 
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Isomerization to the bis vinylic compounds (LV and LVI) was followed by RCM using Grela 
nitro-aryl RCM catalyst to give unsubstituted 1,4-benozdioxine. Remarkably, the RCM reaction 
was enacted using 150-300 ppm catalyst loading. Treatment with NBS, followed by E2 
elimination via base addition gave rise to the desired 2-bromo 1,4-benzodioxine intermediates 
3.1 and 3.2. 
Scheme 3.5. Synthesis of 2-bromo 1,4-benzodioxine starting material 
 
 With access to the intended starting material, it was then necessary to test for a 
catalytic system which would be appropriate for the asymmetric transformation. To this end, it 
was theorized that if good enantioselectivity could be observed for a simple 2-alkyl derivative, as 
a system had yet to be reported for, then the selectivity would likely extend to other substituents 
at the C2 position. Thus, as a proof of concept, the 2-cyclopropyl ortho methylester derivative 
(3.3) was screened against more than 20 commercially available bidentate phosphine ligands 
using Ir[COD]Cl2 as the Ir source (Table 3.3). Reactions for ligand screening were conducted at 
1 mol% Ir loading, 3 mol% ligand loading, 600psi H2, in THF/MeOH/AcOH at 50 oC for 24hrs. 
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Table 3.3. Ligand screen on 2-cyclopropyl test substrate29 
 
 Results of the screen against commercially available ligands were lackluster. All 
ligands provided less than excellent enantioselectivites (<90:10 er), and full conversion to 
product (3.4) was not observed in any case. In light of these results, it was thought that the bis-
dihydrobenzooxaphosphole (BIBOP) type ligands could provide a better selectivity, as previous 
studies had shown the ligands to provide a deep chiral pocket as well as steric tunability for 
enatioinduction.25 As the steric bulk increased on the BIBOP ligand a general trend of increased 
yield and enantioselectivity was observed (Table 3.4). Best results were found with the 2,6-
dimethoxyphenyl-substituted ligand (LXI). Displaying a 97:3 er and an isolated yield of 98%, this 
ligand was selected to carry out the subsequent substrate scope studies. 
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Table 3.4. Screen of BIBOP bidentate phosphine ligands on 2-cyclopropyl test substrate29 
 
 
 
 Having identified a viable catalytic system, attention turned to the synthesis of 
substrates for the hydrogenation reaction. Firstly, a series of 2-alkyl substituted substrates (3.5-
3.9) were synthesized via Negishi and/or Kumada coupling reactions (Table 3.5).  
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Table 3.5. Synthesis of alkyl substrates for asymmetric hydrogenation 
 
 Difficulties in the synthesis of 2-alkyl derivatives limited the scope mostly to cyclic alkyl 
compounds. Observed in many cases was the competing dehalogenation rather than alkyl 
coupling (Figure 3.9). The non-polar nature of the products added the difficulty as desired 
products would co elute with the dehalogenated product. This problem was particularly 
troublesome in the synthesis of 2-ethyl derivative (3.5). As this was a valuable substrate to 
compare to previous methodologies, efforts to separate the compounds were optimized and 
pure 3.5 was obtained through analytical supercritical fluid chromatography. 
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Figure 3.9. 2-ethyl substrate purification by analytical supercritical fluid chromatography 
 
With alkyl substrates in hand, hydrogenation reactions were conducted (Table 3.6). We were 
delighted to find that enantioselectivities were maintained to a high degree to yield compounds 
3.10-3.3.14.  
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Table 3.6. Asymmetric hydrogenation of 2-alkyl substrates 
 
 Cyclopropyl analog (3.6) gave similar selectivity, 94:6 er in 92% yield, as its methyl 
ester derivative displayed in the initial test reaction. Additionally, the 4,6, and 7 member ring 
derivatives (3.7-3.9) were transformed with excellent enantioselectivities as well (93:7-95:7 er). 
For the 2-ethyl compound which presented itself as a benchmark for the methodology, a slightly 
lower er was observed, 90:10. This was less than we had hoped, but represented a significant 
improvement over the previously reported method, 74:26 er.24 
 Pleased with the selectivity on the challenging alkyl substrates we then turned our 
attention to aryl and heteroaryl substrates. Synthesis of which was more easily obtained than 
alkyls through Suzuki coupling procedures (Table 3.7). 
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Table 3.7. Synthesis of 2-aryl and 2-heteroaryl substrates 
 
 Aryl/heteroaryl substrates were then subjected to hydrogenation conditions to obtain 
the reduced, chiral products (3.37-3.54, Table 3.8). Selectivity and yields for this series were 
excellent. The lowest observed selectivity was that of substrate (2.30) with a 94:6 er. For more 
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sterically encumbered substrates such as dibenzofuran (2.35), dibenzothiophene (2.36), and 
trimethoxyphenyl (2.28), er of >99:1 was observed. Importantly, many of the heterocyclic 
derivatives, which have a high pharmaceutical relevance, were obtained in >98:2 er. 
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Table 3.8. Asymmetric hydrogenation of 2-aryl and 2-heteroaryl substrates 
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 Having confirmed selectivity across alkyl and aryl/heteroaryl substrates, it was then 
desired to determine if the methodology could extend to benzodioxanes with polar coordinating 
groups at C2. Synthesis of a series of substrates was then carried out from the 2-bromo 
intermediates (Table 3.9). Pd catalyzed conditions, under CO atmosphere (50 psi), in the 
presence of amine or alcohol (1.5 eq.) gave the corresponding 2-amide/ester compounds, 
including a direct doxazosin precursor (2.54-2.61). 
Table 3.9. Synthesis of 2-caboxyl substrates  
 
 Subjecting amide/ester substrates to hydrogenation conditions gave exciting results 
(Table 3.10). Again, selectivity of >99:1 er was observed for the double methyl ester compound 
(3.54). Single methyl ester compound (3.55) showed slightly lower selectivity of 95:5 er. 
Pyrrolidine (3.56), morpholine (3.59), piperidine (3.60), phenylpiperazine(3.57), and 
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tetrahydroisoquinoline (3.58) derivatives also displayed great to excellent selectivity (from 93:7-
98:2). Of note, tetrhydroisoquinoline derivative (3.58) was reduced and isolated as a mixture of 
two rotamers. More interesting yet, when analyzing specific rotation of the products, it was 
found that the opposite stereochemistry was observed compared to the previous alkyl and aryl 
series. A computation study was then initiated to gain understanding of the underlying 
mechanism of stereoinduction leading to the observed products. 
Table 3.10. Asymmetric hydrogenation of 2-carboxyl substrates 
 
 
 Previous studies on Ir-calalyzed hydrogenations suggest reduction occurs via 
stepwise protonation-hydride transfer mechanism (Figure 3.10).27 
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Figure 3.10. Proposed mechanism for hydrogenation by Iridium catalyst26  
 
*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry) 
 
 In this model, protonation is thought to be the enantiodetermining step. Calculated 
energy of the separated ion pair is much higher than the energy of the transition states for the 
protonation or subsequent hydride transfer. This supports that facial selectivity is established by 
the iridium catalyst during protonation, since transfer the opposite face is highly unfavorable 
energetically. To better understand selectivity, this key protonation step was further analyzed. It 
was found that protonation occurs via a Markovnikov process at C2, and this selectivity was 
confirmed for both faces of the benzodioxine. This finding allows for the same model to be used 
across our range of substrates. Proposed mechanisms for coordinating and non-coordinating 
substrates are shown in figure 3.11. 
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Figure 3.11. Proposed mechanism for coordinating and non-coordinating substrates26 
 
*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry) 
 
 It was thought that different confirmations within these proposed mechanisms results 
in the change in selectivity observed. Testing this idea, computation models were conducted on 
the non-coordinating 2-methyl derivative and the coordinating 2-carboxymethyl derivative 
(Figure 3.12). Analysis of route A protonation of 2-methyl derivative shows that the reaction 
takes place on face A of the benzodioxine. Computational values predicted an 80:20 er whereas 
the observed er was 90:10. 
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Figure 3.12. Computational analysis of non-coordinating 2-methyl substrate transition state26 
 
*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry) 
 
 
 Analysis of route B protonation of 2-carboxymethyl derivative gave opposite selectivity, 
with a computationally predicted er of 7:93 (Figure 3.13). This was in close agreement with the 
experimentally observed 5:95 er for this compound.  
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Figure 3.13. Computational analysis of coordinating carboxymethyl substrate transition state26 
 
*Figure reproduced for use in this thesis with permission of publisher (The Royal Society of Chemistry)  
 
3.7. Conclusion 
 We have demonstrated the development of a catalytic system, Ir/BIDIME-dimer, which 
displays excellent enantioselectivity (>99:1) in asymmetric hydrogenation reactions to access a 
broad range of chiral 2-substitiuted 1,4-benzodioxanes. Substrate scope was shown to tolerate 
alky, aryl, heteroaryl, and polar carboxy (amide/ester) substrates with retained selectivity. This 
represents a significant improvement over previously known methods. Complimentary 
computation studies confirm that enantioselectivity is determined in the protonation step, and 
that polar coordinating substrates (amides/esters) interact with the metal center to flip facial 
selectivity and give opposite stereochemistry at the new chiral center.  
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3.8. Experimental 
Synthesis of 2-alkyl substrates 
GP7: General procedure for synthesis of 2-alkyl 1,4-benzodioxine substrates 
A representative procedure is given for the synthesis of 2-aryl- or 2-heteroaryl-substituted 1,4- 
Benzodioxines; Compound 3.8: To a suspension of methyl 2-bromo-1,4-benzodioxine-5-
carboxylate SI-2 (5.00 g, 18.4 mmol, 1 eq.) and t-Bu3PHBF4 (321 mg, 1.10 mmol, 0.06 eq.) in 
THF (30 mL), Pd(OAc)2 (207 mg, 0.922 mmol, 0.05 eq.) and a solution of ZnBr2 (~30 wt% 
solution, 2.49 g, 11.1 mmol, 0.6 eq.) was added. Cyclopropylmagnesium bromide (59.0 mL, 0.5 
M in THF, 29.5 mmol, 1.6 eq.) was added dropwise over 1 h using a syringe pump while 
maintaining the temperature at 20–25 °C. Reaction was monitored by HPLC. Once starting 
material was consumed (total reaction time within 2 h), reaction was quenched with water (10 
mL) and saturated aqueous ammonium chloride solution (50 mL) was added. The organic 
layer was extracted with EtOAc (3 × 50 mL). The combined organic extracts were dried over 
MgSO4, filtered through a short pad of silica gel, followed by copious EtOAc washes, and 
concentrated in vacuo. Purification by column chromatography (elution gradient from 0–5% 
EtOAc in hexanes) yielded compound 3.8 as a white solid (230 mg, 32% yield) 
 
 
1H NMR (500 MHz, CDCl3): δ 6.80–6.76 (multiple peaks, 2H), 6.65–6.59 (multiple peaks, 2H), 
5.69 (s,1H), 1.91-1.66 (multiple peaks, 6H), 1.31–1.13 (multiple peaks, 5H); 13C NMR (126 MHz, 
CDCl3): δ 143.2, 142.8, 142.4, 123.6, 123.5, 120.7, 116.0, 115.7, 38.4, 29.6, 26.0, 25.6; HRMS 
(DART): m/z calcd for C14H17O2 [M+H]+ 217.12231, found 217.12216 
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Compound 3.9 was prepared according to GP7 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69 
mmol, 1 eq.) and cycloheptylmagnesium bromide (3.8 mL, 2.0 M in Et2O, 7.5 mmol, 1.6 eq.). 
Purification by column chromatography using hexanes yielded as a colorless liquid (202 mg, 
19%yield); 1H NMR (500 MHz, CDCl3): δ 6.80–6.75 (multiple peaks, 2H), 6.66–6.59 (multiple 
peaks, 2H), 5.73 (s, 1H), 2.05 (m, 1H), 1.85-1.40 (multiple peaks, 12H); 13C NMR (126 MHz, 
CDCl3): δ 143.2, 143.1, 142.8, 123.6, 123.5, 120.4, 116.0, 115.7, 40.3, 31.5, 28.3, 26.4; HRMS 
(DART): m/z calcd for C15H19O2 [M+H]+ 231.13796 , found 231.13808. 
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Synthesis of 2-aryl or 2-heteroaryl substrates 
GP8: General procedure for Suzuki coupling reactions 
A representative procedure is given for the synthesis of 2-aryl- or 2-heteroaryl-substituted 1,4- 
benzodioxines: Compound 2.28; A 20 mL tube was charged with 2-bromo-1,4-benzodioxine 
(700 mg, 3.29 mmol, 1 eq.), (3,4,5-trimethoxyphenyl)boronic acid (836 mg, 3.94 mmol, 1.2 eq.), 
Pd2dba3 (75.2 mg, 0.0822 mmol, 0.025 eq.), cataCXium A (88.4 mg, 0.246 mmol, 0.075 eq.), 
Cs2CO3 (3.21 g, 9.86 mmol, 3 eq.), and 1,4-dioxane (14 mL). The tube was sealed and heated 
to 85 °C for 14 h. The reaction was diluted with EtOAc, filtered through a short pad of Celite, 
followed by EtOAc washes, and concentrated in vacuo. Purification by column chromatography 
(elution gradient from 0–10% EtOAc in hexanes) yielded compound 2.28 as an off-white solid 
(615 mg, 62% yield). 
 
 
 
1H NMR (500 MHz, CDCl3): δ 6.90–6.81 (multiple peaks, 3H), 6.71 (m, 1H), 6.68 (s, 2H), 6.39 
(s, 1H), 3.89 (s, 6H), 3.86 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 153.3, 142.7, 142.1, 138.3, 
136.7, 126.9, 124.2, 124.1, 123.1, 116.4, 116.0, 100.8, 60.9, 56.2; HRMS (DART): m/z calcd for 
C17H17O5 [M+H]+ 301.10705, found 301.10716. 
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Compound 3.19 was prepared according to GP8 with methyl 2-bromo-1,4-benzodioxine-5-
carboxylate (1.00 g, 3.69 mmol, 1 eq.) and (6-(trifluoromethyl)pyridin-3-yl)boronic acid (916 mg, 
4.80 mmol, 1.3 eq.). Purification by column chromatography (elution gradient from 0–20% 
EtOAc in hexanes) yielded a white solid (842 mg, 68% yield); 1H NMR (500 MHz, CDCl3): δ 
8.80 (d, J = 1.5 Hz, 1H), 7.92 (dd, J = 8.2, 1.7 Hz, 1H), 7.68 (d, J = 8.2 Hz, 1H), 7.45 (dd, J = 
1.9/7.7 Hz, 1H), 7.00–6.94 (m, 2H), 6.77 (s, 1H), 3.90 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 
164.8, 147.4, 144.5, 142.7, 142.0, 133.9, 131.3, 129.6, 126.7, 125.8, 123.9, 121.4, 120.3, 120.2, 
119.4, 52.4; HRMS (DART): m/z calcd for C16H11O4NF3 [M+H]+ 338.06347, found 338.06309. 
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Synthesis of 2-carboxyl substrates 
GP9: General procedure for the synthesis of 2-amide-1,4-benzodioxine substrates 
A representative procedure is given for the synthesis of 2-carboxyl-substituted 1,4-
benzodioxines: Compound 3.56. A reaction tube was charged with Pd(OAc)2 (52.8 mg, 0.235 
mmol, 0.05 eq.), Xantphos (203.53 mg, 0.35 mmol, 0.075 eq.), 2-bromo-1,4-benzodioxine (1.00 
g, 4.69 mmol, 1 eq.), Na2CO3 (1.49 g, 14.1 mmol, 3 eq.), pyrrolidine (501 mg, 7.04 mmol, 1.5 
eq.), and toluene (4 mL). The reaction was heated to 80 °C under CO (50 psi) for 12 h in 
Biotage Endeavor reactor. The reaction was then diluted with EtOAc (20 mL), filtered through a 
short pad of Celite, concentrated in vacuo, and purified by column chromatography (elution 
gradient 10–20% EtOAc in hexanes) yielded 3.56 as a colorless solid (481 mg, 44% yield). 
 
 
 
 
 
 
1H NMR (500 MHz, CDCl3): δ 6.87–6.84 (multiple peaks, 2H), 6.78 (s, 1H), 6.71–6.66 (multiple 
peaks, 2H), 3.72 (br s, 2H), 3.54 (br s, 2H), 1.91 (br s, 2H), 1.88 (br s, 2H). 13C NMR (126 MHz, 
CDCl3): δ 160.5, 142.2, 141.6, 133.4, 133.0, 124.8, 124.6, 116.5, 116.2, 47.7, 47.2, 26.6, 23.5; 
HRMS (DART): m/z calcd for C13H14O3N [M+H]+ 232.09682, found 232.09684. 
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Compound 3.60 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (426 mg, 2.00 
mmol, 1 eq.) and piperidine (255 mg, 3.00 mmol, 1.5 eq.). Purification by column 
chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a yellow oil (234 mg, 48% 
yield); 1H NMR (500 MHz, CDCl3): δ 6.88–6.85 (multiple peaks, 2H), 6.71–6.67 (multiple peaks, 
2H), 6.54 (s, 1H), 3.56 (m, 4H), 1.70–1.58 (multiple peaks, 6H); 13C NMR (126 MHz, CDCl3): δ 
161.5, 142.1, 141.7, 133.2, 131.9, 124.7, 124.6, 116.5, 116.4, 45.9, 26.1, 24.6; HRMS (DART): 
m/z calcd. for C14H16O3N [M+H]+ 246.11247, found 246.11253 
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Compound 3.59 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69 
mmol, 1 eq.) and morpholine (613 mg, 7.04 mmol, 1.5 eq.). Purification by column 
chromatography (elution gradient 10–30% EtOAc in hexanes) yielded a colorless solid (409 mg, 
37% yield); 1H NMR (500 MHz, CDCl3) δ 6.89–6.86 (multiple peaks, 2H), 6.73–6.66 (multiple 
peaks, 2H), 6.64 (s, 1H), 3.73–3.66 (multiple peaks, 8H); 13C NMR (126 MHz, CDCl3) δ 161.6, 
141.8, 141.5, 133.1, 132.7, 124.94, 124.88, 116.6, 116.3, 66.9, 42.3; HRMS (DART): m/z calcd 
for C13H14O4N [M+H]+ 248.09173, found 248.09180. 
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Compound 3.57 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (500mg, 
2.35mmol, 1 eq.) and 1-phenylpiperazine (571 mg, 3.52 mmol,1.5 eq.). Purification by column 
chromatography (elution gradient 10–25% EtOAc in hexanes) yielded the an off white solid (500 
mg, 17% yield); 1H NMR (500 MHz, CDCl3) δ 7.29 (t, J = 7.8 Hz, 2H), 6.96–6.86 (multiple peaks, 
5H), 6.73–6.69 (multiple peaks, 2H), 6.65 (s, 1H), 3.82 (t, J = 5.0 Hz, 4H), 3.23 (t, J = 5.0 Hz, 
4H); 13C NMR (126 MHz, CDCl3) δ 161.6, 150.9, 141.9, 141.6, 133.0, 132.8, 129.3, 124.92, 
124.85, 120.6, 116.7, 116.6, 116.4, 49.7, 44.6; HRMS (HESI): m/z calcd for C19H19O3N2 [M+H]+ 
323.13902, found 323.13881. 
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Compound 3.58 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69 
mmol, 1 eq.) and tetrahydroisoquinoline (938 mg, 7.04 mmol, 1.5 eq.). Purification by column 
chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a colorless solid (283 mg, 
21% yield); 1H NMR (500 MHz, CDCl3) δ 7.23–7.11 (multiple peaks, 4H), 6.91–6.86 (m, 2H), 
6.74–6.70 (m, 2H), 6.65 (s, 1H), 4.76 (s, 2H), 3.86 (t, J = 5.8 Hz, 2H), 2.96 (t, J = 5.8 Hz, 2H); 
13C NMR (126 MHz, CDCl3) δ 161.0, 141.0, 140.6, 133.4, 132.0, 131.8, 131.7, 127.7, 125.7, 
124.4, 124.3, 123.9, 123.8, 115.5, 115.4, 45.6, 42.2, 28.0; HRMS (DART): m/z calcd for 
C18H16O3N [M+H]+ 294.11247, found 294.11248. 
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Compound 3.61 was prepared according to GP9 with 2-bromo-1,4-benzodioxine (1.00 g, 4.69 
mmol, 1 eq.) and 4-amino-6,7-dimethoxy-2-piperazinyl-chinazolin (318.27mg, 1.1mmol, 1 eq.). 
Purification by column chromatography (elution gradient 10–20% EtOAc in hexanes) yielded a 
colorless solid (283 mg, 21% yield); 1H NMR (500 MHz, CDCl3) δ 6.92 (s, 1H), 6.88 (multiple 
peaks, 2H), 6.82 (s, 1H), 6.71 (m, 2H), 6.65 (s, 1H), 5.22 (s, 2H), 3.97 (s, 3H). 3.93 (s, 3H), 3.97 
(s, 3H), 3.93 (s, 3H), 3.91 (m, 4H), 3.73 (m, 3H); 13C NMR (126 MHz, CDCl3) δ 161.7, 160.5, 
158.5, 155.2, 149.8, 146.0, 141.9, 141.5, 132.8, 132.8, 124.9, 124.8, 116.5, 116.4, 105.8, 102.9, 
101.1, 56.1, 56.0, 44.1, 29.6; HRMS (DART): m/z calcd for C23H23N5O5 [M+H]+ 450.17331, 
found 450.17340 
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A reaction tube containing methyl 2-bromo-1,4-benzodioxine-5-carboxylate (500 mg, 1.84 mmol, 
1 eq.), Pd(OAc)2 (10.4 mg, 0.0461 mmol, 0.025 eq.), cataCXium A (49.6 mg, 0.138 mmol, 0.075 
eq.) in MeOH (3 mL) was heated to 80 °C under CO (100 psi) for 16 h in Biotage Endeavor 
reactor. At the end of the reaction, the reaction was concentrated in vacuo and extracted with 
EtOAc (30 mL). The combined EtOAc extracts were concentrated in vacuo. Purification by 
column chromatography (elution gradient 10–20% EtOAc in hexanes) yielded compound 3.54 
as a white solid (310 mg, 67% yield); 1H NMR (500 MHz, CDCl3) δ 7.38 (dd, J = Hz, 1H), 7.01 
(s, 1H), 6.97–6.90 (multiple peaks, 2H), 3.87 (s, 3H), 3.82 (s, 3H); 13C NMR (126 MHz, CDCl3) δ 
164.6, 161.2, 142.8, 140.9, 135.6, 129.3, 126.4, 124.6, 120.6, 119.7, 52.4, 52.2; HRMS (DART): 
m/z calcd for C12H11O6 [M+H]+ 251.05501, found 251.05514 
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Reductions of 2-substituted 1,4-benzodioxine substrates 
GP10: General procedure for asymmetric hydrogenations 
A representative procedure is given for the asymmetric reduction of 2-substituted 1,4-
benzodioxines: A catalyst solution was prepared in a vial by mixing [Ir(cod)Cl]2 (1.3 mg, 0.0020 
mmol, 0.01 eq.) and ligand LXI (4.3 mg, 91.6 wt%, 0.0060 mmol, 0.03 eq.) in THF (0.3 mL) for 5 
min. 2-substituted benzodioxine substrate  (0.200 mmol, 1 eq.), MeOH (0.3 mL), and AcOH 
(0.46 mL, 8.0 mmol, 40 eq.) were added to the vial. The mixture was purged with N2 three times, 
followed by H2 three times. The reaction was heated to 50 °C or 70 °C under 600 psi H2 and 
stirred for 24 h. Upon completion, the reactor was vented and purged with N2 twice. The 
reaction was concentrated in vacuo, loaded onto silica gel cartridge, and purified by column 
chromatography. Enantiomeric ratios were determined by chiral SFC or chiral HPLC. 
 
Compound 3.14 was prepared according to GP10 with substrate 3.5 (16.2 mg, 0.200 mmol, 1 
eq.) at 25 °C. Conversion (>98%) to product was determined by HPLC. Due to the volatility of 
the compound, only conversion is provided. NMR spectra were obtained after filtration through 
silica gel pad using hexanes as eluent; 1H NMR (500 MHz, CDCl3): δ 6.89–6.80 (multiple peaks, 
4H), 4.24 (dd, J = 2.0/11.2 Hz, 1H), 4.03 (m, 1H), 3.88 (dd, J = 8.0/11.2 Hz, 1H), 1.78–1.57 
(multiple peaks, 2H), 1.07 (t, J = 7.6 Hz, 3H); 13C NMR (126 MHz, CDCl3): δ 143.5, 143.3, 
121.4, 121.1, 117.3, 117.0, 74.3, 67.8, 24.2, 9.4; The enantiomeric excess was determined by 
chiral HPLC on CHIRALCEL OJ-3 column, 4.6 mm ID x150 mm L, 3 um particle size. The 
compounds were eluted with 100% heptane. Column temperature 20 ºC; Flow rate 1.3 mL/min; 
UV detection at 220 nm; tR= 5.67 min (major), 6.56 min (major); er 90:10 
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Compound 3.18 was prepared according to GP10 with substrate 3.9 (52.0 mg, 0.227 mmol, 1 
eq.) at 50 °C. Purification by column chromatography (elution gradient 0–2% EtOAc in hexanes) 
yielded a colorless oil (49.8 mg, 95% yield); 1H NMR (500 MHz, CDCl3): δ 6.88–6.77 (multiple 
peaks, 4H), 4.27 (m, 1H), 3.98–3.89 (multiple peaks, 2H), 1.91–1.42 (multiple peaks, 12H), 1.34 
(m, 1H); 13C NMR (126 MHz, CDCl3): δ 143.9, 143.5, 121.3, 121.0, 117.3, 116.8, 77.3, 66.2, 
40.5, 29.7, 29.2, 28.5, 28.4, 26.7, 26.5; HRMS (DART): m/z calcd for C15H21O2 [M+H]+ 
233.15361, found 233.15382; The enantiomeric excess was determined by chiral SFC on 
Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size. The 
compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a 
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, 
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature 
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 1.31 min 
(minor), 1.42 min (major); er 93.2:6.8 
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Compound 3.37 was prepared according to GP10 with substrate 3.19 (67.5 mg, 0.200 mmol, 1 
eq.) at 70 °C. Purification by column chromatography (15% EtOAc in hexanes) yielded a white 
solid (quantitative yield); 1H NMR (500 MHz, CDCl3): δ 8.80 (s, 1H), 7.97 (dd, J = 8.3/1.7 Hz, 
1H), 7.77 (d, J = 8.1 Hz, 1H), 7.50 (dd, J = 1.4/7.8 Hz, 1H), 7.17 (dd, J = 1.4/8.1 Hz, 1H), 6.95 (t, 
J = 7.9 Hz, 1H), 5.34 (dd, J = 1.9/8.5 Hz, 1H), 4.59 (dd, J = 2.4/11.6 Hz, 1H), 4.11 (dd, J = 
8.5/11.6 Hz, 1H), 3.91 (s, 3H); 13C NMR (125 MHz, CDCl3): δ 165.7, 148.7, 148.2, 143.5, 143.2, 
135.5, 135.0, 124.6, 121.6, 121.3, 121.0, 120.6, 120.2, 72.1, 68.7, 52.2; HRMS (DART): m/z 
calcd for C16H13O4NF3 [M+H]+ 340.07912, found 340.07913; The enantiomeric excess was 
determined by chiral SFC on Phenomenex Lux Cellulose-4 column, 4.6 mm ID x 100 mm L, 5 
um particle size. The compounds were eluted with CO2 (mobile phase A) and methanol (mobile 
phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, 
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature 
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 5.06 min 
(minor), 5.35 min (major); er 99.1:0.9 
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Compound 3.46 was prepared according to GP10 with substrate 3.28 (60.1 mg, 0.200 mmol, 1 
eq.) at 50 °C. Purification by column chromatography (elution gradient 0–10% EtOAc in 
hexanes) yielded a white solid (54.2 mg, 90% yield); 1H NMR (500 MHz, CDCl3): δ 7.00 (m, 1H), 
6.94 (m, 1H), 6.91–6.87 (multiple peaks, 2H), 6.64 (s, 2H), 5.05 (dd, J = 2.2/9.0 Hz, 1H), 4.35 
(dd, J = 2.2/11.4 Hz, 1H), 4.03 (dd, J = 9.0/11.4 Hz, 1H), 3.89 (s, 6H), 3.86 (s, 3H); 13C NMR 
(126 MHz, CDCl3): δ 153.6, 143.8, 143.0, 148.4, 142.0, 121.7, 121.6, 117.6, 117.2, 103.6, 75.2, 
69.4, 60.9, 56.2; HRMS (DART): m/z calcd for C17H19O5 [M+H]+ 303.12270, found 303.12278; 
The enantiomeric excess was determined by chiral SFC on ChromegaChiral CCA column, 4.6 
mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) 
and methanol (mobile phase B) using a gradient. The gradient used was 1% B to 3%B in 3 min, 
3%B to 50%B in 5 min, hold at 50% B for 1 min, then to 1% B in 1 min (analysis time 10 
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV 
detection at 220 nm; tR= 3.98 min (minor), 4.33 min (major); er 99.2:0.8 
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Compound 3.39 was prepared according to GP10 with substrate 3.21 (53.9 mg, 0.200 mmol, 1 
eq.), 2 mol % [Ir(cod)Cl]2 and 6 mol % ligand at 70 °C. Purification by column chromatography 
(60% EtOAc in hexanes) yielded a white solid (45.9 mg, 85% yield); 1H NMR (500 MHz, CDCl3): 
δ 8.69 (s, 1H), 8.66 (d, J = 4.8 Hz, 1H), 7.76 (d, J = 7.9 Hz, 1H), 7.48 (d, J = 7.9 Hz, 1H), 7.38 
(dd, J = 4.8/7.9 Hz, 1H), 7.15 (d, J = 7.9 Hz, 1H), 6.93 (t, J = 7.9 Hz, 1H), 5.23 (d, J = 7.4 Hz, 
1H), 4.56 (dd, J = 1.9/11.5 Hz, 1H), 4.09 (dd, J = 9.1/11.5 Hz, 1H), 3.91 (s, 3H); 13C NMR (126 
MHz, CDCl3): δ 165.9, 150.3, 148.1, 144.0, 143.3, 134.1, 131.7, 124.3, 123.7, 121.6, 120.8, 
120.1, 72.7, 69.1, 52.1; HRMS (DART): m/z calcd for C15H14O4N [M+H]+ 272.09173, found 
272.09174; The enantiomeric excess was determined by chiral SFC on Phenomenex Lux 
Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size. The compounds were eluted 
with CO2 (mobile phase A) and methanol (mobile phase B) using a gradient. The gradient used 
was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min 
(analysis time 10 minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 
3.0 mL/min; UV detection at 220 nm; tR= 4.57 min (minor), 4.16 min (major); er 99.0:1.0 
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Compound 3.44 was prepared according to GP10 substrate 3.26 (48.4 mg, 0.200 mmol, 1 
equiv), 2 mol % [Ir(cod)Cl]2 and 6 mol % ligand at 50 °C. Purification by column chromatography 
(15% EtOAc in hexanes) yielded a white solid (24.4 mg, 50% yield); 1H NMR (500 MHz, CDCl3): 
δ 8.58 (s, 2H), 6.98–6.88 (multiple peaks, 4H), 5.15 (dd, J = 2.1/8.3 Hz, 1H), 4.36 (dd, J = 
2.1/11.5 Hz, 1H), 4.10 (dd, J = 8.3/11.5 Hz, 1H), 4.04 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 
166.0, 158.0, 143.1, 142.7, 123.5, 122.1, 122.0, 117.5, 117.3, 71.1, 68.3, 55.2; HRMS (DART): 
m/z calcd for C13H13O3N2 [M+H]+ 245.09207, found 245.09225; The enantiomeric excess was 
determined by chiral SFC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 
um particle size. The compounds were eluted with CO2 (mobile phase A) and methanol (mobile 
phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, 
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature 
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 3.10 min 
(minor), 3.67 min (major); er 97.7:2.3 
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Compound 3.62 was prepared according to GP10 with substrate 3.54 (50.0 mg, 0.200 mmol, 1 
equiv) at 50 °C. Purification by column chromatography (20% EtOAc in hexanes) yielded a 
colorless oil (49.1 mg, 97% yield). 1H NMR (500 MHz, CDCl3): δ 7.44 (dd, J = 1.0/8.0 Hz, 1H), 
7.17 (dd, J = 1.0/8.0 Hz, 1H), 6.91 (t, J = 8.0 Hz, 1H), 4.87 (dd, J = 3.0/5.1 Hz, 1H), 4.52–4.43 
(multiple peaks, 2H), 3.88(s, 3H), 3.82 (s, 3H); 13C NMR (126 MHz, CDCl3): δ 167.9, 165.7, 
143.4, 142.7, 124.3, 121.5, 121.1, 120.0, 71.5, 65.0, 52.9, 52.1; HRMS (DART): m/z calcd for 
C12H13O6 [M+H]+ 253.07066, found 253.07074; The enantiomeric excess was determined by 
chiral HPLC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 150 mm L, 3 um particle 
size. The compounds were eluted with 0.1% (v/v) HClO4 in water (mobile phase A) and 
acetonitrile (mobile phase B) using an isocratic condition 80% A/20% B. Column temperature 25 
ºC; Flow rate 1.5 mL/min; UV detection at 220 nm; tR= 12.7 min (minor), 11.3 min (major); er 
99.9:0.1 
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Compound 3.63 was prepared according to GP10 with substrate 3.55 (38.4 mg, 0.200 mmol, 1 
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–15% EtOAc in 
hexanes) yielded a white solid (36.8 mg, 95% yield); 1H NMR (500 MHz, CDCl3): δ 7.00 (m, 1H), 
6.92–6.86 (multiple peaks, 3H), 4.85 (t, J = 3.9 Hz, 1H), 4.39 (d, J = 3.9 Hz, 2H), 3.82 (s, 3H); 
13C NMR (126 MHz, CDCl3): δ 168.5, 142.9, 142.3, 122.2, 121.9, 117.4, 117.3, 72.0, 64.9, 52.8; 
HRMS (HESI): m/z calcd for C10H10O4 [M+H]+ 194.05736, found 194.05742; The enantiomeric 
excess was determined by chiral SFC on Phenomenex Lux Cellulose-2 column, 4.6 mm ID x 
100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) and 
methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B 
to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). 
Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 
220 nm; tR= 2.91 min (minor), 2.36 min (major); er 95.4:4.6 
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Compound 3.14 was prepared according to GP10 with substrate 3.56 (46.3 mg, 0.200 mmol, 1 
eq.) at 50 °C. Purification by column chromatography (elution gradient 10–30% EtOAc in 
hexanes) yielded a colorless oil (43.3 mg, 93% yield). 1H NMR (500 MHz, CDCl3): δ 6.95–6.83 
(multiple peaks, 4H), 4.76 (dd, J = 2.5/8.1 Hz, 1H), 4.47 (dd, J = 2.5/11.7 Hz, 1H), 4.33 (dd, J = 
8.1/11.7 Hz, 1H), 3.76 (m, 1H), 3.62–3.52 (multiple peaks, 3H), 2.07–1.85 (multiple peaks, 4H); 
13C NMR (126 MHz, CDCl3): δ 165.0, 143.3, 142.8, 122.0, 121.5, 117.3, 117.3, 72.3, 65.1, 46.7, 
46.4, 26.3, 23.8; HRMS (DART): m/z calcd for C13H16O3N [M+H]+ 234.11247, found 234.11250; 
The enantiomeric excess was determined by chiral SFC on ChromegaChiral CCC column, 4.6 
mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) 
and methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 
3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV 
detection at 220 nm; tR= 6.78 min (minor), 5.33 min (major); er 92.8:7.2 
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Compound 3.67 was prepared according to GP10 with substrate 3.59 (49.5 mg, 0.200 mmol, 1 
equiv) at 50 °C. Purification by column chromatography (elution gradient 10–30% EtOAc in 
hexanes) yielded a colorless oil (46.5 mg, 93% yield); 1H NMR (500 MHz, CDCl3): δ 6.93–6.83 
(multiple peaks, 4H), 4.81 (dd, J = 2.4/8.0 Hz, 1H), 4.49 (dd, J = 2.5/11.8 Hz, 1H), 4.34 (dd, J = 
8.0/11.8 Hz, 1H), 3.83–3.67 (multiple peaks, 6H), 3.63–3.54 (multiple peaks, 2H); 13C NMR (126 
MHz, CDCl3): δ 165.0, 143.3, 142.4, 122.4, 121.6, 117.5, 117.2, 70.6, 66.84, 66.77, 65.1, 46.3, 
42.5; HRMS (DART): m/z calcd for C13H16O4N [M+H]+ 250.10738, found 250.10742; The 
enantiomeric excess was determined by chiral SFC on Phenomenex Lux Cellulose-4 column, 
4.6 mm ID x 100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile 
phase A) and methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B 
in 3 min, 3%B to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 
minutes). Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV 
detection at 220 nm; tR= 5.74 min (minor), 5.08 min (major); er 98.2:1.8 
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Compound 3.68 was prepared according to GP10 with substrate 3.60 (49.1 mg, 0.200 mmol, 1 
eq.) at 50 °C. Purification by column chromatography (elution gradient 5–20% EtOAc in 
hexanes) yielded a colorless oil (44.4 mg, 90% yield); 1H NMR (500 MHz, CDCl3): δ 6.93–6.83 
(multiple peaks, 4H), 4.83 (dd, J = 2.5/8.2 Hz, 1H), 4.48 (dd, J = 2.5/12.0 Hz, 1H), 4.31 (dd, J = 
8.2/12.0 Hz, 1H), 3.75–3.66 (multiple peaks, 2H), 3.53–3.44 (multiple peaks, 2H), 1.76–1.58 
(multiple peaks, 6H); 13C NMR (126 MHz, CDCl3): δ 164.6, 143.4, 142.8, 122.1, 121.4, 117.3, 
117.3, 70.7, 65.4, 46.8, 43.2, 26.6, 25.5, 24.5; HRMS (DART): m/z calcd for C14H18O3N [M+H]+ 
248.12812, found 248.12821; The enantiomeric excess was determined by chiral SFC on 
Phenomenex Lux Cellulose-2 column, 4.6 mm ID x 100 mm L, 5 um particle size. The 
compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a 
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, 
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature 
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 7.15 min 
(minor), 5.20 min (major); er 97.5:2.5 
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Compound 3.66 was prepared according to GP10 with substrate 3.58 (58.7 mg, 0.200 mmol, 1 
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–20% EtOAc in 
hexanes) yielded a tan oil (48.5 mg, 82% yield) as a pair of rotamers (3:2); 1H NMR (600.04 
MHz, DMSO-d6): δ 7.23–7.17 (m, 4H, rotamer 1+2), 6.96-6.91 (m, 0.6H, rotamer 1), 
6.91-6.82 (m, 3.4H, rotamer 1+2), 5.33 (dd, J = 2.4/6.4 Hz, 0.4H, rotamer 2), 5.30 (dd, J = 
2.3/6.4 Hz, 0.6H, rotamer 1), 4.86 (d, J = 16.3 Hz, 0.4H, rotamer 2), 4.81 (d, J = 16.3 Hz, 0.4H, 
rotamer 2), 4.68 (d, J = 16.8 Hz, 0.6H, rotamer 1), 4.59 (d, J = 16.8 Hz, 0.6H, rotamer 1), 4.44-
4.39 (m, 1H, rotamer 1+2), 4.24-4.18 (m, 1H, rotamer 1+2), 3.93-3.87 (m, 0.6H, rotamer 2), 
3.83-3.77 (m, 0.6H, rotamer 2), 3.75-3.65 (m, 0.8H, rotamer 1), 2.94 (t, J = 6.0 Hz, 1.2H, 
rotamer 2), 2.81 (t, J = 6.0 Hz, 0.8H, rotamer 1); 13C NMR (150.88 MHz, DMSO-d6): δ rotamer 
1: 165.3, 143.0, 142.8, 134.3, 132.9, 128.5, 126.5, 126.5, 126.2, 121.5, 121.4, 117.0, 116.9, 
69.8, 64.7, 43.9, 42.7, 28.8; rotamer 2: 165.2, 142.9, 142.8, 134.6, 133.3, 128.5, 126.6, 126.2, 
126.2, 121.4, 121.4, 117.0, 116.8, 69.8, 64.6, 46.3, 40.0, 27.6. HRMS (DART): m/z calcd for 
C18H18O3N [M+H]+ 296.12812, found 296.12814; The enantiomeric excess was determined by 
chiral SFC on Phenomenex Lux Cellulose-3 column, 4.6 mm ID x 100 mm L, 5 um particle size. 
The compounds were eluted with CO2 (mobile phase A) and methanol (mobile phase B) using a 
gradient. The gradient used was 1%B to 3%B in 3 min, 3%B to 50%B in 5 min, 
hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). Column temperature 
35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 220 nm; tR= 4.93 min 
(minor), 5.47 min (major); er 97.5:2.5 
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Compound 3.65 was prepared according to GP10 with substrate 3.57 (64.5 mg, 0.200 mmol, 1 
equiv) at 50 °C. Purification by column chromatography (elution gradient 5–15% EtOAc in 
hexanes) yielded a colorless oil (54.6 mg, 84% yield); 1H NMR (500 MHz, CDCl3): δ 7.30 (m, 
2H), 6.97–6.83 (multiple peaks, 7H), 4.88 (dd, J = 2.5/8.1 Hz, 1H), 4.52 (dd, J = 2.5/11.9 Hz, 
1H), 4.36 (dd, J = 8.1/11.9 Hz, 1H), 3.98–3.90 (multiple peaks, 2H), 3.80–3.67 (multiple peaks, 
2H), 3.32–3.12 (multiple peaks,4H); 13C NMR (126 MHz, CDCl3): δ 164.9, 150.9, 143.3, 142.5, 
129.3, 122.3, 121.6, 120.8, 117.5, 117.3, 116.8, 70.7, 65.2, 50.0, 49.3, 45.7, 42.1; HRMS 
(HESI): m/z calcd for C19H21O3N2 [M+H]+ 325.15467, found 325.15435; The enantiomeric 
excess was determined by chiral SFC on ChromegaChiral CCC column, 4.6 mm ID x 
100 mm L, 5 um particle size. The compounds were eluted with CO2 (mobile phase A) and 
methanol (mobile phase B) using a gradient. The gradient used was 1%B to 3%B in 3 min, 3%B 
to 50%B in 5 min, hold at 50%B for 1 min, then to 1%B in 1 min (analysis time 10 minutes). 
Column temperature 35 ºC; SFC back pressure 150 bar; Flow rate 3.0 mL/min; UV detection at 
220 nm; tR= 7.48 min (minor), 6.63 min (major); er 98.0:2.0 
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